Inducible cell death system

JP2023550469A5Inactive Publication Date: 2024-11-29SENTI BIOSCI INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023530766
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-20
Filing Date
2021-11-22
Publication Date
2024-11-29
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current cell and gene therapy products lack control mechanisms, leading to safety concerns such as toxicity in treated subjects.

Method used

Inducible cell death systems comprising polypeptide monomers with specific ligand binding domains that oligomerize upon ligand binding to induce cell death in a controlled manner, using domains like ABI, PYL, caffeine-binding antibodies, estrogen receptor domains, and FKBP/FRB domains, along with cell death-inducing agents like caspases and toxins.

Benefits of technology

Provides a controlled and safe mechanism to induce cell death, mitigating safety concerns and enhancing the precision of cell and gene therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Provided herein are compositions and methods for inducing cell death in a controlled manner, such as, for example, a safety switch system. Inducible cell death can be triggered by ligand binding to one or more ligand-binding domains. Cell death can include induction of apoptosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] Cross - Reference to Related Applications This application claims the benefit of U.S. Provisional Application No. 63 / 116,433, filed Nov. 20, 2020, which is hereby incorporated by reference in its entirety for all purposes.

[0002] Sequence Listing This application includes a sequence listing submitted via EFS - Web, which is hereby incorporated by reference in its entirety. The ASCII copy created in XX month, 2XXX is named XXXXXUS_sequencelisting.txt and is X,XXX,XXX bytes in size.

Background Art

[0003] Currently available cell and gene therapy products may lack control, which can lead to safety concerns such as toxicity in the subjects being treated. Therefore, additional methods for controlling and regulating these therapies are needed.

Summary of the Invention

[0004] Disclosed herein are inducible cell death systems, such as, for example, safety switch systems, that can be used to induce cell death in a controlled manner.

[0005] In some aspects, the disclosure provides an inducible cell death system comprising two or more polypeptide monomers, each polypeptide monomer comprising one or more ligand - binding domains and a cell - death inducing domain, wherein the polypeptide monomers are configured to oligomerize upon contact with a cognate ligand of the polypeptide monomer and one or more ligand - binding domains and to generate a cell - death inducing signal within the cell in which the polypeptide monomer is expressed, and one or more ligand - binding domains of each of the two or more polypeptide monomers are It includes a domain or functional fragment thereof selected from the group consisting of an ABI domain optionally containing the amino acid sequence of SEQ ID NO: 31, a PYL domain optionally containing the amino acid sequence of SEQ ID NO: 53, a caffeine-binding single-domain antibody optionally containing the amino acid sequence of SEQ ID NO: 33, a cannabidiol-binding domain optionally containing an amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 35, 36, 37, and 38, a hormone-binding domain of an estrogen receptor (ER) domain optionally containing the amino acid sequence of SEQ ID NO: 42, a heavy chain variable region (VH) of an anti-nicotine antibody optionally containing the amino acid sequence of SEQ ID NO: 50 and / or a light chain variable region (VL) of an anti-nicotine antibody optionally containing the amino acid sequence of SEQ ID NO: 51, an FKBP domain optionally containing the amino acid sequence of SEQ ID NO: 43, and a progesterone receptor domain optionally containing the amino acid sequence of SEQ ID NO: 52, or One or more ligand-binding domains of the first of two or more polypeptide monomers include an FKBP domain optionally containing the amino acid sequence of SEQ ID NO: 43, and one or more ligand-binding domains of the second of two or more polypeptide monomers include an FRB domain optionally containing the amino acid sequence of SEQ ID NO: 44, or One or more ligand-binding domains of the first of two or more polypeptide monomers include a cerebron domain optionally containing the amino acid sequence specified in one of SEQ ID NOs. 127 and 129, and one or more ligand-binding domains of the second of two or more polypeptide monomers include a degron optionally containing the amino acid sequence specified in one of SEQ ID NOs. 131 and 133, and Optionally, the cell death induction domains include caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, diphtheria toxin fragment A (DTA), Bax, Bak, Bok, Bad, Bcl-xS, Bak, Bik, Bcl-2-interacting protein 3 (BNIP3), Fas, Fas-related protein with death domain (FADD), tumor necrosis factor receptor 1-associated death domain protein (TRADD), TNF receptor (TNF-R), APAF-1, granzyme B, second mitochondrial-derived activator of caspase (SMAC), Omi, Bmf, Bid, Bim, p53 upregulator of apoptosis (PUMA), Noxa, Blk, Hrk, cytochrome c, Arts, TNF-related cell death induction ligand (TRAIL), and herpes simplex virus. The proteins are derived from a group selected from the following: herpes zoster virus thymidine kinase (HSV-TK), varicella-zoster virus thymidine kinase (VZV-TK), viral spike protein, carboxylesterase, cytosine deaminase, nitroreductase Fksb, carboxypeptidase G2, carboxypeptidase A, horseradish peroxidase, linamorase, hepatic cytochrome P450-2B1, and purine nucleoside phosphorylase. Optionally, caspase 9 or its functional cleavage contains the amino acid sequence of SEQ ID NO: 39; optionally, DTA contains the amino acid sequence of SEQ ID NO: 41; optionally, granzyme B contains the amino acid sequence of SEQ ID NO: 47; and optionally, Bax contains the amino acid sequence of SEQ ID NO: 32.

[0006] In some embodiments, each polypeptide monomer contains the same ligand-binding domain, and optionally, each polypeptide monomer is The FKBP domain is optionally selected from among the homologous ligands FK1012, its derivatives, or its analogues. The ABI domain and PYL domain, or, at will, have a congener ligand of abscisic acid. A first cannabidiol-binding domain comprising the amino acid sequence of SEQ ID NO: 34, wherein the homologous ligand is optionally a plant cannabinoid, and optionally the plant cannabinoid is cannabidiol; and a second cannabidiol-binding domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 35, 36, 37, and 38, or The hormone-binding domain and FKBP domain of the estrogen receptor (ER) domain, optionally selected from the group consisting of 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen, and optionally selected from the group consisting of 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen. Two caffeine-binding single-domain antibodies, each optionally containing the amino acid sequence of SEQ ID NO: 33, and optionally having a homologous ligand of caffeine or a derivative thereof, or The present invention comprises a first progesterone receptor domain containing the amino acid sequence of SEQ ID NO: 52, wherein the homologous ligand is optionally mifepristone or a derivative thereof, and a second progesterone receptor domain containing the amino acid sequence of SEQ ID NO: 52. Optionally, the polypeptide monomer is configured to form a homooligomer upon contact with a congener ligand, and optionally, the homooligomer includes a homodimer.

[0007] In some embodiments, the first polypeptide monomer comprises a first ligand-binding domain, and the second polypeptide monomer comprises a second ligand-binding domain, optionally, The first monomer contains an FKBP domain, the second monomer contains an FRB domain, and optionally, the homologous ligand is rapamycin or a derivative thereof, or

[0008] The first polypeptide monomer contains a hormone-binding domain of the estrogen receptor (ER) domain, and the second polypeptide monomer contains an FKBP domain, and optionally, the homologous ligand is rapamycin or its derivatives, and / or tamoxifen or its metabolites, or The first polypeptide monomer comprises an FRB domain, and the second polypeptide monomer comprises a hormone-binding domain of the estrogen receptor (ER) domain, and optionally, the homologous ligand is rapamycin or its derivatives, and / or tamoxifen or its metabolites, or The first polypeptide monomer comprises the hormone-binding domain and FKBP domain of the estrogen receptor (ER) domain, the second polypeptide monomer comprises the FRB domain and the hormone-binding domain of the estrogen receptor (ER) domain, and optionally, the homologous ligand is rapamycin or its derivatives and / or tamoxifen or its metabolites, or The first polypeptide monomer contains an ABI domain, the second polypeptide monomer contains a PYL domain, and optionally, the homologous ligand contains abscisic acid, or The first polypeptide monomer comprises the heavy chain variable region (VH) of an anti-nicotine antibody, the second polypeptide monomer comprises the light chain variable region (VL) of an anti-nicotine antibody, optionally the anti-nicotine antibody is Nic12 antibody, optionally VH comprises the amino acid sequence of SEQ ID NO: 50, optionally VL comprises the amino acid sequence of SEQ ID NO: 51, and optionally the homologous ligand is nicotine or a derivative thereof. The first polypeptide monomer comprises a cannabidiol-binding domain containing an amino acid sequence selected from the group consisting of SEQ ID NOs. 35, 36, 37, and 38, the second polypeptide monomer comprises a cannabidiol-binding domain containing the amino acid sequence of SEQ ID NO. 34, optionally the homologous ligand is a plant cannabinoid, optionally the plant cannabinoid is cannabidiol, or The first polypeptide monomer contains a cerebron domain with an amino acid sequence specified in one of SEQ ID NOs: 127 and 129, the second polypeptide monomer contains a degron domain with an amino acid sequence specified in one of SEQ ID NOs: 131 and 133, the homologous ligand is optionally IMiD, the homologous ligand is optionally an FDA-approved drug, and the homologous ligand is optionally selected from the group consisting of thalidomide, lenalidomide, and pomalidomide. Optionally, the polypeptide monomer is configured to form a heterooligomer upon contact with a congener ligand, and optionally, the heterooligomer includes a heterodimer.

[0009] In some embodiments, at least one of two or more polypeptide monomers further comprises a linker localized between each ligand-binding domain and a cell death-inducing domain, optionally comprising an amino acid sequence selected from the group consisting of GGGGSGGGGSGGGGSVDGF (SEQ ID NO: 101) and ASGGGGSAS (SEQ ID NO: 102), optionally comprising a linker localized between each ligand-binding domain and a cell death-inducing domain.

[0010] In some embodiments, the disclosure provides an inducible cell death system comprising an activated conditionally controlled polypeptide (ACP). ACP comprises a ligand-binding domain and a transcription effector domain, and Upon binding of its ligand-binding domain to a homologous ligand, ACP can regulate the transcriptional expression of a gene of interest operably linked to an ACP-responsive promoter. The gene of interest includes a cell death-inducing polypeptide, and Optionally, the ligand-binding domain may include degron, and optionally, degron may induce the degradation of ACP, and Optionally, degrons include HCV NS4 degron, PEST (two copies of human κBα residues 277-307), GRR (human p105 residues 352-408), DRR (yeast Cdc34 residues 210-295), SNS (tandem repeat of SP2 and NB (SP2-NB-SP2 of influenza A or influenza B)), RPB (four copies of yeast RPB residues 1688-1702), and SPmix (tandem repeat of SP1 and SP2). Repeat (SP2-SP1-SP2-SP1-SP2 of influenza A virus M2 protein), NS2 (three copies of residues 79-93 of influenza A virus NS protein), ODC (residues 106-142 of ornithine decarboxylase), Nek2A, mouse ODC (residues 422-461), mouse ODC_DA (residues 422-461 of mODC including point mutations D433A and D434A), APC / C Degron, COP1 E3 ligase-conjugated degron motif, CRL4-Cdt2-conjugated PIP degron, actinphylline-conjugated degron, KEAP1-conjugated degron, KLHL2 and KLHL3-conjugated degron, MDM2-conjugated motif, N degron, hydroxyproline modification in hypoxia signaling, plant hormone-dependent SCF-LRR-conjugated degron, SCF ubiquitin ligase-conjugated phosphodegron, plant hormone-dependent SCF-LRR-conjugated degron, SCF ubiquitin ligase-conjugated phosphodegron, plant hormone-dependent SCF-LRR-conjugated degron, DSGxxS phosphate-dependent degron, Siah-conjugated motif, SPOP Selected from the group consisting of an SBC docking motif and a PCNA-binding PIP box, or degron contains a cerebron (CRBN) polypeptide substrate domain that can bind to CRBN in response to an immunomodulatory drug (IMiD), thereby promoting the degradation of modulated polypeptides via the ubiquitin pathway, and optionally the CRBN polypeptide substrate domain is IKZF1, IKZF3, CK1a, ZFP91, GSPT1, MEIS2, GSSSelected from the group consisting of E4F1, ZN276, ZN517, ZN582, ZN653, ZN654, ZN692, ZN787, and ZN827, or fragments thereof capable of drug-inducible binding to CRBN, optionally the CRBN polypeptide substrate domain is a chimeric fusion product of a natural CRBN polypeptide sequence, optionally the CRBN polypeptide substrate domain is an IKZF3 / ZFP91 / IKZF3 chimeric fusion product having the amino acid sequence FNVLMVHKRSHTGERPLQCEICGFTCRQKGNLLRHIKLHTGEKPFKCHLCNYACQRRDAL (SEQ ID NO: 103).

[0011] In some embodiments, the Disclosure provides an inducible cell death system comprising an activated conditionally controlled polypeptide (ACP), the ACP comprising one or more ligand-binding domains, as well as a transcription factor comprising a nucleic acid-binding domain and a transcription effector domain. ACP undergoes nuclear localization upon binding of its ligand-binding domain to a congener ligand, and When localized to the cell nucleus, ACP can induce transcriptional expression of a gene of interest operably linked to an ACP-responsive promoter. The gene of interest contains a cell death-inducing domain, Optionally, the transcription effector domains include: herpes simplex virus protein 16 (VP16) activation domain; activation domain containing four tandem copies of VP16; VP64 activation domain; p65 activation domain of NFκB; Epstein-Barr virus R trans-activator (Rta) activation domain; tripartite activator containing VP64, p65, and Rta activation domains (VPR activation domain); tripartite activator containing VP64, p65, and HSF1 activation domains (VPH activation domain); histone acetyltransferase (HAT) core domain of human E1A-related protein p300 (p300 Selected from the group consisting of: HAT core activating domain; Kruppel association box (KRAB) repression domain; repressor element silencing transcription factor (REST) ​​repression domain; WRPW motif of hairy-associated basic helix-loop-helix repressor protein, known as the WRPW repression domain; DNA (cytosine-5)-methyltransferase 3B (DNMT3B) repression domain; and HP1 alpha-chromoshadow repression domain, and Optionally, each of one or more ligand-binding domains contains a hormone-binding domain of an estrogen receptor (ER) domain which optionally contains the amino acid sequence of SEQ ID NO: 42, and optionally, the homologous ligand is tamoxifen or its metabolites, and optionally, the tamoxifen metabolites are selected from the group consisting of 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen, or optionally, a progesterone receptor domain which optionally contains the amino acid sequence of SEQ ID NO: 52, and optionally, the homologous ligand is mifepristone or its derivatives, or Optionally, each of one or more ligand-binding domains is: The ABI domain contains, by any choice, the amino acid sequence of SEQ ID NO: 31, and by any choice, its homologous ligand is abscisic acid. A PYL domain containing the amino acid sequence of SEQ ID NO: 53, optionally, whose homologous ligand is abscisic acid, A caffeine-binding single-domain antibody that optionally contains the amino acid sequence of SEQ ID NO: 33, and optionally has a homologous ligand of caffeine or a derivative thereof. A cannabidiol-binding domain comprising, optionally, an amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 35, 36, 37, and 38, optionally, a homologous ligand being a plant cannabinoid, and optionally, the plant cannabinoid being cannabidiol. A hormone-binding domain of an estrogen receptor (ER) domain, which optionally contains the amino acid sequence of SEQ ID NO: 42, optionally has a homologous ligand that is tamoxifen or a metabolite thereof, and optionally has a tamoxifen metabolite selected from the group consisting of 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen.

[0012] The heavy chain variable region (VH) of an anti-nicotine antibody, which optionally contains the amino acid sequence of SEQ ID NO: 50 and optionally has a congener ligand of nicotine or a derivative thereof. The light chain variable region (VL) of an anti-nicotine antibody, which optionally contains the amino acid sequence of SEQ ID NO: 51 and optionally has a congener ligand of nicotine or a derivative thereof. A progesterone receptor domain that optionally contains the amino acid sequence of SEQ ID NO: 52, and optionally has a homologous ligand of mifepristone or a derivative thereof. The FKBP domain optionally contains the amino acid sequence of SEQ ID NO: 43, and optionally has a homologous ligand of rapamycin, AP1903, AP20187, FK1012, its derivatives, or analogs, and The molecule optionally contains the amino acid sequence of Sequence ID No. 44, and optionally contains a domain or functional fragment thereof selected from the group consisting of FRB domains whose congener ligand is rapamycin, AP1903, AP20187, FK1012, their derivatives, or analogs. Optionally, the nucleic acid binding domain comprises a DNA binding zinc finger protein domain (ZF protein domain), optionally, the ZF protein domain is of modular design and is composed of an array of zinc finger motifs, optionally, the ZF protein domain comprises from one to ten zinc finger motifs, Optionally, the gene of interest is a cell death-inducing polypeptide, optionally, the cell death-inducing domain is selected from the group consisting of caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, diphtheria toxin fragment A (DTA), Bax, Bak, Bok, Bad, Bcl-xS, Bak, Bik, Bcl-2-interacting protein 3 (BNIP3), Fas, Fas-associated protein with death domain (FADD), tumor necrosis factor receptor type 1-associated death domain protein (TRADD), TNF receptor (TNF-R), APAF-1, granzyme B, second mitochondrial-derived activator of caspases (SMAC), Omi, Bmf, Bid, Bim, p53 upregulated modulator of apoptosis (PUMA), Noxa, Blk, Hrk, cytochrome c, Arts, TNF-related apoptosis-inducing ligand (TRAIL), herpes simplex virus thymidine kinase (HSV-TK), varicella-zoster virus thymidine kinase (VZV-TK), viral spike protein, carboxylesterase, cytosine deaminase, nitroreductase Fksb, carboxypeptidase G2, carboxypeptidase A, horseradish peroxidase, linamarase, liver cytochrome P450-2B1, and purine nucleoside phosphorylase, optionally, caspase 9 or its functional cleavage comprises the amino acid sequence of SEQ ID NO: 39, optionally, DTA comprises the amino acid sequence of SEQ ID NO: 41, optionally, granzyme B comprises the amino acid sequence of SEQ ID NO: 47, optionally, Bax comprises the amino acid sequence of SEQ ID NO: 32.

[0013] An inducible cell death system comprising an engineered controllable cell survival polypeptide, the cell survival polypeptide comprising a survival promoting polypeptide and a heterologous ligand binding domain, When the ligand-binding domain binds to a cognate ligand, the cognate ligand inhibits a survival-promoting polypeptide, Optionally, the survival-promoting polypeptide is selected from the group consisting of XIAP, modified XIAP, Bcl-2, Bcl-xL, Bcl-w, Bcl-2-related protein A1 (BCL2A1), Mcl-1, FLICE-like inhibitory protein (c-FLIP), and adenovirus E1B-19K protein, Optionally, the ligand-binding domain is a system of inducible cell death that is localized to the N-terminal region or the C-terminal region of the survival-promoting polypeptide.

[0014] In some embodiments, the disclosure provides a system of inducible cell death that includes a controllable cell survival polypeptide and a cell death-inducing polypeptide, The cell survival polypeptide includes a survival-promoting polypeptide and a heterologous ligand-binding domain, When expressed, the cell survival polypeptide can inhibit the cell death-inducing polypeptide, and When the cognate ligand binds, the cognate ligand inhibits the survival-promoting polypeptide. Optionally, the cell survival polypeptide is selected from the group consisting of XIAP, modified XIAP, Bcl-2, Bcl-xL, Bcl-w, Bcl-2-related protein A1 (BCL2A1), Mcl-1, FLICE-like inhibitory protein (c-FLIP), and adenovirus E1B-19K protein, Optionally, the ligand-binding domain is a system of inducible cell death that is localized to the N-terminal region or the C-terminal region of the survival-promoting polypeptide.

[0015] In some embodiments, XIAP comprises the amino acid sequence of SEQ ID NO: 107, or modified XIAP comprises one or more amino acid substitutions within positions 305-325 of SEQ ID NO: 107, optionally, one or more amino acid substitutions located at one or more positions of SEQ ID NO: 107 selected from the group consisting of 305, 306, 308, and 325, optionally, the amino acid substitution at position 305 of SEQ ID NO: 107 is G305M, optionally, the amino acid substitution at position 306 of SEQ ID NO: 107 is G306S, optionally, the amino acid substitution at position 308 of SEQ ID NO: 107 is selected from the group consisting of T308S and T308D, and optionally, the amino acid substitution at position 325 of SEQ ID NO: 107 is P325S.

[0016] In some embodiments, the ligand-binding domain is The ABI domain contains, by any choice, the amino acid sequence of SEQ ID NO: 31, and by any choice, its homologous ligand is abscisic acid. A PYL domain containing the amino acid sequence of SEQ ID NO: 53, optionally, whose homologous ligand is abscisic acid, A caffeine-binding single-domain antibody that optionally contains the amino acid sequence of SEQ ID NO: 33, and optionally has a homologous ligand of caffeine or a derivative thereof. A cannabidiol-binding domain comprising, optionally, an amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 35, 36, 37, and 38, optionally, a homologous ligand being a plant cannabinoid, and optionally, the plant cannabinoid being cannabidiol. A hormone-binding domain of an estrogen receptor (ER) domain, which optionally contains the amino acid sequence of SEQ ID NO: 42, optionally has a homologous ligand that is tamoxifen or a metabolite thereof, and optionally has a tamoxifen metabolite selected from the group consisting of 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen. The heavy chain variable region (VH) of an anti-nicotine antibody, which optionally contains the amino acid sequence of SEQ ID NO: 50 and optionally has a congener ligand of nicotine or a derivative thereof. The light chain variable region (VL) of an anti-nicotine antibody, which optionally contains the amino acid sequence of SEQ ID NO: 51 and optionally has a congener ligand of nicotine or a derivative thereof. A progesterone receptor domain that optionally contains the amino acid sequence of SEQ ID NO: 52, and optionally has a homologous ligand of mifepristone or a derivative thereof. The FKBP domain optionally contains the amino acid sequence of SEQ ID NO: 43, and optionally has a homologous ligand of rapamycin, AP1903, AP20187, FK1012, its derivatives, or analogs, and The molecule optionally contains the amino acid sequence of Sequence ID No. 44, and optionally contains a domain or functional fragment thereof selected from the group consisting of FRB domains whose congener ligands are rapamycin, AP1903, AP20187, FK1012, their derivatives, or analogs.

[0017] In some embodiments, the ligand-binding domain includes degron, which can optionally induce the degradation of controllable cell survival polypeptides, and optionally, degron may include HCV NS4 degron, PEST (two copies of human IκBα residues 277-307), GRR (residues 352-408 of human p105), DRR (residues 210-295 of yeast Cdc34), SNS (tandem repeat of SP2 and NB (SP2-NB-SP2 of influenza A or influenza B)), RPB (four copies of yeast RPB residues 1688-1702), SPmix (tandem repeat of SP1 and SP2) Murepeat (SP2-SP1-SP2-SP1-SP2 of influenza A virus M2 protein), NS2 (three copies of residues 79-93 of influenza A virus NS protein), ODC (residues 106-142 of ornithine decarboxylase), Nek2A, mouse ODC (residues 422-461), mouse ODC_DA (residues 422-461 of mODC containing point mutations D433A and D434A), APC / C Degron, COP1 E3 ligase-conjugated degron motif, CRL4-Cdt2-conjugated PIP degron, actinphylline-conjugated degron, KEAP1-conjugated degron, KLHL2 and KLHL3-conjugated degron, MDM2-conjugated motif, N degron, hydroxyproline modification in hypoxia signaling, plant hormone-dependent SCF-LRR-conjugated degron, SCF ubiquitin ligase-conjugated phosphodegron, plant hormone-dependent SCF-LRR-conjugated degron, SCF ubiquitin ligase-conjugated phosphodegron, plant hormone-dependent SCF-LRR-conjugated degron, DSGxxS phosphate-dependent degron, Siah-conjugated motif, SPOP Selected from the group consisting of an SBC docking motif and a PCNA-binding PIP box, and optionally, deglon contains a cerebron (CRBN) polypeptide substrate domain that can bind to CRBN in response to an immunomodulatory drug (IMiD), thereby promoting the degradation of modulated polypeptides via the ubiquitin pathway, and optionally, the CRBN polypeptide substrate domain is IKZF1, IKZF3, CK1a, ZFP91, GSPT1, MEIS2, GSSSelected from the group consisting of E4F1, ZN276, ZN517, ZN582, ZN653, ZN654, ZN692, ZN787, and ZN827, or a fragment thereof capable of drug-inducible binding to CRBN, optionally, the CRBN polypeptide substrate domain is a chimeric fusion product of a natural CRBN polypeptide sequence, optionally, the CRBN polypeptide substrate domain is an IKZF3 / ZFP91 / IKZF3 chimeric fusion product having the amino acid sequence FNVLMVHKRSHTGERPLQCEICGFTCRQKGNLLRHIKLHTGEKPFKCHLCNYACQRRDAL (SEQ ID NO: 103), optionally, the homologous ligand is IMiD, optionally, IMiD is an FDA-approved drug, and optionally, IMiD is selected from the group consisting of thalidomide, lenalidomide, and pomalidomide.

[0018] In some embodiments, the cell death induction domain includes caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, diphtheria toxin fragment A (DTA), Bax, Bak, Bok, Bad, Bcl-xS, Bak, Bik, Bcl-2-interacting protein 3 (BNIP3), Fas, Fas-related protein with death domain (FADD), tumor necrosis factor receptor 1-associated death domain protein (TRADD), TNF receptor (TNF-R), APAF-1, granzyme B, second mitochondrial-derived activator of caspase (SMAC), Omi, Bmf, Bid, Bim, p53 upregulator of apoptosis (PUMA), Noxa, Blk, Hrk, cytochrome c, Arts, and TNF-associated cell death induction. The proteins are derived from a group selected from the following: a leading ligand (TRAIL), herpes simplex virus thymidine kinase (HSV-TK), varicella-zoster virus thymidine kinase (VZV-TK), viral spike protein, carboxylesterase, cytosine deaminase, nitroreductase Fksb, carboxypeptidase G2, carboxypeptidase A, horseradish peroxidase, linamorase, hepatic cytochrome P450-2B1, and purine nucleoside phosphorylase. Optionally, caspase 9 or its functional cleavage contains the amino acid sequence of SEQ ID NO: 39; optionally, DTA contains the amino acid sequence of SEQ ID NO: 41; and optionally, Bax contains the amino acid sequence of SEQ ID NO: 32.

[0019] In some aspects, this disclosure is, a) A first chimeric polypeptide comprising a first ligand-binding domain and a transcriptional activation domain, b) A second chimeric polypeptide comprising a second ligand-binding domain and a nucleic acid-binding domain We provide activated conditionally controlled polypeptides (ACPs) that include the following: The first and second chimeric polypeptides oligomerize to form a multimer ACP via homologous ligands that bind to each ligand-binding domain. Multimeric ACP can induce transcriptional expression of a gene of interest operably linked to an ACP-responsive promoter, and Optionally, the transcriptional activation domains are selected from the group consisting of: the herpes simplex virus protein 16 (VP16) activation domain; the activation domain containing four tandem copies of VP16; the VP64 activation domain; the p65 activation domain of NFκB; the Epstein-Barr virus R trans-activator (Rta) activation domain; the ternary activator containing the VP64, p65, and Rta activation domains (VPR activation domain); the ternary activator containing the VP64, p65, and HSF1 activation domains (VPH activation domain); and the histone acetyltransferase (HAT) core domain of human E1A-related protein p300 (p300 HAT core activation domain). Optionally, one or more ligand-binding domains may be selected. The ABI domain contains, by any choice, the amino acid sequence of SEQ ID NO: 31, and by any choice, its homologous ligand is abscisic acid. A PYL domain containing the amino acid sequence of SEQ ID NO: 53, optionally, whose homologous ligand is abscisic acid, A caffeine-binding single-domain antibody that optionally contains the amino acid sequence of SEQ ID NO: 33, and optionally has a homologous ligand of caffeine or a derivative thereof. A cannabidiol-binding domain comprising, optionally, an amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 35, 36, 37, and 38, optionally, a homologous ligand being a plant cannabinoid, and optionally, the plant cannabinoid being cannabidiol. A hormone-binding domain of an estrogen receptor (ER) domain, which optionally contains the amino acid sequence of SEQ ID NO: 42, optionally has a homologous ligand that is tamoxifen or a metabolite thereof, and optionally has a tamoxifen metabolite selected from the group consisting of 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen. The heavy chain variable region (VH) of an anti-nicotine antibody, which optionally contains the amino acid sequence of SEQ ID NO: 50 and optionally has a congener ligand of nicotine or a derivative thereof. The light chain variable region (VL) of an anti-nicotine antibody, which optionally contains the amino acid sequence of SEQ ID NO: 51 and optionally has a congener ligand of nicotine or a derivative thereof. A progesterone receptor domain that optionally contains the amino acid sequence of SEQ ID NO: 52, and optionally has a homologous ligand of mifepristone or a derivative thereof. The FKBP domain optionally contains the amino acid sequence of SEQ ID NO: 43, and optionally has a homologous ligand of rapamycin, AP1903, AP20187, FK1012, its derivatives, or analogs, and The molecule optionally contains the amino acid sequence of Sequence ID No. 44, and optionally contains a domain or functional fragment thereof selected from the group consisting of FRB domains whose congener ligand is rapamycin, AP1903, AP20187, FK1012, their derivatives, or analogs. Optionally, the genes of interest are cell death-inducing polypeptides, and optionally, the cell death-inducing domains are caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, diphtheria toxin fragment A (DTA), Bax, Bak, Bok, Bad, Bcl-xS, Bak, Bik, Bcl-2-interacting protein 3 (BNIP3), Fas, Fas-related protein with death domain (FADD), tumor necrosis factor receptor 1-associated death domain protein (TRADD), TNF receptor (TNF-R), APAF-1, granzyme B, second mitochondrial-derived activator of caspase (SMAC), Omi, Bmf, Bid, Bim, p53 upregulator of apoptosis (PUMA), Noxa, Blk, Hrk, cytochrome c, Arts, and TNF-related cell death-inducing rig. The proteins are derived from a group selected from the following: TRAIL, herpes simplex virus thymidine kinase (HSV-TK), varicella-zoster virus thymidine kinase (VZV-TK), viral spike protein, carboxylesterase, cytosine deaminase, nitroreductase Fksb, carboxypeptidase G2, carboxypeptidase A, horseradish peroxidase, linamorase, hepatic cytochrome P450-2B1, and purine nucleoside phosphorylase. Optionally, caspase 9 or its functional cleavage contains the amino acid sequence of SEQ ID NO: 39; optionally, DTA contains the amino acid sequence of SEQ ID NO: 41; optionally, granzyme B contains the amino acid sequence of SEQ ID NO: 47; and optionally, Bax contains the amino acid sequence of SEQ ID NO: 32.

[0020] The ACP according to claim 13, wherein the nucleic acid binding domain comprises a DNA-binding zinc finger protein domain (ZF protein domain), optionally the ZF protein domain being of a modular design and comprising an array of zinc finger motifs, and optionally the ZF protein domain comprising one to ten zinc finger motifs.

[0021] In some embodiments, the chimeric polypeptide further comprises a linker localized between a nucleic acid-binding domain and a transcription effector domain, optionally comprising one or more 2A ribosome skipping tags, optionally each 2A ribosome skipping tag selected from the group consisting of: P2A, T2A, E2A, and F2A.

[0022] In some embodiments, the chimeric polypeptide comprises a first ligand-binding domain operably ligated to a nucleic acid-binding domain and a second ligand-binding domain operably ligated to a transcription effector domain, optionally, Each of the first and second ligand-binding domains contains a hormone-binding domain of the estrogen receptor (ER) domain, and optionally the homologous ligand is tamoxifen or its metabolites, and optionally the tamoxifen metabolites are selected from the group consisting of 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen, or Each of the first and second ligand-binding domains contains a progesterone receptor domain, optionally the homologous ligand is mifepristone or a derivative thereof, optionally the ligand-binding domain contains an ABI domain or a PYL domain, the homologous ligand is abscisic acid, or Each of the first and second ligand-binding domains contains a caffeine-binding single-domain antibody, and optionally, the homologous ligand is caffeine or a derivative thereof, or Each of the first and second ligand-binding domains includes a cannabidiol-binding domain, optionally the homologous ligand is a cannabidiol or a plant cannabinoid, optionally the cannabidiol-binding domain includes a single-domain antibody or a nanobody, and optionally the cannabidiol-binding domain includes an amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 35, 36, 37, and 38.

[0023] In some embodiments, the nucleic acid binding domain binds to an ACP-responsive promoter, optionally the ACP-responsive promoter comprises an ACP-binding domain sequence and a promoter sequence, optionally the promoter sequence comprises a minimal promoter, optionally the promoter sequence is an inducible promoter and further comprises a response element selected from the group consisting of an NFκB response element, a CREB response element, an NFAT response element, an SRF response element 1, an SRF response element 2, an AP1 response element, a TCF-LEF response element promoter fusion, a hypoxia response element, a SMAD binding element, a STAT3 binding site, an inducing molecule response promoter, and its tandem repeat, optionally the ACP-responsive promoter comprises a synthetic promoter, and optionally the ACP-binding domain comprises one or more zinc finger binding sites.

[0024] In some embodiments, the ligand-binding domain is localized to the N-terminus or C-terminus of the transcription effector domain.

[0025] In some embodiments, the disclosure provides isolated cells containing the aforementioned inducible cell death system or ACP.

[0026] In some embodiments, the disclosure provides engineered nucleic acids encoding the aforementioned inducible cell death system or the aforementioned ACP.

[0027] In some embodiments, the Specified Information provides isolated cells comprising an inducible cell death polypeptide comprising two or more monomers, each monomer comprising one or more ligand-binding domains and a cell death induction domain, each of which comprises a domain or functional fragment selected from the group consisting of ABI domains, PYL domains, caffeine-binding single-domain antibodies, cannabidiol-binding domains, hormone-binding domains of estrogen receptor (ER) domains, heavy chain variable regions (VH) of anti-nicotinic antibodies, light chain variable regions (VL) of anti-nicotinic antibodies, progesterone receptor domains, FKBP domains, and FRB domains, each monomer being oligomerizable via a homologous ligand bound to the ligand-binding domain, and when the ligand oligomerizes each monomer, a cell death induction signal is generated in the cell.

[0028] In some embodiments, the cell death induction domain includes caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, diphtheria toxin fragment A (DTA), Bax, Bak, Bok, Bad, Bcl-xS, Bak, Bik, Bcl-2-interacting protein 3 (BNIP3), Fas, Fas-related protein with death domain (FADD), tumor necrosis factor receptor 1-associated death domain protein (TRADD), TNF receptor (TNF-R), APAF-1, granzyme B, caspase second mitochondrial-derived activator (SMAC), Omi, Bmf, Bid, Bim, and p53 upregulation of apoptosis. It is derived from proteins selected from the group consisting of regulatory factor (PUMA), Noxa, Blk, Hrk, cytochrome c, Arts, TNF-related apoptosis-inducing ligand (TRAIL), herpes simplex virus thymidine kinase (HSV-TK), varicella-zoster virus thymidine kinase (VZV-TK), viral spike protein, carboxylesterase, cytosine deaminase, nitroreductase Fksb, carboxypeptidase G2, carboxypeptidase A, horseradish peroxidase, linamorase, hepatic cytochrome P450-2B1, and purine nucleoside phosphorylase.

[0029] In some embodiments, the cell death induction domain includes caspase 9 or a functional cleavage thereof. In some embodiments, the cell death induction domain includes the caspase 9 amino acid sequence shown in Table D.

[0030] In some embodiments, the cell death induction domain includes Bid or a functional cleavage thereof. In some embodiments, the cell death induction domain includes the Bid amino acid sequence shown in Table D.

[0031] In some embodiments, the ABI domain contains the amino acid sequence shown in Table D. In some embodiments, the PYL domain contains the amino acid sequence shown in Table D.

[0032] In some embodiments, the caffeine-conjugated single-domain antibody contains the amino acid sequence shown in Table D.

[0033] In some embodiments, the cannabidiol-binding domain includes an amino acid sequence selected from the group consisting of the sequences CA14, DB6, DB11, DB18, and DB21, as shown in Table D.

[0034] In some embodiments, the hormone-binding domain of the estrogen receptor (ER) domain includes the amino acid sequence shown in Table D.

[0035] In some embodiments, the heavy chain variable region (VH) of the anti-nicotine antibody includes the VH amino acid sequence shown in Table D. In some embodiments, the light chain variable region (VL) of the anti-nicotine antibody includes the VL amino acid sequence shown in Table D.

[0036] In some embodiments, the progesterone receptor domain includes the amino acid sequence shown in Table D.

[0037] In some embodiments, the FKBP domain contains the amino acid sequence shown in Table D.

[0038] In some embodiments, the FRB domain includes the amino acid sequence shown in Table D.

[0039] In some embodiments, each monomer contains the same ligand-binding domain. In some embodiments, the inducible cell death polypeptide contains a homooligomer. In some embodiments, the homooligomer contains a homodimer. In some embodiments, each monomer contains an FKBP domain. In some embodiments, the ligand is FK1012, its derivatives, or analogs.

[0040] In some embodiments, the cell death induction domain includes Bid or a functional cleavage thereof. In some embodiments, the cell death induction domain includes the Bid amino acid sequence shown in Table D.

[0041] In some embodiments, each monomer comprises an ABI domain and a PYL domain. In some embodiments, the ligand is abscisic acid. In some embodiments, the cell death induction domain comprises caspase 9 or a functional cleavage thereof. In some embodiments, the cell death induction comprises the caspase 9 amino acid sequence shown in Table D.

[0042] In some embodiments, each monomer comprises a cannabidiol-binding domain containing the CA14 amino acid sequence of Table D, and a cannabidiol-binding domain containing an amino acid sequence selected from the group consisting of the sequences DB6, DB11, DB18, and DB21 of Table D.

[0043] In some embodiments, each monomer comprises a hormone-binding domain and an FKBP domain of the estrogen receptor (ER) domain. In some embodiments, each monomer comprises an FRB domain and a hormone-binding domain of the estrogen receptor (ER) domain. In some embodiments, the cell death-inducing domain comprises caspase 9 or a functional cleavage thereof. In some embodiments, the cell death-inducing domain comprises the caspase 9 amino acid sequence of Table D. In some embodiments, the ligand is rapamycin, its derivatives, or analogs thereof. In some embodiments, the ligand is tamoxifen or its metabolites. In some embodiments, the tamoxifen metabolites are selected from the group consisting of: 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen.

[0044] In some embodiments, each monomer comprises two caffeine-binding single-domain antibodies. In some embodiments, each caffeine-binding single-domain antibody comprises the amino acid sequence shown in Table D. In some embodiments, the ligand is caffeine or a derivative thereof.

[0045] In some embodiments, the first monomer comprises a first ligand-binding domain, and the second monomer comprises a second ligand-binding domain. In some embodiments, the inducible cell death polypeptide comprises a heterooligomer. In some embodiments, the heterooligomer comprises a heterodimer. In some embodiments, the first monomer comprises an FKBP domain, and the second monomer comprises an FRB domain. In some embodiments, the cell death induction domain comprises Bid or a functional cleavage thereof. In some embodiments, the cell death induction domain comprises the Bid amino acid sequence shown in Table D.

[0046] In some embodiments, the first monomer comprises the hormone-binding domain of the estrogen receptor (ER) domain, and the second monomer comprises the FKBP domain. In some embodiments, the first monomer comprises the FRB domain, and the second monomer comprises the hormone-binding domain of the estrogen receptor (ER) domain. In some embodiments, the first monomer comprises the hormone-binding domain and the FKBP domain of the estrogen receptor (ER) domain, and the second monomer comprises the FRB domain, and the second monomer comprises the hormone-binding domain of the estrogen receptor (ER) domain. In some embodiments, the cell death-inducing domain comprises caspase 9 or a functional cleavage thereof. In some embodiments, the cell death-inducing domain comprises the caspase 9 amino acid sequence shown in Table D. In some embodiments, the ligand is rapamycin, its derivatives, or its analogues. In some embodiments, the ligand is tamoxifen or its metabolites. In some embodiments, the tamoxifen metabolites are selected from the group consisting of: 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen.

[0047] In some embodiments, the first monomer includes an ABI domain, and the second monomer includes a PYL domain. In some embodiments, the ligand is abscisic acid.

[0048] In some embodiments, the first monomer comprises the heavy chain variable region (VH) of the anti-nicotine antibody, and the second monomer comprises the light chain variable region (VL) of the anti-nicotine antibody. In some embodiments, the anti-nicotine antibody is Nic12 antibody. In some embodiments, VH comprises the VH amino acid sequence of Table D. In some embodiments, VL comprises the VL amino acid sequence of Table D. In some embodiments, the ligand is nicotine or a derivative thereof.

[0049] In some embodiments, the first monomer comprises a cannabidiol-binding domain containing an amino acid sequence selected from the group consisting of sequences DB6, DB11, DB18, and DB21 in Table D, and the second monomer comprises a cannabidiol-binding domain containing the amino acid sequence CA14 in Table D. In some embodiments, the ligand is cannabidiol or a plant cannabinoid.

[0050] In some embodiments, each monomer further comprises a linker localized between each ligand-binding domain and a cell death-inducing domain. In some embodiments, the linker comprises an amino acid sequence selected from the group consisting of: GGGGSGGGGSGGGGSVDGF (SEQ ID NO: 85) and ASGGGGSAS (SEQ ID NO: 86).

[0051] Isolated cells containing activated conditionally controlled polypeptides (ACPs) are also disclosed herein, each ACP comprising a transcription factor including one or more ligand-binding domains, as well as a nucleic acid-binding domain and a transcription effector domain, wherein the ACP undergoes nuclear localization upon binding of its ligand-binding domain to a homologous ligand, and upon localization to the cell nucleus, the ACP can induce transcriptional expression of a gene of interest operably linked to an ACP-responsive promoter.

[0052] Furthermore, isolated cells containing a multimeric activated conditionally controlled polypeptide (ACP) are disclosed herein, the multimeric ACP comprising (a) a first chimeric polypeptide comprising a first ligand-binding domain and a transcriptional activation domain, and (b) a second chimeric polypeptide comprising a second ligand-binding domain and a nucleic acid-binding domain, wherein the first and second chimeric polypeptides multimerize to form a multimeric ACP via a congeneral ligand bound to each ligand-binding domain, and the multimeric ACP can induce transcriptional expression of a gene of interest operably linked to an ACP-responsive promoter.

[0053] In some embodiments, each ligand-binding domain includes a domain or functional fragment thereof selected from the group consisting of: an ABI domain, a PYL domain, a caffeine-binding single-domain antibody, a cannabidiol-binding domain, a hormone-binding domain of an estrogen receptor (ER) domain, a heavy chain variable region (VH) of an anti-nicotinic antibody, a light chain variable region (VL) of an anti-nicotinic antibody, a progesterone receptor domain, an FKBP domain, and an FRB domain.

[0054] In some embodiments, the ABI domain includes the ABI amino acid sequence from Table D. In some embodiments, the PYL domain includes the PYL amino acid sequence from Table D. In some embodiments, the caffeine-binding single-domain antibody includes the amino acid sequence from Table D. In some embodiments, the cannabidiol-binding domain includes an amino acid sequence selected from the group consisting of CA14, DB6, DB11, DB18, and DB21 sequences from Table D. In some embodiments, the hormone-binding domain of the estrogen receptor (ER) domain includes the amino acid sequence from Table D. In some embodiments, the heavy chain variable region (VH) of the anti-nicotine antibody includes the VH amino acid sequence from Table D. In some embodiments, the light chain variable region (VL) of the anti-nicotine antibody includes the VL amino acid sequence from Table D. In some embodiments, the progesterone receptor domain includes the amino acid sequence from Table D. In some embodiments, the FKBP domain includes the amino acid sequence from Table D. In some embodiments, the FRB domain includes the amino acid sequence from Table D.

[0055] In some embodiments, the nucleic acid binding domain includes a DNA-binding zinc finger protein domain (ZF protein domain). In some embodiments, the ZF protein domain is a modular design and consists of a zinc finger array (ZFA). In some embodiments, the transcription effector domain includes a herpes simplex virus protein 16 (VP16) activation domain; an activation domain containing four tandem copies of VP16; a VP64 activation domain; a p65 activation domain of NFκB; an Epstein-Barr virus R trans-activator (Rta) activation domain; a ternary activator containing VP64, p65, and Rta activation domains (VPR activation domain); a ternary activator containing VP64, p65, and HSF1 activation domains (VPH activation domain); and a histone acetyltransferase (HAT) core domain of human E1A-related protein p300 (p300). The domains selected are: HAT core activating domain; Kruppel association box (KRAB) repression domain; repressor element silencing transcription factor (REST) ​​repression domain; WRPW motif of hairy-associated basic helix-loop-helix repressor protein, known as the WRPW repression domain; DNA (cytosine-5)-methyltransferase 3B (DNMT3B) repression domain; and HP1 alpha-chromoshadow repression domain.

[0056] In some embodiments, the chimeric polypeptide further comprises a linker localized between the nucleic acid-binding domain and the transcription effector domain. In some embodiments, the linker comprises one or more 2A ribosome skipping tags. In some embodiments, each 2A ribosome skipping tag is selected from the group consisting of: P2A, T2A, E2A, and F2A.

[0057] In some embodiments, the chimeric polypeptide comprises a first ligand-binding domain operably ligated to a nucleic acid-binding domain and a second ligand-binding domain operably ligated to a transcription effector domain.

[0058] In some embodiments, each of the first and second ligand-binding domains includes a hormone-binding domain of the estrogen receptor (ER) domain. In some embodiments, the homologous ligand is tamoxifen or a metabolite thereof. In some embodiments, the tamoxifen metabolite is selected from the group consisting of: 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen.

[0059] In some embodiments, each of the first and second ligand-binding domains includes a progesterone receptor domain. In some embodiments, the homologous ligand is mifepristone or a derivative thereof.

[0060] In some embodiments, when the ligand-binding domain includes an ABI domain or a PYL domain, the homologous ligand is abscisic acid.

[0061] In some embodiments, when the ligand-binding domain includes a caffeine-binding single-domain antibody, the homologous ligand is caffeine or a derivative thereof.

[0062] In some embodiments, when the ligand-binding domain includes a cannabidiol-binding domain, the congener ligand is a cannabidiol or a plant cannabinoid. In some embodiments, the cannabidiol-binding domain includes a single-domain antibody or a nanobody. In some embodiments, the cannabidiol-binding domain includes an amino acid sequence selected from the group consisting of the sequences CA14, DB6, DB11, DB18, and DB21 in Table D.

[0063] In some embodiments, when the ligand-binding domain includes the hormone-binding domain of the estrogen receptor (ER) domain, the homologous ligand is tamoxifen or a metabolite thereof. In some embodiments, the tamoxifen metabolite is selected from the group consisting of: 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen.

[0064] In some embodiments, when the ligand-binding domain includes the heavy chain variable region (VH) or the light chain variable region (VL) of an anti-nicotine antibody, the homologous ligand is nicotine or a derivative thereof.

[0065] In some embodiments, when the ligand-binding domain is a progesterone receptor domain, the homologous ligand is mifepristone or a derivative thereof.

[0066] In some embodiments, when the ligand-binding domain includes an FKBP domain or an FRB domain, the homologous ligand is rapamycin, AP1903, AP20187, FK1012, its derivatives, or analogs.

[0067] In some embodiments, the nucleic acid binding domain includes a DNA-binding zinc finger protein domain (ZF protein domain).

[0068] In some embodiments, the ZF protein domain is a modular design and consists of a zinc finger array (ZFA). In some embodiments, the ZF protein domain contains one to ten ZFAs.

[0069] In some embodiments, the nucleic acid-binding domain binds to an ACP-responsive promoter. In some embodiments, the ACP-responsive promoter includes an ACP-binding domain sequence and a promoter sequence. In some embodiments, the promoter sequence is derived from a promoter selected from the group consisting of: minP, NFkB response element, CREB response element, NFAT response element, SRF response element 1, SRF response element 2, AP1 response element, TCF-LEF response element promoter fusion, hypoxia-responsive element, SMAD-binding element, STAT3 binding site, minCMV, YB_TATA, min_TATA, minTK, inducible molecule-responsive promoter, and their tandem repeats. In some embodiments, the ACP-responsive promoter includes a synthetic promoter. In some embodiments, the ACP-responsive promoter includes a minimal promoter.

[0070] In some embodiments, the ACP-binding domain includes one or more zinc finger binding sites.

[0071] In some embodiments, the transcription effector domain is selected from the group consisting of: herpes simplex virus protein 16 (VP16) activation domain; activation domain containing four tandem copies of VP16; VP64 activation domain; p65 activation domain of NFκB; Epstein-Barr virus R trans-activator (Rta) activation domain; ternary activator containing VP64, p65, and Rta activation domains (VPR activation domain); ternary activator containing VP64, p65, and HSF1 activation domains (VPH activation domain); and histone acetyltransferase (HAT) core domain of human E1A-related protein p300 (p300 HAT core activation domain).

[0072] Isolated cells containing an activated conditionally controlled polypeptide (ACP) are also disclosed herein, the ACP comprising a ligand-binding domain and a transcription effector domain, the ACP can regulate the transcriptional expression of a gene of interest operably linked to an ACP-responsive promoter upon binding of the ligand-binding domain to a congener ligand.

[0073] In some embodiments, the ligand-binding domain is localized to the 5' or 3' of the transcription effector domain. In some embodiments, the transcription effector domain includes a transcription repressor domain. In some embodiments, the transcription repressor domain is selected from the group consisting of: a Kruppel association box (KRAB) repressor domain; a repressor element silencing transcription factor (REST) ​​repressor domain; the WRPW motif of the Hairy-associated basic helix-loop-helix repressor protein, the motif known as the WRPW repressor domain; a DNA (cytosine 5) methyltransferase 3B (DNMT3B) repressor domain; and an HP1 alpha-chromoshadow repressor domain.

[0074] In some embodiments, the transcription effector domain includes a transcription activator domain. In some embodiments, the transcription activator domain is selected from the group consisting of: a herpes simplex virus protein 16 (VP16) activation domain; an activation domain containing four tandem copies of VP16; a VP64 activation domain; a p65 activation domain of NFκB; an Epstein-Barr virus R trans-activator (Rta) activation domain; a ternary activator containing VP64, p65, and Rta activation domains (VPR activation domain); a ternary activator containing VP64, p65, and HSF1 activation domains (VPH activation domain); and a histone acetyltransferase (HAT) core domain of human E1A-related protein p300 (p300 HAT core activation domain).

[0075] In some embodiments, ACP is a transcription factor. In some embodiments, ACP is a zinc finger-containing transcription factor. In some embodiments, the zinc finger-containing transcription factor comprises a DNA-binding zinc finger protein domain (ZF protein domain) and a transcriptional repressor domain or transcriptional activator domain. In some embodiments, the ZF protein domain is a modular design and consists of a zinc finger array (ZFA). In some embodiments, the ZFA contains one to ten ZF motifs.

[0076] In some embodiments, the DNA-binding zinc finger protein domain binds to an ACP-responsive promoter. In some embodiments, the ACP-responsive promoter includes an ACP-binding domain and a promoter sequence. In some embodiments, the promoter sequence is derived from a promoter selected from the group consisting of: minP, NFkB response element, CREB response element, NFAT response element, SRF response element 1, SRF response element 2, AP1 response element, TCF-LEF response element promoter fusion, hypoxia-responsive element, SMAD-binding element, STAT3 binding site, minCMV, YB_TATA, min_TATA, minTK, inducible molecule-responsive promoter, and their tandem repeats. In some embodiments, the ACP-responsive promoter is a synthetic promoter. In some embodiments, the ACP-responsive promoter includes a minimal promoter. In some embodiments, the ACP-binding domain includes one or more zinc finger binding sites.

[0077] In some embodiments, the gene of interest is a cell death-inducing polypeptide.

[0078] In some embodiments, the cell death induction domain includes caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, diphtheria toxin fragment A (DTA), Bax, Bak, Bok, Bad, Bcl-xS, Bak, Bik, Bcl-2-interacting protein 3 (BNIP3), Fas, Fas-related protein with death domain (FADD), tumor necrosis factor receptor 1-associated death domain protein (TRADD), TNF receptor (TNF-R), APAF-1, granzyme B, caspase second mitochondrial-derived activator (SMAC), Omi, Bmf, Bid, Bim, and p53 upregulation of apoptosis. It is derived from proteins selected from the group consisting of regulatory factor (PUMA), Noxa, Blk, Hrk, cytochrome c, Arts, TNF-related apoptosis-inducing ligand (TRAIL), herpes simplex virus thymidine kinase (HSV-TK), varicella-zoster virus thymidine kinase (VZV-TK), viral spike protein, carboxylesterase, cytosine deaminase, nitroreductase Fksb, carboxypeptidase G2, carboxypeptidase A, horseradish peroxidase, linamorase, hepatic cytochrome P450-2B1, and purine nucleoside phosphorylase.

[0079] In some embodiments, the cell death-inducing polypeptide is caspase 9 or a functional cleavage thereof. In some embodiments, the cell death-inducing domain includes the caspase 9 amino acid sequence shown in Table D. In some embodiments, the cell death-inducing polypeptide is diphtheria toxin fragment A (DTA). In some embodiments, the cell death-inducing domain includes the DTA amino acid sequence shown in Table D. In some embodiments, the cell death-inducing polypeptide is granzyme B. In some embodiments, the cell death-inducing domain includes the granzyme B amino acid sequence shown in Table D. In some embodiments, the cell death-inducing polypeptide is Bax. In some embodiments, the cell death-inducing domain includes the Bax amino acid sequence shown in Table D.

[0080] Isolated cells containing controllable cell survival polypeptides and cell death-inducing polypeptides are also disclosed herein, the cell survival polypeptides comprising ligand-binding domains, and when expressed, the cell survival polypeptides can inhibit the cell death-inducing polypeptides, and when bound to a congener ligand, the congener ligand inhibits the survival-promoting polypeptide.

[0081] In some embodiments, the cell survival polypeptide is selected from the group consisting of: XIAP, Bcl-2, Bcl-xL, Bcl-w, Bcl-2-related protein A1 (BCL2A1), Mcl-1, FLICE-like inhibitory protein (c-FLIP), and adenovirus E1B-19K protein. In some embodiments, the cell survival polypeptide is XIAP.

[0082] In some embodiments, the ligand-binding domain is localized to the N-terminal region or the C-terminal region of the survival-promoting polypeptide.

[0083] In some embodiments, the ligand-binding domain includes a domain or functional fragment thereof selected from the group consisting of: an ABI domain, a PYL domain, a caffeine-binding single-domain antibody, a cannabidiol-binding domain, a hormone-binding domain of an estrogen receptor (ER domain), a heavy chain variable region (VH) of an anti-nicotine antibody, a light chain variable region (VL) of an anti-nicotine antibody, an FKBB domain of an anti-nicotine antibody, a progesterone receptor domain, an FKBP domain, and an FRB domain.

[0084] In some embodiments, the ABI domain includes the ABI amino acid sequence from Table D. In some embodiments, the PYL domain includes the PYL amino acid sequence from Table D. In some embodiments, the caffeine-binding single-domain antibody includes the amino acid sequence from Table D. In some embodiments, the cannabidiol-binding domain includes an amino acid sequence selected from the group consisting of CA14, DB6, DB11, DB18, and DB21 sequences from Table D. In some embodiments, the hormone-binding domain of the estrogen receptor (ER) domain includes the amino acid sequence from Table D. In some embodiments, the heavy chain variable region (VH) of the anti-nicotine antibody includes the VH amino acid sequence from Table D. In some embodiments, the light chain variable region (VL) of the anti-nicotine antibody includes the VL amino acid sequence from Table D. In some embodiments, the progesterone receptor domain includes the amino acid sequence from Table D. In some embodiments, the FKBP domain includes the amino acid sequence from Table D. In some embodiments, the FRB domain includes the amino acid sequence from Table D.

[0085] In some embodiments, when the ligand-binding domain includes an ABI domain or a PYL domain, the homologous ligand is abscisic acid.

[0086] In some embodiments, when the ligand-binding domain includes a caffeine-binding single-domain antibody, the homologous ligand is caffeine or a derivative thereof.

[0087] In some embodiments, when the ligand-binding domain includes a cannabidiol-binding domain, the congener ligand is cannabidiol or a plant cannabinoid. In some embodiments, when the ligand-binding domain includes a hormone-binding domain of an estrogen receptor (ER) domain, the congener ligand is tamoxifen or a metabolite thereof. In some embodiments, the tamoxifen metabolite is selected from the group consisting of: 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen.

[0088] In some embodiments, when the ligand-binding domain includes the heavy chain variable region (VH) or the light chain variable region (VL) of an anti-nicotine antibody, the homologous ligand is nicotine or a derivative thereof.

[0089] In some embodiments, when the ligand-binding domain is a progesterone receptor domain, the homologous ligand is mifepristone or a derivative thereof.

[0090] In some embodiments, when the ligand-binding domain includes an FKBP domain or an FRB domain, the homologous ligand is rapamycin, AP1903, AP20187, FK1012, its derivatives, or analogs.

[0091] In some embodiments, the ligand-binding domain includes degron. In some embodiments, degron can induce the degradation of controllable cell survival polypeptides. In some embodiments, degron includes HCV NS4 degron, PEST (two copies of human IκBα residues 277-307), GRR (residues 352-408 of human p105), DRR (residues 210-295 of yeast Cdc34), SNS (tandem repeat of SP2 and NB (SP2-NB-SP2 of influenza A or influenza B)), RPB (four copies of yeast RPB residues 1688-1702), SPmix (tandem repeat of SP1 and SP2) Murepeat (SP2-SP1-SP2-SP1-SP2 of influenza A virus M2 protein), NS2 (three copies of residues 79-93 of influenza A virus NS protein), ODC (residues 106-142 of ornithine decarboxylase), Nek2A, mouse ODC (residues 422-461), mouse ODC_DA (residues 422-461 of mODC containing point mutations D433A and D434A), APC / C The group consists of degron, COP1 E3 ligase-conjugated degron motif, CRL4-Cdt2-conjugated PIP degron, actinphylline-conjugated degron, KEAP1-conjugated degron, KLHL2 and KLHL3-conjugated degron, MDM2-conjugated motif, N degron, hydroxyproline modification in hypoxia signaling, plant hormone-dependent SCF-LRR-conjugated degron, SCF ubiquitin ligase-conjugated phosphodegron, plant hormone-dependent SCF-LRR-conjugated degron, SCF ubiquitin ligase-conjugated phosphodegron, plant hormone-dependent SCF-LRR-conjugated degron, DSGxxS phosphate-dependent degron, Siah-conjugated motif, SPOP SBC docking motif, and PCNA-conjugated PIP box. In some embodiments, degron comprises a cerebron (CRBN) polypeptide substrate domain that can bind to CRBN in response to an immunomodulatory drug (IMiD), thereby promoting the degradation of modulated polypeptides via the ubiquitin pathway.In some embodiments, the CRBN polypeptide substrate domain is selected from the group consisting of IKZF1, IKZF3, CK1a, ZFP91, GSPT1, MEIS2, GSS E4F1, ZN276, ZN517, ZN582, ZN653, ZN654, ZN692, ZN787, and ZN827, or is a fragment thereof capable of drug-inducible binding to CRBN. In some embodiments, the CRBN polypeptide substrate domain is a chimeric fusion product of a native CRBN polypeptide sequence. In some embodiments, the CRBN polypeptide substrate domain is an IKZF3 / ZFP91 / IKZF3 chimeric fusion product having the amino acid sequence FNVLMVHKRSHTGERPLQCEICGFTCRQKGNLLRHIKLHTGEKPFKCHLCNYACQRRDAL (SEQ ID NO: 87).

[0092] In some embodiments, the ligand is an IMiD. In some embodiments, the IMiD is an FDA-approved drug. In some embodiments, the IMiD is selected from the group consisting of: thalidomide, lenalidomide, and pomalidomide.

[0093] In some embodiments, the cell death induction domain includes caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, diphtheria toxin fragment A (DTA), Bax, Bak, Bok, Bad, Bcl-xS, Bak, Bik, Bcl-2-interacting protein 3 (BNIP3), Fas, Fas-related protein with death domain (FADD), tumor necrosis factor receptor 1-associated death domain protein (TRADD), TNF receptor (TNF-R), APAF-1, granzyme B, caspase second mitochondrial-derived activator (SMAC), Omi, Bmf, Bid, Bim, and p53 upregulation of apoptosis. It is derived from proteins selected from the group consisting of regulatory factor (PUMA), Noxa, Blk, Hrk, cytochrome c, Arts, TNF-related apoptosis-inducing ligand (TRAIL), herpes simplex virus thymidine kinase (HSV-TK), varicella-zoster virus thymidine kinase (VZV-TK), viral spike protein, carboxylesterase, cytosine deaminase, nitroreductase Fksb, carboxypeptidase G2, carboxypeptidase A, horseradish peroxidase, linamorase, hepatic cytochrome P450-2B1, and purine nucleoside phosphorylase.

[0094] In some embodiments, the cell death-inducing polypeptide is caspase 9 or a functional cleavage thereof. In some embodiments, the cell death-inducing domain comprises the caspase 9 amino acid sequence shown in Table D.

[0095] In some embodiments, the cell death-inducing polypeptide is diphtheria toxin fragment A (DTA). In some embodiments, the cell death-inducing domain contains the DTA amino acid sequence shown in Table D.

[0096] In some embodiments, the cell death-inducing polypeptide is Bax. In some embodiments, the cell death-inducing domain contains the Bax amino acid sequence shown in Table D.

[0097] Furthermore, this specification provides an engineered nucleic acid comprising an expression cassette comprising a promoter and an exogenous polynucleotide sequence encoding an inducible cell death polypeptide monomer, wherein the promoter is operably linked to the exogenous polynucleotide, and the inducible cell death polypeptide monomer comprises one or more ligand-binding domains and a cell death induction domain, each of which comprises a domain or functional fragment selected from the group consisting of an ABI domain, a PYL domain, a caffeine-binding single-domain antibody, a cannabidiol-binding domain, a hormone-binding domain of an estrogen receptor (ER) domain, a heavy chain variable region (VH) of an anti-nicotinic antibody, a light chain variable region (VL) of an anti-nicotinic antibody, a progesterone receptor domain, an FKBP domain, and an FRB domain, wherein when expressed, the cell death polypeptide monomer is oligomerizable via a homologous ligand bound to the ligand-binding domain, and when the ligand oligomerizes two or more cell death polypeptide monomers, a cell death induction signal is generated intracellularly.

[0098] In some embodiments, the cell death induction domain includes caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, diphtheria toxin fragment A (DTA), Bax, Bak, Bok, Bad, Bcl-xS, Bak, Bik, Bcl-2-interacting protein 3 (BNIP3), Fas, Fas-related protein with death domain (FADD), tumor necrosis factor receptor 1-associated death domain protein (TRADD), TNF receptor (TNF-R), APAF-1, granzyme B, caspase second mitochondrial-derived activator (SMAC), Omi, Bmf, Bid, Bim, and p53 upregulation of apoptosis. It is derived from proteins selected from the group consisting of regulatory factor (PUMA), Noxa, Blk, Hrk, cytochrome c, Arts, TNF-related apoptosis-inducing ligand (TRAIL), herpes simplex virus thymidine kinase (HSV-TK), varicella-zoster virus thymidine kinase (VZV-TK), viral spike protein, carboxylesterase, cytosine deaminase, nitroreductase Fksb, carboxypeptidase G2, carboxypeptidase A, horseradish peroxidase, linamorase, hepatic cytochrome P450-2B1, and purine nucleoside phosphorylase.

[0099] In some embodiments, the cell death induction domain includes caspase 9 or a functional cleavage thereof. In some embodiments, the cell death induction domain includes the caspase 9 amino acid sequence shown in Table D.

[0100] In some embodiments, the cell death induction domain includes Bid or a functional cleavage thereof. In some embodiments, the cell death induction domain includes the Bid amino acid sequence shown in Table D.

[0101] In some embodiments, the ABI domain contains the amino acid sequence shown in Table D. In some embodiments, the PYL domain contains the amino acid sequence shown in Table D.

[0102] In some embodiments, the caffeine-conjugated single-domain antibody contains the amino acid sequence shown in Table D.

[0103] In some embodiments, the cannabidiol-binding domain includes an amino acid sequence selected from the group consisting of the sequences CA14, DB6, DB11, DB18, and DB21, as shown in Table D.

[0104] In some embodiments, the hormone-binding domain of the estrogen receptor (ER) domain includes the amino acid sequence shown in Table D.

[0105] In some embodiments, the heavy chain variable region (VH) of the anti-nicotine antibody includes the VH amino acid sequence shown in Table D. In some embodiments, the light chain variable region (VL) of the anti-nicotine antibody includes the VL amino acid sequence shown in Table D.

[0106] In some embodiments, the progesterone receptor domain includes the amino acid sequence shown in Table D.

[0107] In some embodiments, the FKBP domain contains the amino acid sequence shown in Table D.

[0108] In some embodiments, the FRB domain includes the amino acid sequence shown in Table D.

[0109] In some embodiments, each monomer contains the same ligand-binding domain. In some embodiments, the inducible cell death polypeptide contains a homooligomer. In some embodiments, the homooligomer contains a homodimer. In some embodiments, each monomer contains an FKBP domain. In some embodiments, the ligand is FK1012, its derivatives, or analogs.

[0110] In some embodiments, the cell death induction domain includes Bid or a functional cleavage thereof. In some embodiments, the cell death induction domain includes the Bid amino acid sequence shown in Table D.

[0111] In some embodiments, each monomer comprises an ABI domain and a PYL domain. In some embodiments, the ligand is abscisic acid. In some embodiments, the cell death induction domain comprises caspase 9 or a functional cleavage thereof. In some embodiments, the cell death induction domain comprises the caspase 9 amino acid sequence shown in Table D.

[0112] In some embodiments, each monomer comprises a cannabidiol-binding domain containing the CA14 amino acid sequence of Table D, and a cannabidiol-binding domain containing an amino acid sequence selected from the group consisting of the sequences DB6, DB11, DB18, and DB21 of Table D.

[0113] In some embodiments, each monomer comprises a hormone-binding domain and an FKBP domain of the estrogen receptor (ER) domain. In some embodiments, each monomer comprises an FRB domain and a hormone-binding domain of the estrogen receptor (ER) domain. In some embodiments, the cell death-inducing domain comprises caspase 9 or a functional cleavage thereof. In some embodiments, the cell death-inducing domain comprises the caspase 9 amino acid sequence of Table D. In some embodiments, the ligand is rapamycin, its derivatives, or analogs thereof. In some embodiments, the ligand is tamoxifen or its metabolites. In some embodiments, the tamoxifen metabolites are selected from the group consisting of: 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen.

[0114] In some embodiments, each monomer comprises two caffeine-binding single-domain antibodies. In some embodiments, each caffeine-binding single-domain antibody comprises the amino acid sequence shown in Table D. In some embodiments, the ligand is caffeine or a derivative thereof.

[0115] In some embodiments, the first monomer comprises a first ligand-binding domain, and the second monomer comprises a second ligand-binding domain. In some embodiments, the inducible cell death polypeptide comprises a heterooligomer. In some embodiments, the heterooligomer comprises a heterodimer. In some embodiments, the first monomer comprises an FKBP domain, and the second monomer comprises an FRB domain. In some embodiments, the cell death induction domain comprises Bid or a functional cleavage thereof. In some embodiments, the cell death induction domain comprises the Bid amino acid sequence shown in Table D.

[0116] In some embodiments, the first monomer comprises the hormone-binding domain of the estrogen receptor (ER) domain, and the second monomer comprises the FKBP domain. In some embodiments, the first monomer comprises the FRB domain, and the second monomer comprises the hormone-binding domain of the estrogen receptor (ER) domain. In some embodiments, the first monomer comprises the hormone-binding domain and the FKBP domain of the estrogen receptor (ER) domain, and the second monomer comprises the FRB domain, and the second monomer comprises the hormone-binding domain of the estrogen receptor (ER) domain. In some embodiments, the cell death-inducing domain comprises caspase 9 or a functional cleavage thereof. In some embodiments, the cell death-inducing domain comprises the caspase 9 amino acid sequence shown in Table D. In some embodiments, the ligand is rapamycin, its derivatives, or its analogues. In some embodiments, the ligand is tamoxifen or its metabolites. In some embodiments, the tamoxifen metabolites are selected from the group consisting of: 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen.

[0117] In some embodiments, the first monomer includes an ABI domain, and the second monomer includes a PYL domain. In some embodiments, the ligand is abscisic acid.

[0118] In some embodiments, the first monomer comprises the heavy chain variable region (VH) of the anti-nicotine antibody, and the second monomer comprises the light chain variable region (VL) of the anti-nicotine antibody. In some embodiments, the anti-nicotine antibody is Nic12 antibody. In some embodiments, VH comprises the VH amino acid sequence of Table D. In some embodiments, VL comprises the VL amino acid sequence of Table D. In some embodiments, the ligand is nicotine or a derivative thereof.

[0119] In some embodiments, the first monomer comprises a cannabidiol-binding domain containing an amino acid sequence selected from the group consisting of sequences DB6, DB11, DB18, and DB21 in Table D, and the second monomer comprises a cannabidiol-binding domain containing the amino acid sequence CA14 in Table D. In some embodiments, the ligand is cannabidiol or a plant cannabinoid.

[0120] In some embodiments, each monomer further comprises a linker localized between each ligand-binding domain and a cell death-inducing domain. In some embodiments, the linker comprises an amino acid sequence selected from the group consisting of: GGGGSGGGGSGGGGSVDGF (SEQ ID NO: 88) and ASGGGGSAS (SEQ ID NO: 89).

[0121] Engineered nucleic acids comprising an expression cassette containing an exogenous polynucleotide sequence encoding a promoter and an activated conditionally controlled polypeptide (ACP) are also disclosed herein, the ACP comprising one or more ligand-binding domains, and a transcription factor comprising a nucleic acid-binding domain and a transcription effector domain, wherein when expressed, the ACP undergoes nuclear localization upon binding of its ligand-binding domain to a homologous ligand, and when localized to the cell nucleus, the ACP can induce transcriptional expression of a gene of interest operably linked to an ACP-responsive promoter.

[0122] In some embodiments, each ligand-binding domain includes a domain or functional fragment thereof selected from the group consisting of: an ABI domain, a PYL domain, a caffeine-binding single-domain antibody, a cannabidiol-binding domain, a hormone-binding domain of an estrogen receptor (ER) domain, a heavy chain variable region (VH) of an anti-nicotinic antibody, a light chain variable region (VL) of an anti-nicotinic antibody, a progesterone receptor domain, an FKBP domain, and an FRB domain.

[0123] In some embodiments, the ABI domain includes the ABI amino acid sequence from Table D. In some embodiments, the PYL domain includes the PYL amino acid sequence from Table D. In some embodiments, the caffeine-binding single-domain antibody includes the amino acid sequence from Table D. In some embodiments, the cannabidiol-binding domain includes an amino acid sequence selected from the group consisting of CA14, DB6, DB11, DB18, and DB21 sequences from Table D. In some embodiments, the hormone-binding domain of the estrogen receptor (ER) domain includes the amino acid sequence from Table D. In some embodiments, the heavy chain variable region (VH) of the anti-nicotine antibody includes the VH amino acid sequence from Table D. In some embodiments, the light chain variable region (VL) of the anti-nicotine antibody includes the VL amino acid sequence from Table D. In some embodiments, the progesterone receptor domain includes the amino acid sequence from Table D. In some embodiments, the FKBP domain includes the amino acid sequence from Table D. In some embodiments, the FRB domain includes the amino acid sequence from Table D.

[0124] In some embodiments, the nucleic acid binding domain includes a DNA-binding zinc finger protein domain (ZF protein domain). In some embodiments, the ZF protein domain is a modular design and consists of a zinc finger array (ZFA). In some embodiments, the transcription effector domain includes a herpes simplex virus protein 16 (VP16) activation domain; an activation domain containing four tandem copies of VP16; a VP64 activation domain; a p65 activation domain of NFκB; an Epstein-Barr virus R trans-activator (Rta) activation domain; a ternary activator containing VP64, p65, and Rta activation domains (VPR activation domain); a ternary activator containing VP64, p65, and HSF1 activation domains (VPH activation domain); and a histone acetyltransferase (HAT) core domain of human E1A-related protein p300 (p300). The domains selected are: HAT core activating domain; Kruppel association box (KRAB) repression domain; repressor element silencing transcription factor (REST) ​​repression domain; WRPW motif of hairy-associated basic helix-loop-helix repressor protein, known as the WRPW repression domain; DNA (cytosine-5)-methyltransferase 3B (DNMT3B) repression domain; and HP1 alpha-chromoshadow repression domain.

[0125] In some embodiments, the chimeric polypeptide further comprises a linker localized between the nucleic acid-binding domain and the transcription effector domain. In some embodiments, the linker comprises one or more 2A ribosome skipping tags. In some embodiments, each 2A ribosome skipping tag is selected from the group consisting of: P2A, T2A, E2A, and F2A.

[0126] In some embodiments, the chimeric polypeptide comprises a first ligand-binding domain operably ligated to a nucleic acid-binding domain and a second ligand-binding domain operably ligated to a transcription effector domain.

[0127] In some embodiments, each of the first and second ligand-binding domains includes a hormone-binding domain of the estrogen receptor (ER) domain. In some embodiments, the homologous ligand is tamoxifen or a metabolite thereof. In some embodiments, the tamoxifen metabolite is selected from the group consisting of: 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen.

[0128] In some embodiments, each of the first and second ligand-binding domains includes a progesterone receptor domain. In some embodiments, the homologous ligand is mifepristone or a derivative thereof.

[0129] In some embodiments, when the ligand-binding domain includes an ABI domain or a PYL domain, the homologous ligand is abscisic acid.

[0130] In some embodiments, when the ligand-binding domain includes a caffeine-binding single-domain antibody, the homologous ligand is caffeine or a derivative thereof.

[0131] In some embodiments, when the ligand-binding domain includes a cannabidiol-binding domain, the congener ligand is a cannabidiol or a plant cannabinoid. In some embodiments, the cannabidiol-binding domain includes a single-domain antibody or a nanobody. In some embodiments, the cannabidiol-binding domain includes an amino acid sequence selected from the group consisting of the sequences CA14, DB6, DB11, DB18, and DB21 in Table D.

[0132] In some embodiments, when the ligand-binding domain includes the hormone-binding domain of the estrogen receptor (ER) domain, the homologous ligand is tamoxifen or a metabolite thereof. In some embodiments, the tamoxifen metabolite is selected from the group consisting of: 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen.

[0133] In some embodiments, when the ligand-binding domain includes the heavy chain variable region (VH) or the light chain variable region (VL) of an anti-nicotine antibody, the homologous ligand is nicotine or a derivative thereof.

[0134] In some embodiments, when the ligand-binding domain is a progesterone receptor domain, the homologous ligand is mifepristone or a derivative thereof.

[0135] In some embodiments, when the ligand-binding domain includes an FKBP domain or an FRB domain, the homologous ligand is rapamycin, AP1903, AP20187, FK1012, its derivatives, or analogs.

[0136] In some embodiments, the nucleic acid binding domain includes a DNA-binding zinc finger protein domain (ZF protein domain).

[0137] In some embodiments, the ZF protein domain is a modular design and consists of a zinc finger array (ZFA). In some embodiments, the ZF protein domain contains one to ten ZFAs.

[0138] In some embodiments, the nucleic acid-binding domain binds to an ACP-responsive promoter. In some embodiments, the ACP-responsive promoter includes an ACP-binding domain sequence and a promoter sequence. In some embodiments, the promoter sequence is derived from a promoter selected from the group consisting of: minP, NFkB response element, CREB response element, NFAT response element, SRF response element 1, SRF response element 2, AP1 response element, TCF-LEF response element promoter fusion, hypoxia-responsive element, SMAD-binding element, STAT3 binding site, minCMV, YB_TATA, min_TATA, minTK, inducible molecule-responsive promoter, and their tandem repeats. In some embodiments, the ACP-responsive promoter includes a synthetic promoter. In some embodiments, the ACP-responsive promoter includes a minimal promoter.

[0139] In some embodiments, the ACP-binding domain includes one or more zinc finger binding sites.

[0140] In some embodiments, the transcription activator domain is selected from the group consisting of: herpes simplex virus protein 16 (VP16) activation domain; activation domain containing four tandem copies of VP16; VP64 activation domain; p65 activation domain of NFκB; Epstein-Barr virus R trans-activator (Rta) activation domain; ternary activator containing VP64, p65, and Rta activation domains (VPR activation domain); ternary activator containing VP64, p65, and HSF1 activation domains (VPH activation domain); and the histone acetyltransferase (HAT) core domain of human E1A-related protein p300 (p300 HAT core activation domain).

[0141] An engineered nucleic acid comprising an expression cassette comprising a promoter and an exogenous polynucleotide having formula:C1-L-C2, wherein C1 comprises a polynucleotide sequence encoding a first chimeric polypeptide comprising a first ligand-binding domain and a transcriptional activation domain, L comprises a linker polynucleotide sequence, and C2 comprises a polynucleotide sequence encoding a second chimeric polypeptide comprising a second ligand-binding domain and a nucleic acid-binding domain, wherein the promoter is operably ligated to the exogenous polynucleotide, and when expressed, the first and second chimeric polypeptides multimerize to form an activated conditionally controlled polypeptide (ACP) via a congenital ligand that binds to each ligand-binding domain, and the multimerized ACP can induce transcriptional expression of a gene of interest operably ligated to an ACP-responsive promoter.

[0142] In some embodiments, each ligand-binding domain includes a domain or functional fragment thereof selected from the group consisting of: an ABI domain, a PYL domain, a caffeine-binding single-domain antibody, a cannabidiol-binding domain, a hormone-binding domain of an estrogen receptor (ER) domain, a heavy chain variable region (VH) of an anti-nicotinic antibody, a light chain variable region (VL) of an anti-nicotinic antibody, a progesterone receptor domain, an FKBP domain, and an FRB domain.

[0143] In some embodiments, the ABI domain includes the ABI amino acid sequence from Table D. In some embodiments, the PYL domain includes the PYL amino acid sequence from Table D. In some embodiments, the caffeine-binding single-domain antibody includes the amino acid sequence from Table D. In some embodiments, the cannabidiol-binding domain includes an amino acid sequence selected from the group consisting of CA14, DB6, DB11, DB18, and DB21 sequences from Table D. In some embodiments, the hormone-binding domain of the estrogen receptor (ER) domain includes the amino acid sequence from Table D. In some embodiments, the heavy chain variable region (VH) of the anti-nicotine antibody includes the VH amino acid sequence from Table D. In some embodiments, the light chain variable region (VL) of the anti-nicotine antibody includes the VL amino acid sequence from Table D. In some embodiments, the progesterone receptor domain includes the amino acid sequence from Table D. In some embodiments, the FKBP domain includes the FKBP amino acid sequence from Table D. In some embodiments, the FRB domain includes the FRB amino acid sequence from Table D.

[0144] In some embodiments, the nucleic acid binding domain includes a DNA-binding zinc finger protein domain (ZF protein domain). In some embodiments, the ZF protein domain is a modular design and consists of a zinc finger array (ZFA). In some embodiments, the transcription effector domain includes a herpes simplex virus protein 16 (VP16) activation domain; an activation domain containing four tandem copies of VP16; a VP64 activation domain; a p65 activation domain of NFκB; an Epstein-Barr virus R trans-activator (Rta) activation domain; a ternary activator containing VP64, p65, and Rta activation domains (VPR activation domain); a ternary activator containing VP64, p65, and HSF1 activation domains (VPH activation domain); and a histone acetyltransferase (HAT) core domain of human E1A-related protein p300 (p300). The domains selected are: HAT core activating domain; Kruppel association box (KRAB) repression domain; repressor element silencing transcription factor (REST) ​​repression domain; WRPW motif of hairy-associated basic helix-loop-helix repressor protein, known as the WRPW repression domain; DNA (cytosine-5)-methyltransferase 3B (DNMT3B) repression domain; and HP1 alpha-chromoshadow repression domain.

[0145] In some embodiments, the chimeric polypeptide further comprises a linker localized between the nucleic acid-binding domain and the transcription effector domain. In some embodiments, the linker comprises one or more 2A ribosome skipping tags. In some embodiments, each 2A ribosome skipping tag is selected from the group consisting of: P2A, T2A, E2A, and F2A.

[0146] In some embodiments, the chimeric polypeptide comprises a first ligand-binding domain operably ligated to a nucleic acid-binding domain and a second ligand-binding domain operably ligated to a transcription effector domain.

[0147] In some embodiments, each of the first and second ligand-binding domains includes a hormone-binding domain of the estrogen receptor (ER) domain. In some embodiments, the homologous ligand is tamoxifen or a metabolite thereof. In some embodiments, the tamoxifen metabolite is selected from the group consisting of: 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen.

[0148] In some embodiments, each of the first and second ligand-binding domains includes a progesterone receptor domain.

[0149] In some embodiments, the homologous ligand is mifepristone or a derivative thereof.

[0150] In some embodiments, when the ligand-binding domain includes an ABI domain or a PYL domain, the homologous ligand is abscisic acid.

[0151] In some embodiments, when the ligand-binding domain includes a caffeine-binding single-domain antibody, the homologous ligand is caffeine or a derivative thereof.

[0152] In some embodiments, when the ligand-binding domain includes a cannabidiol-binding domain, the congener ligand is a cannabidiol or a plant cannabinoid. In some embodiments, the cannabidiol-binding domain includes a single-domain antibody or a nanobody. In some embodiments, the cannabidiol-binding domain includes an amino acid sequence selected from the group consisting of the sequences CA14, DB6, DB11, DB18, and DB21 in Table D.

[0153] In some embodiments, when the ligand-binding domain includes the hormone-binding domain of the estrogen receptor (ER) domain, the homologous ligand is tamoxifen or a metabolite thereof. In some embodiments, the tamoxifen metabolite is selected from the group consisting of: 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen.

[0154] In some embodiments, when the ligand-binding domain includes the heavy chain variable region (VH) or the light chain variable region (VL) of an anti-nicotine antibody, the homologous ligand is nicotine or a derivative thereof.

[0155] In some embodiments, when the ligand-binding domain is a progesterone receptor domain, the homologous ligand is mifepristone or a derivative thereof.

[0156] In some embodiments, when the ligand-binding domain includes an FKBP domain or an FRB domain, the homologous ligand is rapamycin, AP1903, AP20187, FK1012, its derivatives, or analogs.

[0157] In some embodiments, the nucleic acid-binding domain includes a DNA-binding zinc finger protein domain (ZF protein domain). In some embodiments, the ZF protein domain is a modular design and consists of a zinc finger array (ZFA). In some embodiments, the ZF protein domain contains one to ten ZFAs.

[0158] In some embodiments, the nucleic acid-binding domain binds to an ACP-responsive promoter. In some embodiments, the ACP-responsive promoter includes an ACP-binding domain sequence and a promoter sequence. In some embodiments, the promoter sequence is derived from a promoter selected from the group consisting of: minP, NFkB response element, CREB response element, NFAT response element, SRF response element 1, SRF response element 2, AP1 response element, TCF-LEF response element promoter fusion, hypoxia-responsive element, SMAD-binding element, STAT3 binding site, minCMV, YB_TATA, min_TATA, minTK, inducible molecule-responsive promoter, and their tandem repeats. In some embodiments, the ACP-responsive promoter includes a synthetic promoter. In some embodiments, the ACP-responsive promoter includes a minimal promoter. In some embodiments, the ACP-binding domain includes one or more zinc finger binding sites. In some embodiments, the transcription activator domain is selected from the group consisting of: herpes simplex virus protein 16 (VP16) activation domain; activation domain containing four tandem copies of VP16; VP64 activation domain; p65 activation domain of NFκB; Epstein-Barr virus R trans-activator (Rta) activation domain; ternary activator containing VP64, p65, and Rta activation domains (VPR activation domain); ternary activator containing VP64, p65, and HSF1 activation domains (VPH activation domain); and the histone acetyltransferase (HAT) core domain of human E1A-related protein p300 (p300 HAT core activation domain).

[0159] In some embodiments, the linker polynucleotide sequence is operably associated with the translation of each chimeric polypeptide as a distinct polypeptide. In some embodiments, the linker polynucleotide sequence encodes a 2A ribosome skipping tag. In some embodiments, the 2A ribosome skipping tag is selected from the group consisting of: P2A, T2A, E2A, and F2A. In some embodiments, the linker polynucleotide sequence encodes an intra-sequence ribosome entry site (IRES). In some embodiments, the linker polynucleotide sequence encodes a cleavable polypeptide. In some embodiments, the cleavable polypeptide includes a furin-recognizing polypeptide sequence.

[0160] Engineered nucleic acids comprising an expression cassette containing an exogenous polynucleotide sequence encoding an activated conditionally controlled polypeptide (ACP) including a promoter, a ligand-binding domain, and a transcription effector domain, wherein the promoter is operably ligated to the exogenous polynucleotide, and upon expression and binding of the ligand-binding domain to a homologous ligand, the ACP can regulate the transcriptional expression of a gene of interest operably ligated to the ACP-responsive promoter.

[0161] Engineered nucleic acids comprising an expression cassette containing an exogenous polynucleotide encoding a controllable cell survival polypeptide including a promoter and a ligand-binding domain are also disclosed herein, wherein the promoter is operably ligated to the exogenous polynucleotide, and when expressed, the cell survival polypeptide can inhibit the cell death-inducing polypeptide, and when bound to a congenital ligand, the congenital ligand inhibits the survival-promoting polypeptide.

[0162] In some embodiments, the cell survival polypeptide is selected from the group consisting of: XIAP, Bcl-2, Bcl-xL, Bcl-w, Bcl-2-related protein A1 (BCL2A1), Mcl-1, FLICE-like inhibitory protein (c-FLIP), and adenovirus E1B-19K protein. In some embodiments, the cell survival polypeptide is XIAP.

[0163] In some embodiments, the ligand-binding domain is localized to the N-terminal region or the C-terminal region of the survival-promoting polypeptide.

[0164] In some embodiments, the ligand-binding domain includes a domain or functional fragment thereof selected from the group consisting of: an ABI domain, a PYL domain, a caffeine-binding single-domain antibody, a cannabidiol-binding domain, a hormone-binding domain of an estrogen receptor (ER domain), a heavy chain variable region (VH) of an anti-nicotine antibody, a light chain variable region (VL) of an anti-nicotine antibody, an FKBB domain of an anti-nicotine antibody, a progesterone receptor domain, an FKBP domain, and an FRB domain.

[0165] In some embodiments, the ABI domain includes the ABI amino acid sequence from Table D. In some embodiments, the PYL domain includes the PYL amino acid sequence from Table D. In some embodiments, the caffeine-binding single-domain antibody includes the amino acid sequence from Table D. In some embodiments, the cannabidiol-binding domain includes an amino acid sequence selected from the group consisting of CA14, DB6, DB11, DB18, and DB21 sequences from Table D. In some embodiments, the hormone-binding domain of the estrogen receptor (ER) domain includes the amino acid sequence from Table D. In some embodiments, the heavy chain variable region (VH) of the anti-nicotine antibody includes the VH amino acid sequence from Table D. In some embodiments, the light chain variable region (VL) of the anti-nicotine antibody includes the VL amino acid sequence from Table D. In some embodiments, the progesterone receptor domain includes the amino acid sequence from Table D. In some embodiments, the FKBP domain includes the amino acid sequence from Table D. In some embodiments, the FRB domain includes the amino acid sequence from Table D.

[0166] In some embodiments, when the ligand-binding domain includes an ABI domain or a PYL domain, the homologous ligand is abscisic acid.

[0167] In some embodiments, when the ligand-binding domain includes a caffeine-binding single-domain antibody, the homologous ligand is caffeine or a derivative thereof.

[0168] In some embodiments, when the ligand-binding domain includes a cannabidiol-binding domain, the congener ligand is cannabidiol or a plant cannabinoid. In some embodiments, when the ligand-binding domain includes a hormone-binding domain of an estrogen receptor (ER) domain, the congener ligand is tamoxifen or a metabolite thereof. In some embodiments, the tamoxifen metabolite is selected from the group consisting of: 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen.

[0169] In some embodiments, when the ligand-binding domain includes the heavy chain variable region (VH) or the light chain variable region (VL) of an anti-nicotine antibody, the homologous ligand is nicotine or a derivative thereof.

[0170] In some embodiments, when the ligand-binding domain is a progesterone receptor domain, the homologous ligand is mifepristone or a derivative thereof.

[0171] In some embodiments, when the ligand-binding domain includes an FKBP domain or an FRB domain, the homologous ligand is rapamycin, AP1903, AP20187, FK1012, its derivatives, or analogs.

[0172] In some embodiments, the ligand-binding domain includes degron. In some embodiments, degron can induce the degradation of controllable cell survival polypeptides. In some embodiments, degron includes HCV NS4 degron, PEST (two copies of human κBα residues 277-307), GRR (residues 352-408 of human p105), DRR (residues 210-295 of yeast Cdc34), SNS (tandem repeat of SP2 and NB (SP2-NB-SP2 of influenza A or influenza B)), RPB (four copies of yeast RPB residues 1688-1702), SPmix (tandem repeat of SP1 and SP2) Repeat (SP2-SP1-SP2-SP1-SP2 of influenza A virus M2 protein), NS2 (three copies of residues 79-93 of influenza A virus NS protein), ODC (residues 106-142 of ornithine decarboxylase), Nek2A, mouse ODC (residues 422-461), mouse ODC_DA (residues 422-461 of mODC including point mutations D433A and D434A), APC / C The group consists of degron, COP1 E3 ligase-conjugated degron motif, CRL4-Cdt2-conjugated PIP degron, actinphylline-conjugated degron, KEAP1-conjugated degron, KLHL2 and KLHL3-conjugated degron, MDM2-conjugated motif, N degron, hydroxyproline modification in hypoxia signaling, plant hormone-dependent SCF-LRR-conjugated degron, SCF ubiquitin ligase-conjugated phosphodegron, plant hormone-dependent SCF-LRR-conjugated degron, SCF ubiquitin ligase-conjugated phosphodegron, plant hormone-dependent SCF-LRR-conjugated degron, DSGxxS phosphate-dependent degron, Siah-conjugated motif, SPOP SBC docking motif, and PCNA-conjugated PIP box. In some embodiments, degron comprises a cerebron (CRBN) polypeptide substrate domain that can bind to CRBN in response to an immunomodulatory drug (IMiD), thereby promoting the degradation of modulated polypeptides via the ubiquitin pathway.In some embodiments, the CRBN polypeptide substrate domain is selected from the group consisting of IKZF1, IKZF3, CK1a, ZFP91, GSPT1, MEIS2, GSS E4F1, ZN276, ZN517, ZN582, ZN653, ZN654, ZN692, ZN787, and ZN827, or is a fragment thereof capable of drug-inducible binding to CRBN. In some embodiments, the CRBN polypeptide substrate domain is a chimeric fusion product of a native CRBN polypeptide sequence. In some embodiments, the CRBN polypeptide substrate domain is an IKZF3 / ZFP91 / IKZF3 chimeric fusion product having the amino acid sequence FNVLMVHKRSHTGERPLQCEICGFTCRQKGNLLRHIKLHTGEKPFKCHLCNYACQRRDAL (SEQ ID NO: 90).

[0173] In some embodiments, the ligand is an IMiD. In some embodiments, the IMiD is an FDA-approved drug. In some embodiments, the IMiD is selected from the group consisting of: thalidomide, lenalidomide, and pomalidomide.

[0174] In some embodiments, the cell death induction domain includes caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, diphtheria toxin fragment A (DTA), Bax, Bak, Bok, Bad, Bcl-xS, Bak, Bik, Bcl-2-interacting protein 3 (BNIP3), Fas, Fas-related protein with death domain (FADD), tumor necrosis factor receptor 1-associated death domain protein (TRADD), TNF receptor (TNF-R), APAF-1, granzyme B, caspase second mitochondrial-derived activator (SMAC), Omi, Bmf, Bid, Bim, and p53 upregulation of apoptosis. It is derived from proteins selected from the group consisting of regulatory factor (PUMA), Noxa, Blk, Hrk, cytochrome c, Arts, TNF-related apoptosis-inducing ligand (TRAIL), herpes simplex virus thymidine kinase (HSV-TK), varicella-zoster virus thymidine kinase (VZV-TK), viral spike protein, carboxylesterase, cytosine deaminase, nitroreductase Fksb, carboxypeptidase G2, carboxypeptidase A, horseradish peroxidase, linamorase, hepatic cytochrome P450-2B1, and purine nucleoside phosphorylase.

[0175] In some embodiments, the cell death-inducing polypeptide is caspase 9 or a functional cleavage thereof. In some embodiments, the cell death-inducing domain comprises the caspase 9 amino acid sequence shown in Table D.

[0176] In some embodiments, the cell death-inducing polypeptide is diphtheria toxin fragment A (DTA). In some embodiments, the cell death-inducing domain contains the DTA amino acid sequence shown in Table D.

[0177] In some embodiments, the cell death-inducing polypeptide is Bax. In some embodiments, the cell death-inducing domain contains the Bax amino acid sequence shown in Table D.

[0178] The manipulated nucleic acid comprises (a) a first expression cassette comprising a first promoter and a first exogenous polynucleotide sequence encoding a first chimeric polypeptide, wherein the first chimeric polypeptide comprises a first ligand-binding domain and a transcriptional activation domain, and the first promoter is operably ligated to the first exogenous polynucleotide; and (b) a second expression cassette comprising a second promoter and a second exogenous polynucleotide sequence encoding a second chimeric polypeptide, wherein the second chimeric polypeptide comprises a second ligand-binding domain and a nucleic acid-binding domain. When expressed, the first and second chimeric polypeptides multimerize to form an activated conditionally controlled polypeptide (ACP) via a congeneral ligand that binds to each ligand-binding domain, and the multimerized ACP can induce transcriptional expression of a gene of interest operably ligated to an ACP-responsive promoter.

[0179] In some embodiments, the first promoter, the second promoter, or both the first and second promoters include a constitutive promoter, an inducible promoter, or a synthetic promoter.

[0180] In some embodiments, the constitutive promoter is selected from the group consisting of: CAG, HLP, CMV, EFS, SFFV, SV40, MND, PGK, UbC, hEF1aV1, hCAGG, hEF1aV2, hACTb, heIF4A1, hGAPDH, hGRP78, hGRP94, hHSP70, hKINb, and hUBIb.

[0181] In some embodiments, the inducible promoter is selected from the group consisting of: minP, NFκB response element, CREB response element, NFAT response element, SRF response element 1, SRF response element 2, AP1 response element, TCF-LEF response element promoter fusion, hypoxia response element, SMAD binding element, STAT3 binding site, minCMV, YB_TATA, minTK, inducible molecule responsive promoter, and their tandem repeats.

[0182] In some embodiments, the inducible cell death polypeptide or system described herein comprises a modified XIAP, the modified XIAP comprising one or more amino acid substitutions within positions 306-325 of SEQ ID NO: 107.

[0183] In some embodiments, one or more amino acid substitutions are at one or more positions in SEQ ID NO: 107 selected from the group consisting of 305, 306, 308, and 325.

[0184] In some embodiments, one or more amino acid substitutions are at position 305 of SEQ ID NO: 107. In some embodiments, the amino acid substitution at position 305 of SEQ ID NO: 107 is G305M.

[0185] In some embodiments, one or more amino acid substitutions are at position 306 of SEQ ID NO: 107. In some embodiments, the amino acid substitution at position 306 of SEQ ID NO: 107 is G306S.

[0186] In some embodiments, one or more amino acid substitutions are at position 308 of SEQ ID NO: 107. In some embodiments, the amino acid substitution at position 308 of SEQ ID NO: 107 is selected from the group consisting of T308S and T308D. In some embodiments, the amino acid substitution at position 308 of SEQ ID NO: 107 is T308S. In some embodiments, the amino acid substitution at position 308 of SEQ ID NO: 107 is T308D.

[0187] In some embodiments, one or more amino acid substitutions are at position 325 of SEQ ID NO: 107. In some embodiments, the amino acid substitution at position 325 of SEQ ID NO: 107 is P325S.

[0188] In some embodiments, one or more amino acid substitutions are two amino acid substitutions.

[0189] In some embodiments, each of the two amino acid substitutions is at the position of SEQ ID NO: 107, selected from the group consisting of 305, 306, 308, and 325.

[0190] In some embodiments, the two amino acid substitutions are at positions 305 and 306 of SEQ ID NO: 107. In some embodiments, the amino acid substitution at position 305 of SEQ ID NO: 107 is G305M, and the amino acid substitution at position 306 of SEQ ID NO: 107 is G306S.

[0191] In some embodiments, the two amino acid substitutions are at positions 305 and 308 of SEQ ID NO: 107. In some embodiments, the amino acid substitution at position 305 of SEQ ID NO: 107 is G305M, and the amino acid substitution at position 308 of SEQ ID NO: 107 is T308S.

[0192] In some embodiments, the amino acid substitution at position 305 of SEQ ID NO: 107 is G305M, and the amino acid substitution at position 308 of SEQ ID NO: 107 is T308D.

[0193] In some embodiments, the two amino acid substitutions are at positions 305 and 325 of SEQ ID NO: 107. In some embodiments, the amino acid substitution at position 305 of SEQ ID NO: 107 is G305M, and the amino acid substitution at position 325 of SEQ ID NO: 107 is P325S.

[0194] In some embodiments, the two amino acid substitutions are at positions 306 and 308 of SEQ ID NO: 107. In some embodiments, the amino acid substitution at position 306 of SEQ ID NO: 107 is G306S, and the amino acid substitution at position 308 of SEQ ID NO: 107 is T308S.

[0195] In some embodiments, the amino acid substitution at position 306 of SEQ ID NO: 107 is G306S, and the amino acid substitution at position 308 of SEQ ID NO: 107 is T308D.

[0196] In some embodiments, the two amino acid substitutions are at positions 306 and 325 of SEQ ID NO: 107.

[0197] In some embodiments, the amino acid substitution at position 306 of SEQ ID NO: 107 is G306S, and the amino acid substitution at position 325 of SEQ ID NO: 107 is P325S.

[0198] In some embodiments, the two amino acid substitutions are at positions 308 and 325 of SEQ ID NO: 107.

[0199] In some embodiments, the amino acid substitution at position 308 of SEQ ID NO: 107 is T308S, and the amino acid substitution at position 325 of SEQ ID NO: 107 is P325S.

[0200] In some embodiments, the amino acid substitution at position 308 of SEQ ID NO: 107 is T308D, and the amino acid substitution at position 325 of SEQ ID NO: 107 is P325S.

[0201] In some embodiments, one or more additional amino acid substitutions are three amino acid substitutions. In some embodiments, each of the three amino acid substitutions is a position in SEQ ID NO: 107 selected from the group consisting of 305, 306, 308, and 325. In some embodiments, the three amino acid substitutions are positions 305, 306, and 308 in SEQ ID NO: 107.

[0202] In some embodiments, the amino acid substitution at position 305 of SEQ ID NO: 107 is G305M, the amino acid substitution at position 306 of SEQ ID NO: 107 is G306S, and the amino acid substitution at position 308 of SEQ ID NO: 107 is T308S.

[0203] In some embodiments, the amino acid substitution at position 305 of SEQ ID NO: 107 is G305M, the amino acid substitution at position 306 of SEQ ID NO: 107 is G306S, and the amino acid substitution at position 308 of SEQ ID NO: 107 is T308D.

[0204] In some embodiments, the three amino acid substitutions are at positions 305, 306, and 325 of SEQ ID NO: 107. In some embodiments, the amino acid substitution at position 305 of SEQ ID NO: 107 is G305M, the amino acid substitution at position 306 of SEQ ID NO: 107 is G306S, and the amino acid substitution at position 325 of SEQ ID NO: 107 is P325S.

[0205] In some embodiments, the three amino acid substitutions are at positions 305, 308, and 325 of SEQ ID NO: 107. In some embodiments, the amino acid substitution at position 305 of SEQ ID NO: 107 is G305M, the amino acid substitution at position 308 of SEQ ID NO: 107 is T308S, and the amino acid substitution at position 325 of SEQ ID NO: 107 is P325S. In some embodiments, the amino acid substitution at position 305 of SEQ ID NO: 107 is G305M, the amino acid substitution at position 308 of SEQ ID NO: 107 is T308D, and the amino acid substitution at position 325 of SEQ ID NO: 107 is P325S.

[0206] In some embodiments, the three amino acid substitutions are at positions 306, 308, and 325 of SEQ ID NO: 107. In some embodiments, the amino acid substitution at position 306 of SEQ ID NO: 107 is G306S, the amino acid substitution at position 308 of SEQ ID NO: 107 is T308S, and the amino acid substitution at position 325 of SEQ ID NO: 107 is P325S. In some embodiments, the amino acid substitution at position 306 of SEQ ID NO: 107 is G306S, the amino acid substitution at position 308 of SEQ ID NO: 107 is T3084, and the amino acid substitution at position 325 of SEQ ID NO: 107 is P325S.

[0207] In some embodiments, one or more additional amino acid substitutions are four amino acid substitutions.

[0208] In some embodiments, the four amino acid substitutions are at positions 305, 306, 308, and 325 of SEQ ID NO: 107. In some embodiments, the amino acid substitution at position 305 of SEQ ID NO: 107 is G305M, the amino acid substitution at position 306 of SEQ ID NO: 107 is G306S, the amino acid substitution at position 308 of SEQ ID NO: 107 is T308S, and the amino acid substitution at position 325 of SEQ ID NO: 107 is P325S. In some embodiments, the amino acid substitution at position 305 of SEQ ID NO: 107 is G305M, the amino acid substitution at position 306 of SEQ ID NO: 107 is G306S, the amino acid substitution at position 308 of SEQ ID NO: 107 is T308D, and the amino acid substitution at position 325 of SEQ ID NO: 107 is P325S. [Brief explanation of the drawing]

[0209] These and other features, aspects, and advantages of this disclosure will be better understood in relation to the following description and accompanying drawings.

[0210] [Figure 1A] Figures 1A, 1B, 1C, and 1D provide examples of induced cell death systems. [Figure 1B] Same as above. [Figure 1C] Same as above. [Figure 1D] Same as above. [Figure 2] Figure 2A shows the domains and tissues of the indicated construct against the induced cell death system. Figure 2B shows mCherry expression in cells expressing the indicated construct after IMiD addition. Figure 2A shows the domains and tissues of the indicated construct against the induced cell death system. [Figure 3] Figure 3A shows the domains and tissues of the demonstrated constructs for ligand-induced dimerization of an inducible cell death system using a mifepristone system. Figure 3B shows HEK293 cells engineered to express caspase-9 / progesterone receptor fusion and cell death (both apoptosis and viable / dead) upon addition of mifepristone. [Figure 4A] Figure 4A shows the domains and tissues of the demonstrated constructs for ligand-induced dimerization of an inducible cell death system using a mifepristone system. [Figure 4B] Figure 4B shows the cell death (toxic activity) of various induced cell death systems (both apoptosis and life / death). [Figure 4C] Figure 4C shows mKate reporter expression for various induced cell death systems (both apoptosis and life / death). [Figure 4D] Figure 4D shows the cell viability on day 5 as a ratio to the cell viability on day 3. It shows the untreated state (left column) and the 1 μM pomalidomide treatment (right column). [Figure 5A]Figure 5A shows the domains and tissues of the demonstrated constructs for the induced cell death system. [Figure 5B] Figure 5B shows the density calculated using the Incucyte system for Smac / Diablo structures. [Figure 5C] Figure 5C shows the density calculated using the Incucyte system for tBid structures. [Figure 5D] Figure 5C shows the density calculated using the Incucyte system for Bax structures. [Figure 6A] Figure 6A shows the domains and tissues of the directed construct for the Bax-induced cell death system. [Figure 6B] Figure 6B shows the density calculated using the Incucyte system for the Bax structure. [Figure 6C] Figure 6C shows the survival rate for Bax structures. [Figure 6D] Figure 6D shows the survival rate for Bax structures. [Figure 7] Figure 7 shows the domains and organization of IMiD and the tamoxifen-inducible caspase 9 dimerization (iCast9) system. [Modes for carrying out the invention]

[0211] Detailed explanation Unless otherwise specified, terms used in the claims and specification are defined as follows:

[0212] The term "improvement" refers to any therapeutically beneficial outcome in the treatment of a medical condition, such as cancer, including, for example, prevention, reduction in severity or progression, remission, or cure.

[0213] The term "in situ" refers to processes that occur within living cells growing away from a living organism, such as living cells growing in a tissue culture.

[0214] The term "in vivo" refers to processes that occur within a living organism.

[0215] As used herein, the term “mammal” includes both humans and non-humans, and includes, but is not limited to, humans, non-human primates, dogs, cats, mice, cattle, horses, and pigs.

[0216] The term "percentage identity" in relation to the sequences of two or more nucleic acids or polypeptides refers to two or more sequences or subsequences that have a specific percentage of the same nucleotide or amino acid residues, measured using one of the following sequence comparison algorithms (e.g., BLASTP and BLASTN, or other algorithms available to those skilled in the art) or by visual inspection, when compared and aligned for the greatest match. Depending on the application, the percentage "identity" may be present, for example, over a region of the sequences being compared, e.g., a functional domain, or alternatively, over the entire length of the two sequences being compared.

[0217] For sequence comparison, typically one sequence acts as the reference sequence against which the test sequence is compared. When using a sequence comparison algorithm, the test and reference sequences are entered into a computer, the coordinates of any subsequences are specified as needed, and the program parameters for the sequence comparison algorithm are specified. The sequence comparison algorithm then calculates the sequence identity percentage of the test sequence relative to the reference sequence based on the specified program parameters.

[0218] The optimal alignment of sequences for comparison can be performed, for example, by the local homology algorithm of Smith & Waterman, Adv.Appl.Math.2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J.Mol.Biol.48:443 (1970), by the similarity search of Pearson & Lipman, Proc.Nat'l.Acad.Sci.USA 85:2444 (1988), by computerized execution of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection (see Ausubel et al., infra in general).

[0219] One example of a suitable algorithm for determining sequence identity and sequence similarity is the BLAST algorithm described in Altschul et al., J.Mol.Biol.215:403-410 (1990). Software for performing BLAST analysis is available from the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov / ).

[0220] The term "sufficient amount" means an amount sufficient to produce the desired effect, for example, an amount sufficient to regulate intracellular protein aggregation.

[0221] The term "therapeutic dose" refers to the amount of medication that is effective in improving the symptoms of a disease. Since prevention can be considered a form of treatment, the therapeutic dose can also be called the "preventive dose."

[0222] As used herein and in the appended claims, the singular forms "a," "an," and "the" refer to multiple subjects unless the context otherwise explicitly indicates otherwise.

[0223] Manipulated nucleic acids and polypeptides The engineered nucleic acid may comprise a first expression cassette comprising a first promoter and a first exogenous polynucleotide sequence. The first promoter can be operably or directly ligated to the first exogenous polynucleotide sequence. The first exogenous polynucleotide sequence may encode a first polypeptide, such as an activated conditionally controlled polypeptide (ACP). In some embodiments, a single engineered nucleic acid comprises at least one, two, three, four, five, or more expression cassettes, for example, multiple. Generally, each expression cassette may refer to a promoter operably ligated to a polynucleotide sequence encoding a protein of interest.

[0224] The manipulated nucleic acid may include an expression cassette comprising a promoter operably ligated to an exogenous polynucleotide sequence encoding at least one inducible cell death polypeptide monomer. The inducible cell death polypeptide monomer may include one or more ligand-binding domains and at least one cell death-inducing domain. When expressed in cells, the cell death polypeptide monomer is oligomerizable via a homologous ligand (e.g., a small molecule) that binds to the ligand-binding domain. When the ligand oligomerizes two or more of the cell death polypeptide monomers, a cell death-inducing signal may be generated in the cell. This generally results in cell death.

[0225] The manipulated nucleic acid may comprise an expression cassette containing a promoter operably linked to an exogenous polynucleotide sequence encoding at least one activated conditionally controlled polypeptide (ACP). The ACP may comprise at least one transcription factor comprising one or more ligand-binding domains, at least one nucleic acid-binding domain, and at least one transcription effector domain. When expressed in cells, ACPs may undergo nuclear localization upon binding of their ligand-binding domains to a cognate ligand. Upon localization to the nucleus, ACPs can induce transcriptional expression of a gene of interest operably linked to an ACP-responsive promoter. The gene of interest may be associated with or may induce cell death, such as apoptosis. This can result in cell death.

[0226] The manipulated nucleic acid may comprise an expression cassette containing a promoter operably ligated to an exogenous polynucleotide sequence encoding at least one ACP. The ACP may comprise at least one ligand-binding domain and at least one transcription effector domain. When expressed intracellularly and upon binding of the ligand-binding domain to a congenital ligand, ACP can regulate the transcriptional expression of a gene of interest operably ligated to an ACP-responsive promoter. For example, in some embodiments, when expressed intracellularly and upon binding of the ligand-binding domain to a congenital ligand, the activity of ACP regulates the transcriptional expression of a gene of interest operably ligated to an ACP-responsive promoter. Alternatively, in some embodiments, binding of the ligand-binding domain to a congenital ligand induces degradation of ACP, and therefore, the ACP-system regulation of the transcriptional expression of the gene of interest is invalidated by binding to the congenital ligand. The gene of interest may be associated with, or may induce, cell death, such as apoptosis. This can result in cell death.

[0227] The manipulated nucleic acid may contain an expression cassette comprising a promoter operably ligated to an exogenous polynucleotide sequence encoding at least one controllable cell survival polypeptide containing at least one ligand-binding domain. When expressed in cells, at least one cell survival polypeptide can inhibit at least one cell death-inducing polypeptide, and upon binding to a congenital ligand, the congenital ligand inhibits at least one survival-promoting polypeptide. This can lead to cell death.

[0228] The manipulated nucleic acid may comprise an expression cassette comprising a promoter operably ligated to an exogenous polynucleotide sequence having the formula: C1-L-C2, where C1 comprises a polynucleotide sequence encoding at least a first chimeric polypeptide comprising at least a first ligand-binding domain and at least a transcriptional activation domain, L comprises at least a linker polynucleotide sequence, and C2 comprises a polynucleotide sequence encoding at least a second chimeric polypeptide comprising a second ligand-binding domain and at least a nucleic acid-binding domain. When expressed in cells, the first and second chimeric polypeptides can multimerize to form activated conditionally controlled polypeptides (ACPs) via homologous ligands that bind to each ligand-binding domain. The multimerized ACPs can then induce transcriptional expression of a gene of interest operably ligated to an ACP-responsive promoter. This can lead to cell death.

[0229] The manipulated nucleic acid may comprise an expression cassette comprising (a) a first expression cassette comprising a first promoter operably ligated to a first exogenous polynucleotide sequence encoding a first chimeric polypeptide, wherein the first chimeric polypeptide comprises a first expression cassette comprising a first ligand-binding domain and a transcriptional activation domain, and (b) a second expression cassette comprising a second promoter operably ligated to a second exogenous polynucleotide sequence encoding a second chimeric polypeptide, wherein the second chimeric polypeptide comprises a second expression cassette comprising a second ligand-binding domain and a nucleic acid-binding domain. When expressed in a cell, the first and second chimeric polypeptides can multimerize to form activated conditionally controlled polypeptides (ACPs) via homologous ligands that bind to each ligand-binding domain. The multimerized ACPs then induce transcriptional expression of a gene of interest operably ligated to an ACP-responsive promoter in the cell, which can lead to cell death.

[0230] One or more linkers can be used between different domains of the manipulated nucleic acid. For example, a polypeptide linker encoded by the manipulated nucleic acid may contain one or more of the following amino acid sequences: GGGGSGGGGSGGGGSVDGF (SEQ ID NO: 91) and ASGGGGSAS (SEQ ID NO: 92). Additional exemplary linkers are shown in Table D.

[0231] In some embodiments, one or more expression cassettes may be multicistronic, i.e., multiple distinct polypeptides (e.g., multiple exogenous polynucleotides or effector molecules) may be produced from a single transcript. For example, a multicistronic expression cassette may encode both a first ACP and a second ACP, e.g., both expressed from a single expression cassette driven by a constitutive promoter. In another example, a multicistronic expression cassette may encode both an effector molecule and an antigen-recognition receptor, e.g., both expressed from a single expression cassette driven by an ACP-responsive promoter. Expression cassettes may also be multicistronic by the use of various linkers, e.g., a polynucleotide sequence encoding a first protein of interest may be linked to a nucleotide sequence encoding a second protein of interest (e.g., first gene:linker:second gene, 5' to 3' direction). The features and options of multicistronicity are described in the section "Multicistronic and Multiple Promoter Systems".

[0232] In some embodiments, the engineered nucleic acid is selected from DNA, cDNA, RNA, mRNA, and naked plasmids (linear or circular). Expression vectors containing the engineered nucleic acid are also provided herein.

[0233] In some embodiments, the engineered nucleic acid further comprises an insulator. The insulator can be localized between a first expression cassette and a second expression cassette. The insulator is a cis-regulatory element having an enhancer-blocking or barrier function. Enhancer-blocker insulators block enhancers from acting on the promoter of a proximal gene. Barrier insulators prevent euchromatin silencing. An example of a preferred insulator of this disclosure is the A2 insulator described in Liu M, et al., Nat Biotechnol. 2015 Feb;33(2):198-203. Additional insulators are described in West et al, Genes & Dev, 002.16:271-288, both of which are incorporated in whole by reference. Other suitable insulators include, but are not limited to, A1 insulators, CTCF insulators, Gypsy insulators, HS5 insulators, and β-globin locus insulators such as cHS4. In some embodiments, the insulator is an A2 insulator, an A1 insulator, a CTCF insulator, an HS5 insulator, a Gypsy insulator, a β-globin locus insulator, or a cHS4 insulator.

[0234] Ligand-binding domain Ligand-binding domains can interact with ligands, such as homologous ligands. Such interactions can lead to oligomerization, for example, dimerization, of multiple ligand-binding domains via ligand binding.

[0235] Exemplary ligand-binding domains include one or more of the following domains or functional fragments thereof: ABI domain, PYL domain, caffeine-binding single-domain antibody, cannabidiol-binding domain, hormone-binding domain of estrogen receptor (ER) domain, heavy chain variable region (VH) of anti-nicotine antibody, light chain variable region (VL) of anti-nicotine antibody, progesterone receptor domain, FKBP domain, and / or FRB domain. Examples of sequences of such domains are shown in Table D.

[0236] The ligand-binding domain may contain degrons. As used herein, the terms “degron” and “degron domain” refer to a protein or part thereof that is important for controlling the rate of proteolysis. Various degrons known in the art, including but not limited to short amino acid sequences, structural motifs, and exposed amino acids, may be used in various embodiments of this disclosure. Degrons identified from various organisms may be used. Degrons and degron pathways are generally known, see, for example, Varshazsky A., PNAS 2019 Jan 8;116(2):358-366, incorporated herein by reference.

[0237] As used herein, the term “degradation sequence” refers to a sequence that promotes the degradation of a bound protein by either the proteasome or the autophagy-lysosome pathway. Degradation sequences known in the art may be used in various embodiments of this disclosure. In some embodiments, the degradation sequence includes degrons identified from living organisms, or modifications thereof. In some embodiments, the degradation sequence is a polypeptide that destabilizes a protein such that, when fused to the protein, the protein’s half-life is reduced by at least twofold. Many different degradation sequences / signals (e.g., the ubiquitin-proteasome system) are known in the art, and any of these may be used as provided herein. The degradation sequence may be operably ligated to a cell receptor, but does not need to be adjacent to it, as long as the degradation sequence still functions to direct the degradation of the cell receptor. In some embodiments, the degradation sequence induces rapid degradation of the cell receptor. For discussions on degradation sequences and their functions in protein degradation, see, for example, Kanemaki et al. (2013) Pflugers Arch. 465(3):4l9-425, Erales et al. (2014) Biochim Biophys Acta 1843(l):216-221, Schrader et al. (2009) Nat. Chem. Biol. 5(11):815-822, Ravid et al. (2008) Nat. Rev. Mol. Cell. Biol. 9(9):679-690, Tasaki et al. (2007) Trends Biochem Sci. 32(1):520-528, Meinnel et al. (2006) Biol. Chem. 387(7):839-851, and Kim et al. (2013) Autophagy, which are referenced herein by reference. See 9(7):1100-1103, Varshavsky (2012) Methods Mol. Biol. 832:1-11, and Fayadat et al. (2003) Mol Biol Cell. 14(3):1268-1278.

[0238] In some embodiments, the degron or degraded sequence is selected from the following: HCV NS4 degron, PEST (two copies of human IκBα residues 277-307), GRR (human p105 residues 352-408), DRR (yeast Cdc34 residues 210-295), SNS (tandem repeat of SP2 and NB of influenza A or influenza B (SP2-NB-SP2)), RPB (four copies of yeast RPB residues 1688-1702), SPmix (influenza A virus M2 protein) The following are the results of the analysis: SP1 and SP2 tandem repeats (SP2-SP1-SP2-SP1-SP2), NS2 (three copies of residues 79-93 of the influenza A virus NS protein), ODC (residues 106-142 of ornithine decarboxylase), Nek2A, mouse ODC (residues 422-461), mouse ODC_DA (residues 422-461 of mODC including D433A and D434A point mutations), APC / C degron, COP1 E3 ligase-binding degron motif, CRL4-Cdt2-binding PIP degron, actinphylline-binding degron, KEAP1-binding degron, KLHL2 and KLHL3-binding degron, MDM2-binding motif, N-degron, hydroxyproline modification in hypoxia signaling, plant hormone-dependent SCF-LRR-binding degron, SCF ubiquitin ligase-binding phosphodegron, plant hormone-dependent SCF-LRR-binding degron, DSGxxS phosphate-dependent degron, Siah-binding motif, SPOP SBC docking motif, and PCNA-binding PIP box. In some embodiments, degrons include modifications / mutations that reduce ubiquitination of the wild-type protein, for example, to the peptide sequence or domain from which the degron originates. Modifications / mutations that reduce ubiquitination may include substitutions or more lysine residues. Modifications / mutations that reduce ubiquitination may include substitutions of all lysine residues.

[0239] In some embodiments, degron includes a cerebron (CRBN) polypeptide substrate domain that can bind to CRBN in response to an immunomodulatory drug (IMiD), thereby promoting the degradation of ACP via the ubiquitin pathway. In some embodiments, the CRBN polypeptide substrate domain is selected from: IKZF1, IKZF3, CKla, ZFP91, GSPT1, MEIS2, GSS E4F1, ZN276, ZN517, ZN582, ZN653, ZN654, ZN692, ZN787, and ZN827, or fragments thereof capable of drug-inducible binding to CRBN. In some embodiments, the CRBN polypeptide substrate domain is a chimeric fusion product of a native CRBN polypeptide sequence. In some embodiments, the CRBN polypeptide substrate domain is an IKZF3 / ZFP91 / IKZF3 chimeric fusion product having the amino acid sequence FNVLMVHKRSHTGERPLQCEICGFTCRQKGNLLRHIKLHTGEKPFKCHLCNYACQRRDAL (SEQ ID NO: 93).

[0240] In some embodiments, degron includes degron having the amino acid sequence of SEQ ID NO: 131. Degron may include modified d913 degron, which includes amino acid substitutions to the amino acid sequence of SEQ ID NO: 131. In some embodiments, degron includes modified degron having the amino acid sequence of SEQ ID NO: 133. d913 degron may include modifications / mutations that reduce ubiquitination of unmodified d913 having the amino acid sequence of SEQ ID NO: 131. d913 degron may include, for example, substitution of one or more lysine residues in unmodified d913 having the amino acid sequence of SEQ ID NO: 131; for example, d913 degron may include substitution of all lysine residues in unmodified d913 having the amino acid sequence of SEQ ID NO: 131. d913 degron may include, for example, substitution of one or more lysine residues with arginine residues in unmodified d913 having the amino acid sequence of SEQ ID NO: 131. d913 degron may include, for example, a modified degron having the amino acid sequence of SEQ ID NO: 133, in which all lysine residues are replaced with arginine residues, for example, a modified degron having the amino acid sequence of SEQ ID NO: 133.

[0241] In some embodiments, cerebron (CRBN) is a wild-type CRBN polypeptide, for example, the amino acid sequence of SEQ ID NO: 127. In some embodiments, CRBN is a modified CRBN polypeptide. Modified CRBN may contain mutations that reduce ubiquitination compared to wild-type CRBN. Modified CRBN may contain deletions of amino acids 194-247, which are the DDB1 interaction domain, for example, modified CRBN contains the amino acid sequence of SEQ ID NO: 129.

[0242] Ligand-cognate ligand pair A ligand can bind to a ligand-binding domain. A given ligand that consistently binds to a given ligand-binding domain may be called a homologous ligand pair.

[0243] In some embodiments, the ligand is FK1012, its derivatives, or analogs thereof.

[0244] In some embodiments, the ligand is abscisic acid.

[0245] In some embodiments, the ligand is rapamycin, its derivatives, or analogs. In some embodiments, the ligand is tamoxifen or its metabolites. In some embodiments, the tamoxifen metabolites are selected from the group consisting of: 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen.

[0246] In some embodiments, the ligand is caffeine or a derivative thereof.

[0247] In some embodiments, the ligand is nicotine or a derivative thereof.

[0248] In some embodiments, the ligand is cannabidiol or a plant-derived cannabinoid.

[0249] In some embodiments, the ligand is mifepristone or a derivative thereof.

[0250] In some embodiments, the ligand is an IMiD. In some embodiments, the IMiD is an FDA-approved drug. In some embodiments, the IMiD is selected from the group consisting of: thalidomide, lenalidomide, and pomalidomide.

[0251] In some embodiments, the ligand-binding domain comprises the hormone-binding domain of the estrogen receptor (ER) domain, and the homologous ligand is tamoxifen or its metabolites. In some embodiments, the tamoxifen metabolites are selected from the group consisting of: 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen.

[0252] In some embodiments, the ligand-binding domain comprises a progesterone receptor domain, and the cognate ligand is mifepristone or a derivative thereof.

[0253] In some embodiments, the ligand-binding domain comprises an ABI domain or a PYL domain, and the cognate ligand is abscisic acid.

[0254] In some embodiments, the ligand-binding domain comprises a caffeine-binding single-domain antibody, and the cognate ligand is caffeine or a derivative thereof.

[0255] In some embodiments, the ligand-binding domain comprises a cannabidiol-binding domain, and the cognate ligand is cannabidiol or a phytocannabinoid. In some embodiments, the cannabidiol-binding domain comprises a single-domain antibody or a nanobody. In some embodiments, the cannabidiol-binding domain comprises an amino acid sequence selected from the group consisting of the sequences of CA14, DB6, DB11, DB18, and DB21 of Table D.

[0256] In some embodiments, the ligand-binding domain comprises the hormone-binding domain of an estrogen receptor (ER) domain, and the cognate ligand is tamoxifen or a metabolite thereof. In some embodiments, the tamoxifen metabolite is selected from the group consisting of: 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen.

[0257] In some embodiments, the ligand-binding domain comprises the heavy-chain variable region (VH) of an anti-nicotine antibody or the light-chain variable region (VL) of an anti-nicotine antibody, and the cognate ligand is nicotine or a derivative thereof.

[0258] In some embodiments, the ligand-binding domain comprises a progesterone receptor domain, and the cognate ligand is mifepristone or a derivative thereof.

[0259] In some embodiments, the ligand-binding domain comprises an FKBP domain or an FRB domain, and the homologous ligand is rapamycin, AP1903, AP20187, FK1012, its derivatives, or analogs.

[0260] Cell death induction domain An inducible cell death polypeptide may contain one or more ligand-binding domains and at least one cell death-inducing domain.

[0261] Exemplary cell death-inducing domains are derived from proteins selected from one or more of the following groups: caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, diphtheria toxin fragment A (DTA), Bax, Bak, Bok, Bad, Bcl-xS, Bak, Bik, Bcl-2-interacting protein 3 (BNIP3), Fas, Fas-related protein with death domain (FADD), tumor necrosis factor receptor 1-associated death domain protein (TRADD), TNF receptor (TNF-R), APAF-1, granzyme B, second mitochondrial-derived activator of caspase (SMAC), Omi, Bm f, Bid, Bim, p53 upregulatory factor for apoptosis (PUMA), Noxa, Blk, Hrk, cytochrome c, Arts, TNF-associated apoptosis-inducing ligand (TRAIL), herpes simplex virus thymidine kinase (HSV-TK), varicella-zoster virus thymidine kinase (VZV-TK), viral spike protein, carboxylesterase, cytosine deaminase, nitroreductase Fksb, carboxypeptidase G2, carboxypeptidase A, horseradish peroxidase, linamorase, hepatic cytochrome P450-2B1, and / or purine nucleoside phosphorylase. Exemplary sequences can be found in Table D.

[0262] The cell death-inducing domain may include or be derived from caspase 9, for example, the amino acid sequence shown in SEQ ID NO: 39 or 123. Derivatives of caspase 9 include inducible caspase 9 ("iCasp-9"), which can induce apoptosis by drug-based dimerization, such as the amino acid sequence shown in SEQ ID NO: 48 or 125.

[0263] The cell death induction domain includes Bax, for example, the amino acid sequence shown in SEQ ID NO: 32.

[0264] Controllable Cell Survival Polypeptides A controllable cell survival polypeptide may contain at least one ligand-binding domain.

[0265] Exemplary cell survival polypeptides include one or more XIAP, Bcl-2, Bcl-xL, Bcl-w, Bcl-2-related protein A1 (BCL2A1), Mcl-1, FLICE-like inhibitory protein (c-FLIP), and adenovirus E1B-19K protein. A cell survival polypeptide may include XIAP. A cell survival polypeptide may include wild-type XIAP, e.g., having the amino acid sequence of SEQ ID NO: 107. A cell survival polypeptide may include modified XIAP. A modified XIAP may include one or more amino acid substitutions related to SEQ ID NO: 107. A modified XIAP may include one or more amino acid substitutions within positions 305-325 related to SEQ ID NO: 107. A modified XIAP may include one or more amino acid substitutions including positions 305, 306, 308, or 325 related to SEQ ID NO: 107. A modified XIAP may include one or more amino acid substitutions including positions 305, 306, 308, and 325 related to SEQ ID NO: 107. Modified XIAP may contain one or more amino acid substitutions, including positions 305, 306, 308, and 325, as associated with SEQ ID NO: 107, including T308S, G306S, G305M, and P325S. Modified XIAP may contain one or more amino acid substitutions, including positions 305, 306, 308, and 325, as associated with SEQ ID NO: 107, including T308D, G306S, G305M, and P325S. Modified XIAP may contain the amino acid substitution at position 305 of SEQ ID NO: 107. Modified XIAP may contain the amino acid substitution at position 305 of SEQ ID NO: 107, which is G305M. Modified XIAP may contain the amino acid substitution at position 306 of SEQ ID NO: 107. Modified XIAP may contain the amino acid substitution at position 306 of SEQ ID NO: 107, which is G306S. Modified XIAP may contain the amino acid substitution at position 308 of SEQ ID NO: 107. Modified XIAP may contain the amino acid substitution at position 308 of SEQ ID NO: 107, which is T308S or T308D. Modified XIAP may contain the amino acid substitution at position 308 of SEQ ID NO: 107, which is T308S. Modified XIAP may contain the amino acid substitution at position 308 of SEQ ID NO: 107, which is T308D. Modified XIAP may contain the amino acid substitution at position 325 of SEQ ID NO: 107. Modified XIAP may contain the amino acid substitution at position 325 of SEQ ID NO: 107, which is T325S.

[0266] Activated conditionally controlled polypeptide (ACP) In some embodiments, ACP comprises a transcription regulator. In some embodiments, ACP is a transcription repressor. In some embodiments, ACP is a transcription activator. In some embodiments, ACP is a transcription factor. In some embodiments, ACP comprises a DNA-binding domain and a transcription effector domain. In some embodiments, the transcription factor comprises a zinc finger-containing transcription factor. In some embodiments, the zinc finger-containing transcription factor may be a synthetic transcription factor. In some embodiments, the ACP DNA-binding domain comprises a DNA-binding zinc finger protein domain (ZF protein domain). In some embodiments, the DNA-binding domain comprises a tetracycline (or derivative thereof) repressor (TetR) domain. ACP may comprise one or more ligand-binding domains.

[0267] nucleic acid binding domain The manipulated nucleic acid may encode at least one transcription factor containing at least one nucleic acid-binding domain. The manipulated nucleic acid may encode at least one transcription factor containing at least one nucleic acid-binding domain and at least one transcription effector domain.

[0268] In some embodiments, the nucleic acid binding domain includes a DNA-binding zinc finger protein domain (ZF protein domain). In some embodiments, the ZF protein domain is a modular design and consists of a zinc finger array (ZFA). In some embodiments, the transcription effector domain includes a herpes simplex virus protein 16 (VP16) activation domain; an activation domain containing four tandem copies of VP16; a VP64 activation domain; a p65 activation domain of NFκB; an Epstein-Barr virus R trans-activator (Rta) activation domain; a ternary activator containing VP64, p65, and Rta activation domains (VPR activation domain); a ternary activator containing VP64, p65, and HSF1 activation domains (VPH activation domain); and a histone acetyltransferase (HAT) core domain of human E1A-related protein p300 (p300). The domains selected are: HAT core activating domain; Kruppel association box (KRAB) repression domain; repressor element silencing transcription factor (REST) ​​repression domain; WRPW motif of hairy-associated basic helix-loop-helix repressor protein, known as the WRPW repression domain; DNA (cytosine-5)-methyltransferase 3B (DNMT3B) repression domain; and HP1 alpha-chromoshadow repression domain.

[0269] In some embodiments, the ZF protein domain is a modular design and consists of a zinc finger array (ZFA). The zinc finger array contains multiple zinc finger protein motifs linked together. Each zinc finger motif binds to a different nucleic acid motif. This results in a ZFA specific to any desired nucleic acid sequence. The ZF motifs may be directly adjacent to each other or separated by a mobile linker sequence. In some embodiments, the ZFA is an array, string, or chain of ZF motifs arranged in tandem. The ZFA may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 zinc finger motifs. ZFA may have zinc finger motifs in the following order: 1-10, 1-15, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 2-3, 2-4, 2-5, 2-6, 2-7, 2-8, 2-9, 2-10, 3-4, 3-5, 3-6, 3-7, 3-8, 3-9, 3-10, 4-5, 4-6, 4-7, 4-8, 4-9, 4-10, 5-6, 5-7, 5-8, 5-9, 5-10, or 5-15.

[0270] A ZF protein domain may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more ZFAs. A ZF domain may have 1-10, 1-15, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 2-3, 2-4, 2-5, 2-6, 2-7, 2-8, 2-9, 2-10, 3-4, 3-5, 3-6, 3-7, 3-8, 3-9, 3-10, 4-5, 4-6, 4-7, 4-8, 4-9, 4-10, 5-6, 5-7, 5-8, 5-9, 5-10, or 5-15 ZFAs. In some embodiments, a ZF protein domain contains one to ten ZFAs. In some embodiments, a ZF protein domain contains at least one ZFA. In some embodiments, the ZF protein domain contains at least two ZFAs. In some embodiments, the ZF protein domain contains at least three ZFAs. In some embodiments, the ZF protein domain contains at least four ZFAs. In some embodiments, the ZF protein domain contains at least five ZFAs. In some embodiments, the ZF protein domain contains at least ten ZFAs.

[0271] An example ZF protein domain is shown in sequence SRPGERPFQCRICMRNFSRRHGLDRHTRTHTGEKPFQCRICMRNFSDHSSLKRHLRTHTGSQKPFQCRICMRNFSVRHNLTRHLRTHTGEKPFQCRICMRNFSDHSNLSRHLKTHTGSQKPFQCRICMRNFSQRSSLVRHLRTHTGEKPFQCRICMRNFSESGHLKRHLRTHLRGS (SEQ ID NO: 94).

[0272] Transcription Effector Domain The inducible cell death polypeptides (ACPs) provided herein may comprise at least one transcription effector domain. For example, an inducible cell death polypeptide (ACP) may encode at least one transcription effector domain. Furthermore, an inducible cell death polypeptide (ACP) may encode at least one ligand-binding domain and at least one transcription effector domain.

[0273] In some embodiments, the transcription effector domain includes one or more of the following: herpes simplex virus protein 16 (VP16) activation domain; activation domain containing four tandem copies of VP16, VP64 activation domain; p65 activation domain of NFκB; Epstein-Barr virus R trans-activator (Rta) activation domain; ternary activator containing VP64, p65, and Rta activation domains (VPR activation domain); ternary activator containing VP64, p65, and HSF1 activation domains (VPH activation domain); histone acetyltransferase (HAT) core domain of human E1A-related protein p300 (p300 HAT core activating domain; Kruppel association box (KRAB) repression domain; repressor element silencing transcription factor (REST) ​​repression domain; WRPW motif of hairy-associated basic helix-loop-helix repressor protein, known as the WRPW repression domain; DNA (cytosine-5)-methyltransferase 3B (DNMT3B) repression domain; and HP1 alpha-chromoshadow repression domain.

[0274] In some embodiments, the transcription effector domain includes a transcription repressor domain. In some embodiments, the transcription repressor domain is selected from the group consisting of: a Kruppel association box (KRAB) repressor domain; a repressor element silencing transcription factor (REST) ​​repressor domain; the WRPW motif of the hairy-associated basic helix-loop-helix repressor protein, the motif known as the WRPW repressor domain; a DNA (cytosine 5) methyltransferase 3B (DNMT3B) repressor domain; and an HP1 alpha-chromoshadow repressor domain.

[0275] In some embodiments, the transcriptional effector domain comprises a transcriptional activation domain. In some embodiments, the transcriptional activation domain is selected from the group consisting of: the herpes simplex virus protein 16 (VP16) activation domain; an activation domain comprising four tandem copies of VP16; the VP64 activation domain; the p65 activation domain of NFκB; the Epstein-Barr virus R transactivator (Rta) activation domain; a triple activator comprising the VP64, p65, and Rta activation domains (VPR activation domain); a triple activator comprising the VP64, p65, and HSF1 activation domains (VPH activation domain); and the histone acetyltransferase (HAT) core domain of human E1A-associated protein p300 (p300 HAT core activation domain). The transcriptional activation domain can also be referred to as a transcriptional activator domain.

[0276] The inducible cell death polypeptide or ACP provided herein can encode at least one transcription factor comprising at least one transcriptional effector domain. The inducible cell death polypeptide or ACP provided herein can encode at least one transcription factor comprising at least one nucleic acid binding domain and at least one transcriptional effector domain. For example, the ACP can encode at least one transcription factor comprising at least one nucleic acid binding domain and at least one transcriptional effector domain. Further, the ACP can encode at least one transcription factor comprising at least one ligand binding domain as well as at least one nucleic acid binding domain and at least one transcriptional effector domain.

[0277] Manipulated nucleic acids may encode effector domains, such as transcription effector domains. For example, a transcription effector domain may be the effector domain of a transcription factor (e.g., an activator domain or a repressor domain). Transcription factor effector domains are also known as trans-activation domains and act as scaffold domains for proteins such as transcription co-regulators that act to activate or repress the transcription of genes. Any suitable transcription effector domains, but are not limited to, the herpes simplex virus protein 16 (VP16) activation domain; the VP64 activation domain, which is an activation domain consisting of four tandem copies of VP16; the p65 activation domain of NFκB; the Epstein-Barr virus R trans-activator (Rta) activation domain; tripartite activators containing the VP64, p65, and Rta activation domains (tripartite activators are known as VPR activation domains); and the histone acetyltransferase (HAT) core domain (p3) of human E1A-related protein p300. The following domains may be used, including: the HAT core activation domain (known as a core activation domain); the Kruppel association box (KRAB) repression domain; the cleavage Kruppel association box (KRAB) repression domain; the repressor element silencing transcription factor (REST) ​​repression domain; the WRPW motif of the hairy-associated basic helix-loop-helix repressor protein (this motif is known as a WRPW repression domain); the DNA (cytosine-5)-methyltransferase 3B (DNMT3B) repression domain; and the HP1 alpha-chromoshadow repression domain, or any combination thereof.

[0278] Table 1 shows exemplary transcription effector domain protein sequences. Table 2 shows exemplary transcription effector domain nucleotide sequences.

[0279] (Table 1) Transcriptional effector domains (proteins) TIFF2023550469000002.tif97156

[0280] (Table 2) Transcriptional effector domains (nucleotides) TIFF2023550469000003.tif57156

[0281] promoter In some embodiments, the engineered nucleic acid of the Disclosure comprises a first expression cassette comprising a first promoter operably ligated to an exogenous polynucleotide sequence. In some embodiments, the engineered nucleic acid of the Disclosure comprises a second expression cassette comprising a second promoter operably ligated to a second exogenous polynucleotide sequence encoding one or more effector molecules. In some embodiments, the first and second expression cassettes are each encoded by separate engineered nucleic acids of the Disclosure. In other embodiments, the first and second expression cassettes are encoded by the same engineered nucleic acid of the Disclosure.

[0282] In some embodiments, the ACP-responsive promoter of this disclosure comprises an ACP-binding domain and a promoter sequence. In some embodiments, the ACP-responsive promoter is operably ligated to a nucleotide sequence encoding an effector molecule (e.g., a protein of interest).

[0283] A “promoter” refers to a regulatory region of a nucleic acid sequence that controls the initiation and rate of the rest of the transcription of that sequence. A promoter may also contain a small region to which regulatory proteins and molecules, such as RNA polymerase and other transcription factors, can bind. A promoter may be constitutive, inductive, repressive, tissue-specific, or any combination thereof. A promoter drives the expression or transcription of the nucleic acid sequence it regulates. In this specification, a promoter is considered “operably linked” when it is in the correct functional location and orientation with respect to the nucleic acid sequence it regulates in order to control (“drive") the initiation and / or expression of the transcription of that sequence.

[0284] A promoter may be one that is naturally associated with a gene or sequence, such that it can be obtained by isolating a 5' non-coding sequence located upstream of the coding segment of a given gene or sequence. Such a promoter may be referred to as “endogenous.” In some embodiments, the coding nucleic acid sequence may be placed under the control of a recombinant or heterologous promoter, which refers to a promoter that is not typically associated with the coded sequence in its natural environment. Such promoters may include promoters of other genes; promoters isolated from any other cell; and synthetic promoters or enhancers that are not “native,” such as those containing different elements and / or mutations of different transcriptional regulatory regions whose expression is modified by genetic engineering methods known in the Art. In addition to synthetically producing nucleic acid sequences of promoters and enhancers, sequences may be produced using nucleic acid amplification techniques, including recombinant cloning and / or polymerase chain reaction (PCR) (see, e.g., U.S. Patents 4,683,202 and 5,928,906).

[0285] The promoters of the manipulated nucleic acids in this disclosure may be “inducible promoters,” which are characterized by modulating (e.g., initiating or activating) transcriptional activity in the presence of, being affected by, or in contact with a signal. The signal may be an endogenous or usually exogenous state (e.g., light), a compound (e.g., a chemical or non-chemical compound), or a protein (e.g., a cytokine) that comes into contact with the inducible promoter in a manner that is active in modulating transcriptional activity from the inducible promoter. Activation of transcription may include acting directly on the promoter to drive transcription, or acting indirectly on the promoter by inactivating a repressor that prevents the promoter from driving transcription. Conversely, inactivation of transcription may include acting directly on the promoter to prevent transcription, or acting indirectly on the promoter by activating a repressor that then acts on the promoter.

[0286] A promoter is “responsive” or “modulated” to a signal if, in the presence of a local tumor condition (e.g., inflammation or hypoxia), or any such condition or signal, transcription from the promoter is activated, inactivated, increased, or decreased. In some embodiments, the promoter includes a response element, which is a short sequence of DNA within the promoter region that binds to a specific molecule (e.g., a transcription factor) that modulates (controls) gene expression from the promoter. Response elements that may be used in accordance with this disclosure include, but are not limited to, the phloretin-adjustable regulatory element (PEACE), zinc finger DNA-binding domain (DBD), interferon-gamma activating sequence (GAS) (Decker, T. et al. J Interferon Cytokine Res. 1997 Mar; 17(3): 121-34, incorporated herein by reference), interferon-stimulated response element (IRE) (Han, K. et al. J Biol Chem. 2004 Apr 9; 279(15): 15652-61, incorporated herein by reference), NF-kappa B response element (Wang, V. et al. Cell Reports. 2012; 2(4): 824-839, incorporated herein by reference), and STAT3 response element (Zhang, D. et al. J of Biol Chem. 1996; This includes 271:9503-9509 (incorporated herein by reference). Other response elements are incorporated herein. Response elements may also include tandem repeats (e.g., consecutive repeats of the same nucleotide sequence encoding the response element) to generally increase the sensitivity of the response element to its homologous molecules. Tandem repeats may be labeled as 2×, 3×, 4×, 5×, etc., to indicate the number of repeats present.

[0287] Table 3 lists non-limiting examples of responsive promoters (also referred to as "inducible promoters") (e.g., the TGF-beta responsive promoter), which illustrate the promoter and transcription factor design, as well as the effects of inducible molecule toward transcription factor (TF) and transgene transcription (T) (B, binding; D, dissociation; nd, undetermined) (A, activation; DA, deactivation; DR, derepression) (see Horner, M. & Weber, W. FEBS Letters 586 (2012) 20784-2096m and the references cited therein). Table 4 shows non-limiting examples of components that may be included in inducible promoters (e.g., minimal promoters and responsive elements).

[0288] (Table 3) Exemplary Inducible Promoter TIFF2023550469000004.tif247158TIFF2023550469000005.tif139158

[0289] (Table 4) Exemplary components of an inductive promoter TIFF2023550469000006.tif189155

[0290] Other non-limiting examples of promoters include the cytomegalovirus (CMV) promoter, the elongation factor 1-alpha (EF1a) promoter, the elongation factor (EFS) promoter, the MND promoter (a synthetic promoter containing the U3 region of a modified MoMuLV LTR with a myeloproliferative sarcoma virus enhancer), the phosphoglycerate kinase (PGK) promoter, the splenic fociforming virus (SFFV) promoter, the Simian virus 40 (SV40) promoter, and the ubiquitin C (UbC) promoter. In some embodiments, the promoter is a constitutive promoter. Exemplary constitutive promoters are shown in Table 5.

[0291] (Table 5) Exemplary constitutive promoters TIFF2023550469000007.tif248160TIFF2023550469000008.tif248160TIFF20235504690 00009.tif248160TIFF2023550469000010.tif248160TIFF2023550469000011.tif218160

[0292] In some embodiments, the promoter sequence is derived from a promoter selected from the following: minP, NFkB response element, CREB response element, NFAT response element, SRF response element 1, SRF response element 2, AP1 response element, TCF-LEF response element promoter fusion, hypoxia-responsive element, SMAD binding element, STAT3 binding site, minCMV, YB_TATA, minTK, inducible molecule-responsive promoter, and their tandem repeats.

[0293] In some embodiments, the first promoter is a constitutive promoter, an inducible promoter, or a synthetic promoter. In some embodiments, the constitutive promoter is selected from: CMV, EFS, SFFV, SV40, MND, PGK, UbC, hEF1aV1, hCAGG, hEF1aV2, hACTb, heIF4A1, hGAPDH, hGRP78, hGRP94, hHSP70, hKINb, and hUBIb.

[0294] In some embodiments, the ACP-responsive promoter is a synthetic promoter. In some embodiments, the ACP-responsive promoter includes a minimal promoter. In some embodiments, the ACP-binding domain includes one or more zinc finger binding sites. The ACP-binding domain may include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more zinc finger binding sites. In some embodiments, the ACP-binding domain includes one zinc finger binding site. In some embodiments, the ACP-binding domain includes two zinc finger binding sites. In some embodiments, the ACP-binding domain includes three zinc finger binding sites. In some embodiments, the ACP-binding domain includes four zinc finger binding sites. An exemplary ACP-binding domain containing a zinc finger binding site is shown in the following sequence: cgggtttcgtaacaatcgcatgaggattcgcaacgccttcGGCGTAGCCGATGTCGCGctcccgtctcagtaaaggtcGGCGTAGCCGATGTCGCGcaatcggactgccttcgtacGGCGTAGCCGATGTCGCGcgtatcagtcgcctcggaacGGCGTAGCCGATGTCGCGcattcgtaagaggctcactctcccttacacggagtggataACTAGTTCTAGAGGGTATATAATGGGGGCCA (SEQ ID NO: 100).

[0295] In some embodiments, the ACP-responsive promoter includes an enhancer that promotes transcription when the antigen-recognition receptor binds to a congeneral antigen, e.g., an antigen expressed on a target cell. The enhancer may include, but is not limited to, an enhancer enhanced in the ATAC sequence of activated T cells (Gate et al. Nat Genet. Author manuscript; available in PMC 2019 Jan 9, incorporated herein by reference for all purposes) or a cell-associated enhancer upregulated by single-cell RNA sequence data (Xhangolli et al. Genomics Proteomics Bioinformatics. 2019 Apr;17(2):129-139. Doi:10.1016 / j.gpb.2019.03.002, incorporated herein by reference for all purposes). The enhancer may be a synthetic enhancer, e.g., a pair of transcription factors known or predicted to be upregulated in activated T cells or NK cells. The synthetic enhancer may include multiple repeats of the transcription factor binding site, for example, four repeats of two different transcription factor binding sites in aaaabbbb or abababab composition. Exemplary, non-exclusive examples of genes that can induce enhancers include, but are not limited to, ATF2, ATF7, BACH1, BATF, Bcl-6, Blimp-1, BMI1, CBFB, CREB1, CREM, CTCF, E2F1, EBF1, EGR1, ETV6, FOS, FOXA1, FOXA2, GATA3, HIF1A, IKZF1, IKZF2, IRF4, JUN, JUNB, JUND, Lef1, NFAT, NFIA, NFIB, NFKB, NR2F1, Nur77, PU.1, RELA, RUNX3, SCRT1, SCRT2, SP1, STAT4, STAT5A, T-Bet, Tcf7, ZBED1, ZNF143, or ZNF217.

[0296] Multi-cistronic and multiple promoter systems In some embodiments, the manipulated nucleic acid is configured to produce multiple polypeptides. For example, the nucleic acid may be configured to produce 2 to 20 different polypeptides. In some embodiments, nucleic acids are 2-20, 2-19, 2-18, 2-17, 2-16, 2-15, 2-14, 2-13, 2-12, 2-11, 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, 2-4, 2-3, 3-20, 3-19, 3-18, 3-17, 3-16, 3-15, 3-14, 3-13, 3-12, 3-11, 3-10, 3-9, 3-8, 3-7, 3-6, 3-5, 3-4, 4-20, 4-19, 4-18, 4-17, 4-16, 4-15, 4-14, 4-13, 4-12, 4-11, 4-1 0, 4~9, 4~8, 4~7, 4~6, 4~5, 5~20, 5~19, 5~18, 5~17, 5~16, 5~15, 5~14, 5~13, 5~12, 5~11, 5~10, 5~9, 5~8, 5~7, 5~6, 6~20, 6~19, 6~18, 6~17, 6~16, 6~15, 6~14, 6~13, 6~12, 6~11, 6~10, 6~9, 6~8, 6~7, 7~20, 7~19, 7~18, 7~17, 7~16, 7~15, 7~14, 7~13, 7~12, 7~11, 7~10, 7~9, 7~8, 8~20, 8~ 19, 8~18, 8~17, 8~16, 8~15, 8~14, 8~13, 8~12, 8~11, 8~10, 8~9, 9~20, 9~19, 9~18, 9~17, 9~16, 9~15, 9~14, 9~13, 9~12, 9~11, 9~10, 10~20, 10~19, 10~18, 10~17, 10~16, 10~15, 10~14, 10~13, 10~12, 10~11, 11~20, 11~19, 11~18, 11~17, 11~16, 11~15, 11~14, 11~13, 11~12, 12~20, 12~ It is configured to produce polypeptides of 19, 12-18, 12-17, 12-16, 12-15, 12-14, 12-13, 13-20, 13-19, 13-18, 13-17, 13-16, 13-15, 13-14, 14-20, 14-19, 14-18, 14-17, 14-16, 14-15, 15-20, 15-19, 15-18, 15-17, 15-16, 16-20, 16-19, 16-18, 16-17, 17-20, 17-19, 17-18, 18-20, 18-19, or 19-20.In some embodiments, the nucleic acid is configured to produce polypeptides 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0297] In some embodiments, the engineered nucleic acid may be multicistronic, meaning that multiple distinct polypeptides (e.g., multiple exogenous polynucleotides or effector molecules) can be produced from a single transcript. The engineered nucleic acid may be multicistronic by the use of various linkers, for example, a polynucleotide sequence encoding a first exogenous polynucleotide or effector molecule can be linked in the 5' to 3' direction, such as first gene:linker:second gene, to a nucleotide sequence encoding a second exogenous polynucleotide or effector molecule. The linker polynucleotide sequence may encode a 2A ribosome skipping element, such as T2A. Other 2A ribosome skipping elements include, but are not limited to, E2A, P2A, and F2A. The 2A ribosome skipping element enables the production of separate polypeptides encoded by the first and second genes during translation. The linker may encode a cleavable linker polypeptide sequence, such as a furin cleavage site or a TEV cleavage site, where, following expression, the cleavable linker polypeptide is cleaved to produce separate polypeptides encoded by the first and second genes. The cleavable linker may also include polypeptide sequences that further facilitate cleavage, such as a mobile linker (e.g., a Gly-Ser-Gly sequence).

[0298] Linkers can encode intra-sequence ribosome entry sites (IRESs), ensuring that separate polypeptides encoded by the first and second genes are produced during translation. Linkers can also encode splice acceptors, such as viral splice acceptors.

[0299] The linker can be a combination of linkers, such as a furin-2A linker, which can produce separate polypeptides by 2A ribosome skipping, followed by further cleavage of the furin site allowing for complete removal of the 2A residue. In some embodiments, the linker combination may include a furin sequence, a mobile linker, and a 2A linker. Thus, in some embodiments, the linker is a furin-Gly-Ser-Gly-2A fusion polypeptide. In some embodiments, the linker is a furin-Gly-Ser-Gly-T2A fusion polypeptide.

[0300] In general, a multicistronic system can express any number of genes or portions thereof using any number or combination of linkers (for example, the engineered nucleic acid may encode first, second, and third effector molecules, each separated by a linker, so that distinct polypeptides are produced, each encoded by a first, second, and third effector molecule).

[0301] As used herein, "linker" may refer to a polypeptide that links a first polypeptide sequence with a second polypeptide sequence, or the multi-cistronic linker described above.

[0302] Post-transfer regulatory elements In some embodiments, the manipulated nucleic acids of the Disclosure include post-transcriptional regulatory elements (PREs). PREs can enhance gene expression by enabling tertiary RNA structure stability and 3' end formation. Non-limiting examples of PREs include hepatitis B virus PREs (HPREs) and woodchuck hepatitis virus PREs (WPREs). In some embodiments, the post-transcriptional regulatory element is a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE). In some embodiments, the WPRE includes the alpha, beta, and gamma components of the WPRE element. In some embodiments, the WPRE includes the alpha component of the WPRE element.

[0303] Manipulated cells This specification also provides cells containing one or more engineered nucleic acids, and methods for producing these cells. These cells are referred to herein as “engineered cells.” Generally, these cells containing one or more engineered nucleic acids do not occur in nature. In some embodiments, the cells are isolated cells recombinantly expressing one or more engineered nucleic acids. In some embodiments, the engineered one or more nucleic acids are expressed from one or more vectors or selected loci derived from the cell’s genome. In some embodiments, the cells are engineered to contain a first nucleic acid comprising a promoter operably ligated to a nucleotide sequence.

[0304] The manipulated cells in this disclosure may include manipulated nucleic acids that are integrated into the cell's genome. The manipulated cells may also include manipulated nucleic acids that can be expressed without being integrated into the cell's genome, for example, by a transient expression system, such as a plasmid or mRNA.

[0305] Types of manipulated cells The manipulated or isolated cells in this disclosure may be human cells. The manipulated or isolated cells may be human primary cells. The manipulated primary cells may be any somatic cells. The manipulated primary cells may be any stem cells. The manipulated primary cells may be induced pluripotent stem cells (iPSCs). In some embodiments, the manipulated cells are derived from the subject. In some embodiments, the manipulated cells are allogeneic with respect to the subject.

[0306] The manipulated cells described herein can be isolated from a subject, for example, a subject known or suspected of having cancer. Methods of cell isolation are known to those skilled in the art and include, but are not limited to, sorting techniques based on cell surface marker expression, e.g., FACS sorting, positive isolation techniques, and negative isolation, magnetic isolation, and combinations thereof. The manipulated cells may be allogeneic with respect to the subject being treated. Allogeneically modified cells can be HLA-matched to the subject being treated. The manipulated cells may be cultured cells, e.g., ex vivo cultured cells. The manipulated cells may be ex vivo cultured cells, e.g., primary cells isolated from a subject. Cultured cells can be cultured with one or more cytokines.

[0307] In some embodiments of the Disclosure, the manipulated or isolated cells are selected from: T cells (e.g., CD8+ T cells, CD4+ T cells, or gamma delta T cells), cytotoxic T lymphocytes (CTLs), regulatory T cells, natural killer T (NKT) cells, natural killer (NK) cells, B cells, tumor-infiltrating lymphocytes (TILs), innate lymphoid cells, mast cells, eosinophils, basophils, neutrophils, myeloid cells, macrophages (e.g., M1 macrophages or M2 macrophages), monocytes, dendritic cells, erythrocytes, platelet cells, neurons, oligodendrocytes, astrocytes, placode-derived cells, Schwann cells, cardiomyocytes, endothelial cells, nodular myocytes, microglia, hepatocytes, cholangiocarcinomas, beta cells, human embryonic stem cells (ESCs), ESC-derived cells, pluripotent stem cells, mesenchymal stromal cells (MSCs), induced pluripotent stem cells (iPSCs), and iPSC-derived cells.

[0308] In some embodiments, the manipulated or isolated cells of the Disclosure are T cells (e.g., CD8+ T cells, CD4+ T cells, or gamma delta T cells). In some embodiments, the manipulated or isolated cells of the Disclosure are cytotoxic T lymphocytes (CTLs). In some embodiments, the manipulated or isolated cells of the Disclosure are regulatory T cells. In some embodiments, the manipulated or isolated cells of the Disclosure are natural killer T cells (NTKs). In some embodiments, the manipulated or isolated cells of the Disclosure are natural killer cells (NKs). In some embodiments, the manipulated or isolated cells of the Disclosure are B cells. In some embodiments, the manipulated or isolated cells of the Disclosure are tumor-infiltrating lymphocytes (TILs). In some embodiments, the manipulated or isolated cells of the Disclosure are innate lymphoid cells. In some embodiments, the manipulated or isolated cells of the Disclosure are mast cells. In some embodiments, the manipulated or isolated cells of the Disclosure are eosinophils. In some embodiments, the manipulated or isolated cells of the Disclosure are basophils. In some embodiments, the manipulated or isolated cells of the Disclosure are neutrophils. In some embodiments, the manipulated or isolated cells of the Disclosure are myeloid cells. In some embodiments, the manipulated or isolated cells of the Disclosure are macrophages (e.g., M1 macrophages or M2 macrophages). In some embodiments, the manipulated or isolated cells of the Disclosure are monocytes. In some embodiments, the manipulated or isolated cells of the Disclosure are dendritic cells. In some embodiments, the manipulated or isolated cells of the Disclosure are erythrocytes. In some embodiments, the manipulated or isolated cells of the Disclosure are platelet cells. In some embodiments, the manipulated or isolated cells of the Disclosure are neurons. In some embodiments, the manipulated or isolated cells of the Disclosure are oligodendrocytes. In some embodiments, the manipulated or isolated cells of the Disclosure are astrocytes. In some embodiments, the manipulated or isolated cells of the Disclosure are placode-derived cells.In some embodiments, the manipulated or isolated cells of the Disclosure are Schwann cells. In some embodiments, the manipulated or isolated cells of the Disclosure are cardiomyocytes. In some embodiments, the manipulated or isolated cells of the Disclosure are endothelial cells. In some embodiments, the manipulated or isolated cells of the Disclosure are nodular myocytes. In some embodiments, the manipulated or isolated cells of the Disclosure are microglia cells. In some embodiments, the manipulated or isolated cells of the Disclosure are hepatocytes. In some embodiments, the manipulated or isolated cells of the Disclosure are cholangiocarcinomas. In some embodiments, the manipulated or isolated cells of the Disclosure are beta cells. In some embodiments, the manipulated or isolated cells of the Disclosure are human embryonic stem cells (ESCs). In some embodiments, the manipulated or isolated cells of the Disclosure are ESC-derived cells. In some embodiments, the manipulated or isolated cells of the Disclosure are pluripotent stem cells. In some embodiments, the manipulated or isolated cells of the Disclosure are mesenchymal stromal cells (MSCs). In some embodiments, the manipulated or isolated cells of the Disclosure are induced pluripotent stem cells (iPSCs). In some embodiments, the manipulated or isolated cells of the Disclosure are iPSC-derived cells. In some embodiments, the manipulated cells are autologous. In some embodiments, the manipulated cells are allogeneic. In some embodiments, the manipulated or isolated cells of the Disclosure are CD34+ cells, CD3+ cells, CD8+ cells, CD16+ cells, and / or CD4+ T cells.

[0309] In some embodiments, the manipulated cells of this disclosure are tumor cells selected from adenocarcinoma cells, bladder tumor cells, brain tumor cells, breast tumor cells, cervical tumor cells, colorectal tumor cells, esophageal tumor cells, glioma cells, kidney tumor cells, liver tumor cells, lung tumor cells, melanoma cells, mesothelioma cells, ovarian tumor cells, pancreatic tumor cells, prostate tumor cells, skin tumor cells, thyroid tumor cells, and uterine tumor cells.

[0310] In some embodiments of the present disclosure, the manipulated cells are bacterial cells selected from: Clostridium beijerinckii, Clostridium sporogenes, Clostridium novyi, Escherichia coli, Pseudomonas aeruginosa, Listeria monocytogenes, Salmonella typhimurium, and Salmonella choleraesuis.

[0311] Furthermore, provided herein are methods for culturing the manipulated cells described herein. Methods for culturing manipulated cells as described herein are known. Those skilled in the art will recognize that the culture conditions depend on the specific manipulated cells of interest. Those skilled in the art will also recognize that the culture conditions depend on the specific culture conditions for the specific downstream use of the manipulated cells, for example, the subsequent administration of the manipulated cells to a subject.

[0312] Methods for manipulating cells Compositions and methods for manipulating cells having any of the nucleic acids described herein are also provided herein.

[0313] Generally, cells are manipulated by the introduction (i.e., delivery) of one or more polynucleotides of the present disclosure. Delivery methods include, but are not limited to, virus-mediated delivery, lipid-mediated transfection, nanoparticle delivery, electroporation, sonication, and physical deformation of the cell membrane. Those skilled in the art will understand that the choice of delivery method may depend on the specific cell type to be manipulated.

[0314] In some embodiments, the manipulated cells are transduced using an oncolytic virus. Examples of oncolytic viruses include, but are not limited to, oncolytic herpes simplex virus, oncolytic adenovirus, oncolytic measles virus, oncolytic influenza virus, oncolytic Indianabecyclovirus, oncolytic Newcastle disease virus, oncolytic vaccinia virus, oncolytic poliovirus, oncolytic myxoma virus, oncolytic reovirus, oncolytic mumps virus, oncolytic marabavirus, oncolytic rabies virus, oncolytic rotavirus, oncolytic hepatitis virus, oncolytic rubella virus, oncolytic dengue virus, oncolytic chikungunya virus, oncolytic respiratory syncytial virus, oncolytic lymphocytic choriomeningitis virus, oncolytic morbillivirus, oncolytic lentivirus, oncolytic replication retrovirus, oncolytic rhabdovirus, oncolytic seneca-valley virus, oncolytic sindobisvirus, and any variants or derivatives thereof. In some embodiments, the oncolytic virus is a recombinant oncolytic virus comprising a first expression cassette and a second expression cassette. In some embodiments, the oncolytic virus further comprises a third expression cassette.

[0315] A virus comprising any of the oncolytic viruses described herein may be a recombinant virus encoding one or more transgenes encoding one or more effector molecules, such as any of the engineered nucleic acids described herein. A virus comprising any of the oncolytic viruses described herein may be a recombinant virus encoding one or more transgenes encoding one or more of two or more effector molecules, such as any of the engineered nucleic acids described herein. In some embodiments, cells are engineered via transduction with an oncolytic virus.

[0316] Virus-borne delivery Cells can be manipulated using viral vector delivery platforms. Generally, cells are manipulated by introducing (i.e., delivering) a viral vector delivery platform into a host cell. For example, a viral vector delivery platform can manipulate cells by introducing one of the manipulated nucleic acids described herein. While a viral vector delivery platform can be a nucleic acid, such manipulated nucleic acids may also include nucleic acids derived from manipulated viruses. Such nucleic acids derived from manipulated viruses may also be referred to as recombinant viruses or manipulated viruses.

[0317] A viral vector delivery platform may encode two or more engineered nucleic acids, genes, or transgenes within the same nucleic acid. For example, an engineered virus-derived nucleic acid, such as a recombinant virus or engineered virus, may encode one or more transgenes, including, but not limited to, any of the engineered nucleic acids described herein that encode one or more effector molecules. One or more transgenes encoding one or more effector molecules can be configured to express one or more effector molecules. In addition to one or more transgenes (e.g., transgenes encoding one or more effector molecules), a viral vector delivery platform may encode one or more genes called cis-acting elements or cis-acting genes, such as viral genes necessary for viral infectivity and / or viral production (e.g., capsid proteins, envelope proteins, viral polymerases, viral transcriptases, etc.).

[0318] A viral vector delivery platform may include two or more viral vectors, such as separate viral vectors encoding engineered nucleic acids, genes, or transgenes, as described herein and referred to as transactive elements or genes. For example, a helper-dependent viral vector delivery platform may provide additional genes necessary for viral infectivity and / or viral production on one or more additional separate vectors, in addition to a vector encoding one or more effector molecules. A single viral vector may deliver multiple engineered nucleic acids, such as a single vector delivering engineered nucleic acids configured to produce two or more effector molecules. Multiple viral vectors may deliver multiple engineered nucleic acids, such as multiple vectors delivering one or more engineered nucleic acids configured to produce one or more effector molecules. The number of viral vectors used may depend on the packaging capacity of the viral vector-based vaccine platform mentioned above, but those skilled in the art can select a suitable number of viral vectors.

[0319] In general, any viral vector system can be used for the in vitro production of molecules such as effector molecules, or for in vivo and ex vivo gene therapy procedures to deliver, for example, engineered nucleic acids encoding one or more effector molecules in vitro. The selection of a suitable viral vector system depends on various factors, such as cargo / payload size, immunogenicity of the viral system, target cells of interest, intensity and timing of gene expression, and other factors recognized by those skilled in the art.

[0320] Viral vector delivery platforms may be RNA-based viruses or DNA-based viruses. Exemplary viral vector delivery platforms include, but are not limited to, herpes simplex virus, adenovirus, measles virus, influenza virus, Indiana beshiclovirus, Newcastle disease virus, vaccinia virus, poliovirus, myxoma virus, reovirus, mumps virus, maraba virus, rabies virus, rotavirus, hepatitis virus, rubella virus, dengue virus, chikungunya virus, respiratory syncytial virus, lymphocytic choriomeningitis virus, morbillivirus, lentivirus, replication retrovirus, rhabdovirus, Seneca Valley virus, Sindbisvirus, and any variants or derivatives thereof.Other exemplary viral vector delivery platforms have been described in the Art, e.g., vaccinia, fowlpox, self-replicating alphavirus, marabavirus, adenovirus (see, e.g., Tatsis et al., Adenoviruses, Molecular Therapy (2004) 10, 616-629), or, but not limited to, second, third, or hybrid second / third generation lentiviruses and any generation of recombinant lentiviruses designed to target specific cell types or receptors (e.g., Hu et al., Immunization Delivered by Lentiviral Vectors for Cancer and Infectious Diseases, Immunol Rev. (2011) 239(1):45-61, Sakuma et al., Lentiviral vectors: basic to translational, Biochem J. (2012) 443(3):603-18, Cooper et al., Rescue of splicing-mediated intron loss maximizes expression in lentiviral vectors containing the human ubiquitin These include lentiviruses, such as those containing the C promoter (see Nucl. Acids Res. (2015) 43(1):682-690, Zufferey et al., Self-Inactivating Lentivirus Vector for Safe and Efficient In vivo Gene Delivery, J. Virol. (1998) 72(12):9873-9880).

[0321] This sequence may be preceded by one or more sequences that target intracellular compartments. Upon introduction (i.e., delivery) to host cells, infected cells (i.e., manipulated cells) may express and, in some cases, secrete one or more effector molecules. Cowpox vectors and methods useful in immunization protocols are described, for example, in U.S. Patent No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). The BCG vector is described in Stover et al. (Nature 351:456-460 (1991)). A wide variety of other vectors useful for the introduction (i.e., delivery) of manipulated nucleic acids, such as Salmonella cyfi vectors, will be apparent to those skilled in the art from the description herein.

[0322] The viral vector delivery platform may be a virus that targets tumor cells, and is referred to herein as an oncolytic virus. Examples of oncolytic viruses include, but are not limited to, oncolytic herpes simplex virus, oncolytic adenovirus, oncolytic measles virus, oncolytic influenza virus, oncolytic Indianabecyclovirus, oncolytic Newcastle disease virus, oncolytic vaccinia virus, oncolytic poliovirus, oncolytic myxoma virus, oncolytic reovirus, oncolytic mumps virus, oncolytic maraba virus, oncolytic rabies virus, oncolytic rotavirus, oncolytic hepatitis virus, oncolytic rubella virus, oncolytic dengue virus, oncolytic chikungunya virus, oncolytic respiratory syncytial virus, oncolytic lymphocytic choriomeningitis virus, oncolytic morbillivirus, oncolytic lentivirus, oncolytic replication retrovirus, oncolytic rhabdovirus, oncolytic seneca-valley virus, oncolytic sindobisvirus, and any variants or derivatives thereof. Any of the oncolytic viruses described herein may be recombinant oncolytic viruses containing another transgene (e.g., engineered nucleic acid) encoding one or more effector molecules. The transgene encoding one or more effector molecules can be configured to express one or more effector molecules.

[0323] In some embodiments, the virus is selected from lentiviruses, retroviruses, oncolytic viruses, adenoviruses, adeno-associated viruses (AAVs), and virus-like particles (VLPs).

[0324] Viral vector delivery platforms can be retrovirus-based. Generally, retroviral vectors consist of cis-acting long terminal repeats with packaging capabilities for exogenous sequences up to 6–10 kb. The smallest cis-acting LTR is sufficient for vector replication and packaging, after which one or more manipulated nucleic acids (e.g., transgenes encoding one or more effector molecules) are incorporated into target cells to provide persistent transgene expression. Retroviral delivery systems include, but are not limited to, delivery systems based on mouse leukemia virus (MuLV), gibbon leukemia virus (GaLV), simian immunodeficiency virus (SIV), human immunodeficiency virus (HIV), and combinations thereof (e.g., Buchscher et al., J.Virol.66:2731-2739(1992); Johann et al., J.Virol.66:1635-1640(1992); Sommnerfelt et al., Virol.176:58-59(1990); Wilson et al., J.Virol.63:2374-2378(1989); Miller et al, J.Virol.65:2220-2224(1991); see PCT / US94 / 05700). Other retroviral systems include the Phoenix retroviral system.

[0325] Viral vector delivery platforms can be lentiviral. Generally, lentiviral vectors are retroviral vectors that can transduce or infect non-dividing cells and typically produce high viral titers. Lentiviral delivery platforms can be HIV-based, such as the ViraPower system (ThermoFisher) or the pLenti system (Cell Biolabs). Lentiviral delivery platforms can also be SIV or FIV-based. Other exemplary lentiviral delivery platforms are described in more detail in U.S. Patents Nos. 7,311,907; 7,262,049; 7,250,299; 7,226,780; 7,220,578; 7,211,247; 7,160,721; 7,078,031; 7,070,993; 7,056,699; and 6,955,919, each incorporated herein by reference for all purposes.

[0326] Viral vector delivery platforms can be adenovirus-based. Generally, adenovirus vectors can exhibit very high transduction efficiency in many cell types, do not require cell division, achieve high titer and expression levels, and can be produced in large quantities in relatively simple systems. Adenoviruses can generally be used for transient expression of transgenes within infected cells because they typically do not integrate into the host genome. Adenovirus-based delivery platforms are described in more detail in Li et al., Invest Opthalmol Vis Sci 35:2543 2549, 1994; Borras et al., Gene Ther 6:515 524, 1999; Li and Davidson, PNAS 92:7700 7704, 1995; Sakamoto et al., H Gene Ther 5:1088 1097, 1999; WO 94 / 12649, WO 93 / 03769; WO 93 / 19191; WO 94 / 28938; WO 95 / 11984 and WO 95 / 00655, each incorporated herein by reference for all purposes. Other exemplary adenovirus-based delivery platforms are described in more detail in U.S. Patents 5,585,362; 6,083,716, 7,371,570; 7,348,178; 7,323,177; 7,319,033; 7,318,919; and 7,306,793, as well as in International Patent Application WO96 / 13597, each of which is incorporated herein by reference for all purposes.

[0327] The viral vector delivery platform may be an adeno-associated virus (AAV) system. Adeno-associated virus (AAV) vectors may be used to transduce cells with engineered nucleic acids (e.g., any of the engineered nucleic acids described herein). The AAV system can be used for the in vitro production of effector molecules, or for in vivo delivery of engineered nucleic acids encoding one or more effector molecules in in vivo and ex vivo gene therapy procedures (e.g., West et al., Virology 160:38-47 (1987); U.S. Patent Nos. 4,797,368; 5,436,146; 6,632,670; 6,642,051; 7,078,387; 7,314,912; 6,498,244; 7,906,111; U.S. Patent Publications US 2003-0138772, US 2007 / 0036760, and US 2009 / 0197338; Gao, et al.). al., J. Virol, 78(12):6381-6388 (June 2004); Gao, et al, Proc Natl Acad Sci USA, 100(10):6081-6086 (May 13, 2003); and international patent applications WO 2010 / 138263 and WO 93 / 24641; Kotin, Human Gene Therapy 5:793-801 (1994); Muzyczka, J. Clin. Invest. 94:1351 (1994), each of which is incorporated herein by reference for all purposes, exemplary methods for constructing recombinant AAV vectors are U.S. Patent No. 5,173,414; Tratschin et al., Mol. Cell. Biol. 5:3251-3260 (1985); Tratschin, et al. Further details are provided in ah, Mol. Cell, Biol. 4:2072-2081 (1984); Hermonat & Muzyczka, PNAS 81:64666470 (1984); and Samuiski et ah, J. Virol. 63:03822-3828 (1989), each incorporated herein by reference for all purposes.Generally, AAV vectors contain a capsid protein having an amino acid sequence corresponding to one of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV.Rh10, AAV11, or their variants.

[0328] Viral vector delivery platforms can be virus-like particle (VLP) platforms. Generally, VLPs are constructed by producing viral structural proteins and purifying the resulting viral particles. After purification, the cargo / payload (e.g., any of the engineered nucleic acids described herein) is then ex vivo encapsulated within the purified particles. Thus, VLP production maintains the separation of the nucleic acid encoding the viral structural protein from the nucleic acid encoding the cargo / payload. The viral structural proteins used in VLP production can be produced in a variety of expression systems, including mammalian, yeast, insect, bacterial, or in vivo translational expression systems. The purified viral particles can be denatured and reformed in the presence of the desired cargo using methods known to those skilled in the art to produce VLPs. VLP production is described in more detail in Seow et al. (Mol Ther. 2009 May; 17(5):767-777), which is incorporated herein by reference for all purposes.

[0329] Viral vector delivery platforms can be manipulated to target (i.e., infect) a range of cells, a narrow subset of cells, or specific cells. Generally, the tropism of the virus is determined by the envelope protein selected for the viral vector delivery platform. The virus used in a viral vector delivery platform can be pseudotyped to target specific cells of interest. A viral vector delivery platform can be generalized and capable of infecting a range of cells. For example, a generalized viral vector delivery platform may contain the VSV-G envelope. A viral vector delivery platform can be bispecific and capable of infecting mammalian cells. Therefore, those skilled in the art can select the appropriate tropism, pseudotype, and / or envelope protein to target the desired cell type.

[0330] Lipid structure delivery system The engineered nucleic acids described herein (e.g., any of the engineered nucleic acids described herein) can be introduced into cells using lipid-mediated delivery systems. Generally, lipid-mediated delivery systems use structures consisting of an outer lipid membrane enclosing an internal compartment. Examples of lipid structures include, but are not limited to, lipid nanoparticles, liposomes, micelles, exosomes, vesicles, extracellular vesicles, cells, or tissues. Lipid structure delivery systems can deliver cargo / payloads (e.g., any of the engineered nucleic acids described herein) in vitro, in vivo, or ex vivo.

[0331] Lipid nanoparticles may include, but are not limited to, monolayer liposomes, multilayer liposomes, and lipid preparations. As used herein, “liposome” is a general term encompassing in vitro preparations of lipid media formed by encapsulating a desired cargo, e.g., engineered nucleic acids, e.g., any of the engineered nucleic acids described herein, within a lipid shell or lipid aggregate. Liposomes may generally be characterized as having a vesicular structure with a phospholipid-containing bilayer membrane and an internal medium generally containing an aqueous composition. Liposomes may include, but are not limited to, emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, layered layers, etc. Liposomes may be monolayer liposomes. Liposomes may be multilayer liposomes. Liposomes may be multivesicular liposomes. Liposomes may be positively charged, negatively charged, or neutrally charged. In certain embodiments, liposomes are neutrally charged. Liposomes can be formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids, as well as sterols such as cholesterol. The selection of lipids is generally guided by consideration of the desired purpose, e.g., criteria for in vivo delivery, such as liposome size, acid instability, and liposome stability in the bloodstream. Various methods are available for preparing liposomes, as described in Szokan et al., Ann. Rev. Biophys. Bioeng. 9; 467 (1980), U.S. Patents No. 4,235,871, No. 4,501,728, No. 4,501,728, No. 4,837,028, and No. 5,019,369, each incorporated herein by reference for all purposes.

[0332] Multilayer liposomes are spontaneously formed when lipids containing phospholipids are suspended in an excess aqueous solution, so that multiple lipid layers are separated by the aqueous medium. The water and dissolved solute are encapsulated in a closed structure between the lipid bilayers after the self-reconstitution of the lipid components. Desired cargo (e.g., polypeptides, nucleic acids, small molecule drugs, engineered nucleic acids, such as any of the engineered nucleic acids described herein, viral vectors, viral delivery systems, etc.) can be encapsulated within the aqueous interior of the liposome, attached to the liposome via linking molecules that associate with both the liposome and the polypeptide / nucleic acid, scattered within the lipid bilayer of the liposome, encapsulated within the liposome, compounded with the liposome, or otherwise associated with the liposome so that it can be delivered to a target entity. Lipophilic molecules or molecules with lipophilic regions can also dissolve in or associate with the lipid bilayer.

[0333] Liposomes used according to this embodiment can be prepared by different methods that will be known to those skilled in the art. The preparation of liposomes is described in more detail in WO 2016 / 201323, international applications PCT / US85 / 01161 and PCT / US89 / 05040, and U.S. Patents 4,728,578, 4,728,575, 4,737,323, 4,533,254, 4,162,282, 4,310,505, and 4,921,706; each is incorporated herein by reference for all purposes.

[0334] Liposomes may be cationic liposomes. Examples of cationic liposomes are described in more detail in U.S. Patents 5,962,016; 5,030,453; 6,680,068, U.S. Patent Application 2004 / 0208921, and International Patent Applications WO03 / 015757A1, WO04029213A2, and WO02 / 100435A1, each incorporated herein by reference in whole.

[0335] Lipid-mediated gene delivery methods are described, for example, in WO 96 / 18372; WO 93 / 24640; Mannino & Gould-Fogerite, BioTechniques 6(7):682-691 (1988); U.S. Patent No. 5,279,833; Rose Patent No. 5,279,833; WO91 / 06309; and Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7414 (1987), each incorporated herein by reference for all purposes.

[0336] Exosomes are small membrane vesicles of endocytosis that are released into the extracellular environment after fusion of the polyendoplasmic reticulum with the plasma membrane. Exosomes range in size from 30 to 100 nm in diameter. Their surface consists of a lipid bilayer from the donor cell membrane, they contain cytosol from the exosome-producing cell, and exhibit membrane proteins from the parent cell on their surface. Exosomes useful for nucleic acid delivery are known to those skilled in the art; for example, exosomes are described in more detail in U.S. Patent No. 9,889,210, which is incorporated herein by reference for all purposes.

[0337] As used herein, the term “extracellular vesicle” or “EV” refers to a cell-derived vesicle containing a membrane that encloses an internal space. Generally, extracellular vesicles include all membrane-bound vesicles having a diameter smaller than the cell from which they originate. Generally, extracellular vesicles range in diameter from 20 nm to 1000 nm and may contain a variety of macromolecular cargoes, either within the internal space presented on the outer surface of the extracellular vesicle and / or across the membrane. Cargoes may include nucleic acids (e.g., any of the manipulated nucleic acids described herein), proteins, carbohydrates, lipids, small molecules, and / or combinations thereof. By example, but not limited to, extracellular vesicles include apoptotic bodies, cell fragments, vesicles derived from cells by direct or indirect manipulation (e.g., by continuous extrusion or treatment with alkaline solution), vesicle-forming organelles, and vesicles produced by living cells (e.g., by direct plasma membrane budding or fusion of late endosomes with the plasma membrane). Extracellular vesicles may originate from living or dead organisms, explanted tissues or organs, and / or cultured cells.

[0338] As used herein, the term “exosome” refers to a small cell-derived vesicle (20–300 nm in diameter, more preferably 40–200 nm in diameter) that contains a membrane surrounding its internal space and is produced from a cell by direct plasma membrane budding or fusion of late endosomes with the plasma membrane. Exosomes contain lipids or fatty acids and polypeptides and optionally include a payload (e.g., therapeutic agents), a receiver (e.g., a targeting portion), polynucleotides (e.g., nucleic acids, RNA, or DNA, such as any of the engineered nucleic acids described herein), sugars (e.g., monosaccharides, polysaccharides, or glycans), or other molecules. Exosomes originate from the producing cell and can be isolated from the producing cell based on their size, density, biochemical parameters, or a combination thereof. Exosomes are a type of extracellular vesicle. Generally, exosome production / biogenesis does not result in the destruction of the producing cell. The exosomes and their preparation are described in further detail in WO 2016 / 201323, which is incorporated herein by reference in its entirety.

[0339] As used herein, the term “nanopes” (also referred to as “microvesicles”) refers to small, cell-derived vesicles (20–250 nm in diameter, more preferably 30–150 nm in diameter) that contain a membrane surrounding their internal space and are produced by cells through direct or indirect manipulation, and that nanovesicles are not produced by the producing cell without such manipulation. Generally, nanovesicles are a subspecies of extracellular vesicles. Suitable manipulations of the producing cell include, but are not limited to, serial extrusion, treatment with alkaline solutions, sonication, or a combination thereof. Nanovesicle production may, in some cases, result in the destruction of the producing cell. Preferably, the nanovesicle population is substantially free of vesicles derived from the producing cell by direct budding from the plasma membrane or fusion of late endosomes with the plasma membrane. Nanovesicles contain lipids or fatty acids and polypeptides and optionally include a payload (e.g., therapeutic agent), a receiver (e.g., targeting portion), polynucleotides (e.g., nucleic acids, RNA, or DNA, such as any of the engineered nucleic acids described herein), sugars (e.g., monosaccharides, polysaccharides, or glycans), or other molecules. Once the nanovesicles are induced from the producing cells according to the engineered procedure, they can be isolated from the producing cells based on their size, density, biochemical parameters, or a combination thereof.

[0340] Lipid nanoparticles (LNPs) are generally synthetic lipid structures that form membrane and vesicle-like structures depending on the amphiphilic nature of the lipid (Riley 2017). Typically, these vesicles are absorbed into the membrane of target cells and deliver cargo / payloads, such as any of the engineered nucleic acid or viral systems described herein, by releasing the cargo into the cytosol. The lipids used in LNP formation may be cationic, anionic, or neutral. The lipids may be synthetic or naturally occurring, and in some cases, biodegradable. Lipids may include fats, cholesterol, phospholipids, lipid conjugates (including, but not limited to, polyethylene glycol (PEG) conjugates (PEGylated lipids)), waxes, oils, glycerides, and fat-soluble vitamins. Lipid compositions generally include defined mixtures of materials, such as cationic, neutral, anionic, and amphiphilic lipids. In some examples, specific lipids are included to provide functional chemical groups that prevent LNP aggregation, prevent lipid oxidation, or promote the adhesion of additional portions. Lipid composition can influence the overall LNP size and stability. For example, the lipid composition may include dilinoleylmethyl-4-dimethylaminobutyrate (MC3) or an MC3-like molecule. MC3 and MC3-like lipid compositions can be formulated to include one or more other lipids, such as PEG or PEG-conjugate lipids, sterols, or neutral lipids. Furthermore, LNPs can be further manipulated or functionalized to enhance targeting of specific cell types. Another consideration in LNP design is the balance between targeting efficiency and cytotoxicity.

[0341] A micelle is generally a spherical synthetic lipid structure formed using single-chain lipids, where the hydrophilic head of the single-chain lipid forms the outer layer or membrane, and the hydrophobic tail of the single-chain lipid forms the micelle center. Typically, a micelle refers to a lipid structure containing only a lipid monolayer. Micelles are described in more detail in Quader et al. (Mol Ther. 2017 Jul 5; 25(7):1501-1513), which is incorporated herein by reference for all purposes.

[0342] Nucleic acid vectors, such as expression vectors directly exposed to serum, can have several undesirable consequences, including degradation of the nucleic acid by serum nucleases or off-target stimulation of the immune system by free nucleic acids. Similarly, viral delivery systems directly exposed to serum can trigger undesirable immune responses and / or neutralization of the viral delivery system. Therefore, encapsulation of engineered nucleic acid and / or viral delivery systems can be used to avoid degradation while also avoiding potential off-target effects. In certain examples, the engineered nucleic acid and / or viral delivery system is completely encapsulated within a delivery medium, for example, within the aqueous interior of a LNP. Encapsulation of engineered nucleic acid and / or viral delivery systems within LNPs can be carried out by techniques well known to those skilled in the art, such as droplet generation performed on microfluidic mixing and microfluidic droplet generation devices. Such devices include, but are not limited to, standard T-junction devices or flow focusing devices. In one example, a desired lipid formulation, such as MC3 or an MC3-like composition, is supplied to a droplet generation device in parallel with an engineered nucleic acid or viral delivery system and any other desired drug, so that the delivery vector and the desired drug are completely encapsulated within the MC3 or MC3-like LNP. In one example, the droplet generation device can control the size range and size distribution of the produced LNPs. For example, the LNPs may have sizes in the range of 1 to 1000 nanometers in diameter, e.g., 1, 10, 50, 100, 500, or 1000 nanometers. Following droplet generation, the delivery medium (e.g., engineered nucleic acid and / or viral delivery system) encapsulating the cargo / payload can be further processed or manipulated to prepare them for administration.

[0343] Nanoparticle delivery Nanomaterials can be used to deliver engineered nucleic acids (e.g., any of the engineered nucleic acids described herein). Importantly, the nanomaterial medium can be made of non-immunogenic materials and generally avoid inducing immunity to its delivery vector itself. These materials include, but are not limited to, lipids (as previously described), inorganic nanomaterials, and other polymer materials. Nanomaterial particles are described in more detail in Riley et al. (Recent Advances in Nanomaterials for Gene Delivery - A Review. Nanomaterials 2017, 7(5), 94), which is incorporated herein by reference for all purposes.

[0344] genome editing system Genome editing systems can be used to manipulate the host genome to encode an engineered nucleic acid, for example, the engineered nucleic acid described herein. Generally, “genome editing system” refers to any system for incorporating an exogenous gene into the genome of a host cell. Genome editing systems include, but are not limited to, transposon systems, nuclease genome editing systems, and viral vector delivery platforms.

[0345] Transposon systems can be used to incorporate engineered nucleic acids, e.g., engineered nucleic acids, into the host genome. Transposons typically consist of a cargo / payload nucleic acid and a terminal inversion repeat (TIR) ​​adjacent to the transposase. Transposon systems can provide transposons in cis or trans orientation, accompanied by a TIR-adjacent cargo. Transposon systems can be retrotransposon systems or DNA transposon systems. Generally, transposon systems randomly incorporate cargo / payloads (e.g., engineered nucleic acids) into the host genome. Examples of transposon systems include systems using transposons from the Tc1 / mariner transposon superfamily, such as the Sleeping Beauty transposon system, which are described in more detail in Hudecek et al. (Crit Rev Biochem Mol Biol. 2017 Aug;52(4):355-380) and U.S. Patents 6,489,458, 6,613,752, and 7,985,739, each of which is incorporated herein by reference for all purposes. Another example of a transposon system includes the PiggyBac transposon system, which is described in more detail in U.S. Patents 6,218,185 and 6,962,810, each of which is incorporated herein by reference for all purposes.

[0346] Nuclease-mediated gene editing systems can be used to manipulate the host genome to encode an engineered nucleic acid, for example, the engineered nucleic acid disclosed herein. While we do not wish to dwell on theory, generally speaking, nuclease-mediated gene editing systems used to introduce exogenous genes utilize the cell's innate DNA repair mechanisms, particularly the homologous recombination (HR) repair pathway. Simply put, following damage to genomic DNA (typically a double-strand break), the cell can resolve the damage by using another DNA source having identical or substantially identical sequences at both its 5' and 3' ends as a template during DNA synthesis to repair the damage. In natural contexts, HDR can use other chromosomes present in the cell as templates. Gene editing systems introduce exogenous polynucleotides into the cell and use them as homologous recombination templates (HRT or HR templates). Generally, any additional exogenous sequences not naturally found in the chromosome, involving damage between the 5' and 3' complementary ends of an HRT (e.g., a gene or a portion of a gene), can be incorporated into a given genomic locus in a templated HDR. Thus, a typical HR template for a given genomic locus has a nucleotide sequence identical to the first region of the endogenous genomic target locus, a nucleotide sequence identical to the second region of the endogenous genomic target locus, and a nucleotide sequence encoding a cargo / payload nucleic acid (e.g., any of the engineered nucleic acids described herein, e.g., any of the engineered nucleic acids encoding one or more effector molecules).

[0347] In some cases, HR templates can be linear. Examples of linear HR templates include, but are not limited to, linearized plasmid vectors, ssDNA, synthetic DNA, and PCR-amplified DNA. In certain cases, HR templates can be circular, such as plasmids. Circular templates may include supercoiled templates.

[0348] Identical or substantially identical sequences found at the 5' and 3' ends of the HR template are generally referred to as arms (HR arms) with respect to the introduced exogenous sequence. HR arms may be identical (i.e., 100% identical) to the region of the endogenous genomic target locus. In some cases, HR arms may be substantially identical to the region of the endogenous genomic target locus. While substantially identical HR arms can be used, it may be advantageous for the HR arms to be identical. This is because the efficiency of the HDR pathway may be affected by HR arms with less than 100% identity.

[0349] Each HR arm, i.e., the 5' and 3' HR arms, may be the same size or different sizes. The length of each HR arm may be 50, 100, 200, 300, 400, or 500 base pairs or more, respectively. While HR arms can generally be of any length, practical considerations, such as the effect of HR arm length and overall template size on overall editing efficiency, may also be taken into account. Each HR arm may be identical or substantially identical to a region of an endogenous genomic target locus directly adjacent to the cleavage site. Each HR arm may be identical or substantially identical to a region of an endogenous genomic target locus directly adjacent to the cleavage site. Each HR arm may be identical or substantially identical to a region of an endogenous genomic target locus located within a certain distance from the cleavage site, for example, equal to 1 base pair, 10 base pairs or less, 50 base pairs or less, or 100 base pairs or less from each other.

[0350] Nuclease genome editing systems can cleave target genomic loci using a variety of nucleases, including, but not limited to, clustered and regularly arranged short palindromic repeat (CRISPR) family nucleases or derivatives, transcription activator-like effector nucleases (TALENs) or derivatives, zinc finger nucleases (ZFNs) or derivatives, and homing endonucleases (HEs) or derivatives.

[0351] Using CRISPR-mediated gene editing systems, it is possible to manipulate the host genome to encode, for example, an engineered nucleic acid encoding one or more of the effector molecules described herein. CRISPR systems are described in more detail in M. Adli ("The CRISPR tool kit for genome editing and beyond," Nature Communications; volume 9 (2018), Article number: 1911), and all that it teaches are incorporated herein by reference. Generally, CRISPR-mediated gene editing systems include a CRISPR-associated (Cas) nuclease and RNA that leads to cleavage at a specific target sequence. An exemplary CRISPR-mediated gene editing system is the CRISPR / Cas9 system, which consists of a Cas9 nuclease and RNA having a CRISPR RNA (crRNA) domain and a transactivating CRISPR (tracrRNA) domain. A crRNA typically has two RNA domains: a guide RNA sequence (gRNA), e.g., a genomic sequence, which directs specificity to the target sequence ("defined nucleotide sequence") through base-pair hybridization; and an RNA domain that hybridizes to tracrRNA. TracrRNAs can interact with nucleases (e.g., Cas9) to facilitate recruitment to genomic loci. The crRNA and tracrRNA polynucleotides may be separate polynucleotides. The crRNA and tracrRNA polynucleotides may also be single polynucleotides, but are also referred to as single guide RNAs (sgRNAs). While the Cas9 system is described herein, other CRISPR systems, such as the Cpf1 system, may also be used. Nucleases may include their derivatives, such as Cas9 functional mutants, which generally mediate single-strand breaks of defined nucleotide sequences, in contrast to the complete double-strand breaks typically produced by the Cas9 enzyme, known as Cas9 "nickase" mutants.

[0352] Generally, the components of a CRISPR system interact with each other to form ribonucleoprotein (RNP) complexes, which mediate sequence-specific cleavage. In some CRISPR systems, each component can be produced separately and used to form the RNP complex. In some CRISPR systems, each component can be produced separately in vitro and brought into contact with each other in vitro (i.e., "complexed") to form the RNP complex. The RNP produced in vitro can then be introduced (i.e., "delivered") into the cytosol and / or nucleus of a cell, for example, into the cytosol and / or nucleus of a T cell. The RNP complex produced in vitro can be delivered to cells by a variety of means, but are not limited to electroporation, lipid-mediated transfection, physical cell membrane deformation, lipid nanoparticles (LNPs), virus-like particles (VLPs), and sonication. In certain cases, the RNP complex produced in vitro can be delivered to cells using the Nucleofactor / Nucleofection® electroporation delivery system (Lonza®). Other electroporation systems include, but are not limited to, the MaxCyte electroporation system, the Miltenyi CliniMACS electroporation system, the Neon electroporation system, and the BTX electroporation system. CRISPR nucleases, such as Cas9, can be produced (i.e., synthesized and purified) in vitro using various protein production techniques known to those skilled in the art. CRISPR system RNAs, such as sgRNA, can be produced (i.e., synthesized and purified) in vitro using various RNA production techniques known to those skilled in the art, such as in vitro transcription or chemical synthesis.

[0353] RNP complexes produced in vitro can be complexed with nucleases and gRNAs in different ratios. RNP complexes produced in vitro can also be used in different amounts in CRISPR-mediated editing systems. For example, the total amount of RNP added can be adjusted depending on the number of cells to be edited, such as reducing the amount of RNP complex added when editing a large number of cells in the reaction.

[0354] In some CRISPR systems, each component (e.g., Cas9 and sgRNA) is encoded separately by a polynucleotide, and each polynucleotide can be introduced into the cell together or separately. In some CRISPR systems, each component can be encoded by a single polynucleotide (i.e., a multi-promoter or multi-cistronic vector; see the description of exemplary multi-cistronic systems below) and introduced into the cell. Following the expression of the CRISPR components encoded by each polynucleotide in the cell (e.g., translation of nucleases and transcription of CRISPR RNA), an RNP complex can be formed in the cell and then directed for site-specific cleavage.

[0355] Some RNPs can be engineered to have a portion that facilitates the delivery of RNPs into the nucleus. For example, if the Cas9 RNP complex is delivered into the cytosol of a cell, or if, after Cas9 translation and subsequent RNP formation, the NLS can facilitate further transport of Cas9 RNPs into the nucleus, the Cas9 nuclease may have a nuclear localization signaling (NLS) domain.

[0356] The manipulated cells described herein can be manipulated using nonviral methods, for example, the nucleases and / or CRISPR-mediated gene editing systems described herein can be delivered to cells using nonviral methods. The manipulated cells described herein can be manipulated using viral methods, for example, the nucleases and / or CRISPR-mediated gene editing systems described herein can be delivered to cells using any of the viral methods, such as adenovirus, retrovirus, lentivirus, or other viral delivery methods described herein.

[0357] Some CRISPR systems can provide two or more CRISPR compositions, each designed to independently target the same gene or common genomic locus with two or more target nucleotide sequences. For example, two separate CRISPR compositions can be provided to direct cleavage at two different target nucleotide sequences within a specific distance of each other. Some CRISPR systems can provide two or more CRISPR compositions, each designed to independently target the reverse strand of the same gene or common genomic locus. For example, two separate CRISPR "nickase" compositions can be provided to direct cleavage at the same gene or common genomic locus on the reverse strand.

[0358] In general, the features of the CRISPR-mediated editing systems described herein can be applied to other nuclease-based genome editing systems. A TALEN is an engineered site-specific nuclease comprising a DNA-binding domain of a TALE (transmission activator-like effector) and a catalytic domain of the restriction endonuclease Fokl. Different artificial TALENs can be created to target various nucleotide sequences by altering the amino acids present in the highly variable residue region of the monomer of the DNA-binding domain. The DNA-binding domain then guides the nuclease to the target sequence, creating a double-strand break. TALEN systems are described in detail in U.S. Patent Applications 12 / 965,590; 8,450,471; 8,440,431; 8,440,432; 10,172,880; and U.S. Patent Application 13 / 738,381, all of which are incorporated herein by reference in their entirety. The TALEN editing systems are described in more detail in U.S. Patent Nos. 6,453,242; 6,534,261; 6,599,692; 6,503,717; 6,689,558; 7,030,215; 6,794,136; 7,067,317; 7,262,054; 7,070,934; 7,361,635; 7,253,273; and U.S. Patent Publications 2005 / 0064474; 2007 / 0218528; and 2005 / 0267061, all of which, in whole, are incorporated herein by reference for all purposes.

[0359] Other operational delivery systems Various additional means for introducing a manipulated nucleic acid (e.g., any of the manipulated nucleic acids described herein) into a cell or other target recipient entity, such as any of the lipid structures described herein.

[0360] Polynucleotides can be delivered to recipient entities using electroporation. Electroporation is a method of internalizing cargo / payloads into the internal compartments of a target cell or entity by applying an electric field to transiently permeate the outer membrane or shell of the target cell or entity. Generally, this method involves placing a cell or target entity between two electrodes in a solution containing the cargo of interest (e.g., one of the manipulated nucleic acids described herein). The lipid membrane of the cell is then disrupted, i.e., permeated by the application of a transient set voltage, thereby allowing the cargo to enter the interior of the entity, e.g., the cytoplasm of the cell. In the case of cells, at least some, though not the majority, of the cells remain viable. Cells and other entities can be electroporated in vitro, in vivo, or ex vivo. Electroporation conditions (e.g., cell number, cargo concentration, recovery conditions, voltage, time, volume, pulse type, pulse length, volume, cuvette length, electroporation solution composition, etc.) vary considerably depending on several factors, including but not limited to the type of cells or other recipient entities, the cargo to be delivered, the desired internalization efficiency, and the desired viability. Optimizing such criteria is within the scope of the art of the art. Various devices and protocols can be used for electroporation. Examples include, but are not limited to, the Neon® transfection system, MaxCyte® Flow Electroporation® system, Lonza® Nucleofector® system, and Bio-Rad® electroporation system.

[0361] Other means for introducing manipulated nucleic acids (e.g., any of the manipulated nucleic acids described herein) into cells or other target recipient entities include, but are not limited to, sonication, gene guns, hydrodynamic injection, and cell membrane deformation by physical means.

[0362] Compositions and methods for in vivo delivery of manipulated mRNA, such as naked plasmids or mRNA, are described in detail in Kowalski et al. (Mol Ther. 2019 Apr 10; 27(4):710-728) and Kaczmarek et al. (Genome Med. 2017; 9:60), which are incorporated herein by reference for all purposes.

[0363] How to use Methods for treating diseases are also included in this disclosure. Such methods include administering a therapeutically effective dose of engineered nucleic acids, engineered cells, or isolated cells, as described above. In some embodiments, this specification provides methods for treating subjects requiring treatment, such methods include administering a therapeutically effective dose of any of the engineered cells, isolated cells, or compositions disclosed herein.

[0364] In vivo expression Methods provided herein also include in vivo delivery of compositions capable of producing manipulated cells, for example, any of the manipulated nucleic acids described herein, in vivo to cells. Such compositions include any of the virus-mediated delivery platforms, any of the lipid structure delivery systems, any of the nanoparticle delivery systems, any of the genome editing systems, or any of the other genetically engineered delivery systems described herein that can manipulate cells in vivo.

[0365] The methods provided herein also include delivering in vivo a composition capable of producing any of the effector molecules described herein. The methods provided herein also include delivering in vivo a composition capable of producing two or more of the effector molecules described herein. Compositions capable of in vivo production of effector molecules include, but are not limited to, any of the manipulated nucleic acids described herein. Compositions capable of in vivo production of effector molecules may be naked mRNA or naked plasmids.

[0366] Pharmaceutical composition Manipulated nucleic acids or manipulated cells can be formulated into pharmaceutical compositions. These compositions may contain, in addition to one or more manipulated nucleic acids or manipulated cells, pharmaceutically acceptable excipients, carriers, buffers, stabilizers, or other materials well known to those skilled in the art. Such materials must be non-toxic and must not interfere with the efficacy of the active ingredient. The exact properties of the carrier or other materials may depend on the route of administration, e.g., oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, or intraperitoneal routes.

[0367] Regardless of whether what is administered to an individual is a cell, polypeptide, nucleic acid, small molecule, or other pharmaceutically useful compound as disclosed herein, the administration is preferably a “therapeutic effective dose” or a “preventive effective dose” (in some cases, prevention may be considered treatment), which is sufficient to demonstrate benefit to the individual. The actual amount administered, as well as the rate and time course of administration, will depend on the nature and severity of the protein aggregation disorder being treated. The prescription of treatment, e.g., the determination of the dosage, is the responsibility of the general practitioner and other physicians, and usually takes into account the disorder to be treated, the individual patient’s condition, the site of delivery, the method of administration, and other factors known to the practitioner. Examples of the above techniques and protocols are found in Remington’s Pharmaceutical Sciences, 16 th It can be found in edition, Osol, A. (ed), 1980.

[0368] Depending on the condition to be treated, the composition can be administered alone, in combination with other treatments, concurrently, or sequentially.

[0369] Embodiment 1. Isolated cells comprising an inducible cell death polypeptide comprising two or more monomers, wherein each monomer comprises one or more ligand-binding domains and a cell death-inducing domain. Each of the one or more ligand-binding domains includes a domain or functional fragment selected from the group consisting of an ABI domain, a PYL domain, a caffeine-binding single-domain antibody, a cannabidiol-binding domain, a hormone-binding domain of an estrogen receptor (ER) domain, a heavy chain variable region (VH) of an anti-nicotine antibody, a light chain variable region (VL) of an anti-nicotine antibody, a progesterone receptor domain, an FKBP domain, and an FRB domain, a cerebron domain optionally containing the amino acid sequence specified in one of SEQ ID NOs. 127 and 129, a degron domain optionally containing the amino acid sequence specified in one of SEQ ID NOs. 131 and 133, and a progesterone receptor domain optionally containing the amino acid sequence of SEQ ID NO. 52. Each monomer is oligomerizable via a homologous ligand that binds to its ligand-binding domain, and when the ligand oligomerizes each monomer, a cell death-inducing signal is generated within the isolated cell. 2. The cell death induction domain is involved with caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, diphtheria toxin fragment A (DTA), Bax, Bak, Bok, Bad, Bcl-xS, Bak, Bik, Bcl-2-interacting protein 3 (BNIP3), Fas, Fas-related protein with death domain (FADD), tumor necrosis factor receptor 1-associated death domain protein (TRADD), TNF receptor (TNF-R), APAF-1, granzyme B, second mitochondrial-derived activator of caspase (SMAC), Omi, Bmf, Bid, Bim, and p53 upregulatory factors of apoptosis. Isolated cells of Embodiment 1 derived from a protein selected from the group consisting of PUMA, Noxa, Blk, Hrk, cytochrome c, Arts, TNF-associated cell death-inducing ligand (TRAIL), herpes simplex virus thymidine kinase (HSV-TK), varicella-zoster virus thymidine kinase (VZV-TK), viral spike protein, carboxylesterase, cytosine deaminase, nitroreductase Fksb, carboxypeptidase G2, carboxypeptidase A, horseradish peroxidase, linamorase, hepatic cytochrome P450-2B1, and purine nucleoside phosphorylase. 3. The isolated cell according to Embodiment 1, wherein the cell death induction domain includes caspase 9 or a functional cleavage thereof. 4. The isolated cell according to Embodiment 3, wherein the cell death induction domain contains the amino acid sequence of SEQ ID NO: 39. 5. The isolated cell according to Embodiment 1, wherein the cell death induction domain includes Bid or a functional cleavage thereof. 6. The isolated cell according to Embodiment 5, wherein the cell death induction domain contains the amino acid sequence of SEQ ID NO: 54. 7. The isolated cell according to Embodiment 1, wherein the ABI domain contains the amino acid sequence of SEQ ID NO: 31. 8. The isolated cell according to Embodiment 1, wherein the PYL domain contains the amino acid sequence of SEQ ID NO: 53. 9. Isolated cells according to Embodiment 1, wherein the caffeine-conjugated single-domain antibody contains the amino acid sequence of SEQ ID NO: 33. 10. The isolated cell according to Embodiment 1, wherein the cannabidiol-binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 35, 36, 37, and 38. 11. The isolated cell according to Embodiment 1, wherein the hormone-binding domain of the estrogen receptor contains the amino acid sequence of SEQ ID NO: 42. 12. Isolated cells according to Embodiment 1, wherein the heavy chain variable region (VH) of the anti-nicotinic antibody contains the amino acid sequence of SEQ ID NO: 50. 13. Isolated cells according to Embodiment 1, wherein the light chain variable region (VL) of the anti-nicotinic antibody contains the amino acid sequence of SEQ ID NO: 51. 14. The isolated cell according to Embodiment 1, wherein the progesterone receptor domain contains the amino acid sequence of SEQ ID NO: 52. 15. The isolated cell according to Embodiment 1, wherein the FKBP domain contains the amino acid sequence of SEQ ID NO: 43. 16. The isolated cell according to Embodiment 1, wherein the FRB domain contains the amino acid sequence of SEQ ID NO: 44. 17. An isolated cell according to any one of Embodiments 1 to 16, wherein each monomer contains the same ligand-binding domain. 18. Isolated cells according to Embodiment 17, wherein the inducible cell death polypeptide contains a homooligomer. 19. Isolated cells according to Embodiment 18, wherein the homooligomer contains a homodimer. 20. An isolated cell according to any one of Embodiments 17 to 19, wherein each monomer contains an FKBP domain. 21. Isolated cells according to Embodiment 20, wherein the ligand is FK1012, a derivative thereof, or an analog thereof. 22. Isolated cells according to Embodiment 20 or Embodiment 21, wherein the cell death induction domain includes Bid or a functional cleavage thereof. 23. The isolated cell according to Embodiment 22, wherein the cell death induction domain comprises the amino acid sequence of Sequence ID No. 54. 24. An isolated cell according to any one of Embodiments 1 to 6, wherein each monomer comprises an ABI domain and a PYL domain. 25. Isolated cells according to Embodiment 24, wherein the ligand is abscisic acid. 26. Isolated cells according to Embodiment 24 or Embodiment 25, wherein the cell death induction domain includes caspase 9 or a functional cleavage thereof. 27. The isolated cell according to Embodiment 26, wherein the cell death induction domain comprises the amino acid sequence of Sequence ID No. 39. 28. An isolated cell according to any one of Embodiments 1 to 6, wherein each monomer comprises a cannabidiol-binding domain comprising the amino acid sequence of SEQ ID NO: 34 and a cannabidiol-binding domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 35, 36, 37, and 38. 29. Isolated cells according to any one of Embodiments 1 to 6, wherein each monomer comprises a hormone-binding domain and an FKBP domain of the estrogen receptor (ER) domain. 30. Isolated cells according to any one of Embodiments 1 to 6, wherein each monomer comprises a hormone-binding domain of an FRB domain and an estrogen receptor (ER) domain. 31. Isolated cells according to Embodiment 29 or Embodiment 30, wherein the cell death induction domain includes caspase 9 or a functional cleavage thereof. 32. The isolated cell according to Embodiment 31, wherein the cell death induction domain contains the amino acid sequence of Sequence ID No. 39. 33. Isolated cells according to any one of embodiments 29 to 32, wherein the ligand is rapamycin, a derivative thereof, or an analog thereof. 34. Isolated cells according to any one of embodiments 29 to 33, wherein the ligand is tamoxifen or a metabolite thereof. 35. Isolated cells according to Embodiment 34, wherein the tamoxifen metabolite is selected from the group consisting of 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen. 36. Isolated cells according to any one of Embodiments 1 to 6, wherein each monomer contains two caffeine-binding single-domain antibodies. 37. Isolated cells according to Embodiment 36, wherein each caffeine-conjugated single-domain antibody contains the amino acid sequence of SEQ ID NO: 33. 38. Isolated cells according to Embodiment 36 or Embodiment 37, wherein the ligand is caffeine or a derivative thereof. 39. An isolated cell according to any one of Embodiments 1 to 38, wherein each monomer comprises a progesterone receptor domain containing the amino acid sequence of SEQ ID NO: 52. 40. Isolated cells according to Embodiment 39, wherein the ligand is mifepristone or a derivative thereof. 41. An isolated cell according to any one of Embodiments 1 to 38, wherein the first monomer comprises a first ligand-binding domain and the second monomer comprises a second ligand-binding domain. 42. Isolated cells according to Embodiment 41, wherein the inducible cell death polypeptide comprises a heterooligomer. 43. Isolated cells according to Embodiment 42, wherein the heterooligomer contains a heterodimer. 44. An isolated cell according to any one of Embodiments 41 to 43, wherein the first monomer comprises an FKBP domain and the second monomer comprises an FRB domain. 45. Isolated cells according to Embodiment 44, wherein the cell death-inducing domain includes Bid or a functional cleavage thereof. 46. ​​The isolated cell according to Embodiment 45, wherein the cell death induction domain comprises the amino acid sequence of Sequence ID No. 54. 47. An isolated cell according to any one of Embodiments 41 to 43, wherein the first monomer comprises a hormone-binding domain of an estrogen receptor (ER) domain, and the second monomer comprises an FKBP domain. 48. An isolated cell according to any one of Embodiments 41 to 43, wherein the first monomer comprises an FRB domain and the second monomer comprises a hormone-binding domain of an estrogen receptor (ER) domain. 49. An isolated cell according to any one of Embodiments 41 to 43, wherein the first monomer comprises the hormone-binding domain and FKBP domain of the estrogen receptor (ER) domain, the second monomer comprises the FRB domain, and the third monomer comprises the hormone-binding domain of the estrogen receptor (ER) domain. 50. An isolated cell according to any one of embodiments 47 to 49, wherein the cell death induction domain includes caspase 9 or a functional cleavage thereof. 51. The isolated cell according to Embodiment 50, wherein the cell death induction domain comprises the amino acid sequence of Sequence ID No. 39. 52. Isolated cells according to any one of Embodiments 44 to 51, wherein the ligand is rapamycin, a derivative thereof, or an analog thereof. 53. Isolated cells according to any one of Embodiments 47 to 52, wherein the ligand is tamoxifen or a metabolite thereof. 54. Isolated cells according to Embodiment 53, wherein the tamoxifen metabolite is selected from the group consisting of 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen. 55. An isolated cell according to any one of Embodiments 41 to 43, wherein the first monomer comprises an ABI domain and the second monomer comprises a PYL domain. 56. Isolated cells according to Embodiment 55, wherein the ligand is abscisic acid. 57. An isolated cell according to any one of Embodiments 41 to 43, wherein the first monomer comprises the heavy chain variable region (VH) of an anti-nicotinic antibody, and the second monomer comprises the light chain variable region (VL) of an anti-nicotinic antibody. 58. Isolated cells according to Embodiment 57, wherein the anti-nicotinic antibody is Nic12 antibody. 59. Isolated cells according to Embodiment 57 or Embodiment 58, wherein VH contains the amino acid sequence of Sequence ID No. 50. 60.VL contains the amino acid sequence of SEQ ID NO: 51, an isolated cell according to any one of embodiments 57 to 59. 61. Isolated cells according to any one of embodiments 57 to 60, wherein the ligand is nicotine or a derivative thereof. 62. An isolated cell according to any one of Embodiments 41 to 43, wherein the first monomer comprises a cannabidiol-binding domain having an amino acid sequence selected from the group consisting of SEQ ID NOs. 35, 36, 37, and 38, and the second monomer comprises a cannabidiol-binding domain having an amino acid sequence of SEQ ID NO. 34. 63. Isolated cells according to Embodiment 62, wherein the ligand is cannabidiol or a plant cannabinoid. 64. An isolated cell according to any one of Embodiments 41 to 43, wherein the first monomer comprises a cerebron domain having an amino acid sequence specified in one of Sequence IDs 127 and 129, and the second monomer comprises degron having an amino acid sequence specified in one of Sequence IDs 131 and 133. 65. Isolated cells according to Embodiment 64, wherein the ligand is IMiD. 66. Isolated cells according to Embodiment 65, wherein IMiD is an FDA-approved drug. 67. Isolated cells according to Embodiment 65 or Embodiment 66, wherein IMiD is selected from the group consisting of thalidomide, lenalidomide, and pomalidomide. 68. An isolated cell according to any one of Embodiments 1 to 67, wherein each monomer further comprises a linker localized between each ligand-binding domain and a cell death-inducing domain. 69. Isolated cells according to Embodiment 68, wherein the linker comprises an amino acid sequence selected from the group consisting of GGGGSGGGGSGGGGSVDGF (SEQ ID NO: 101) and ASGGGGSAS (SEQ ID NO: 102). 70. Isolated cells containing activated conditionally controlled polypeptides (ACPs), ACP comprises a transcription factor including one or more ligand-binding domains, as well as nucleic acid-binding domains and transcription effector domains. ACP undergoes nuclear localization upon binding of its ligand-binding domain to a congener ligand, and When localized to the cell nucleus, ACP can induce transcriptional expression of a gene of interest operably linked to an ACP-responsive promoter in isolated cells. 71. Isolated cells containing a multimer-activated conditionally controlled polypeptide (ACP), wherein the multimer ACP is a) The first chimeric polypeptide comprises a first ligand-binding domain and a transcriptional activation domain, b) The second chimeric polypeptide comprises a second ligand-binding domain and a nucleic acid-binding domain, The first and second chimeric polypeptides multimerize to form a multimer ACP via homologous ligands that bind to each ligand-binding domain. Multimeric ACP is an isolated cell that can induce transcriptional expression of a gene of interest operably linked to an ACP-responsive promoter. 72. Isolated cells according to Embodiment 70 or Embodiment 71, wherein each ligand-binding domain comprises a domain selected from the group consisting of an ABI domain, a PYL domain, a caffeine-binding single-domain antibody, a cannabidiol-binding domain, a hormone-binding domain of an estrogen receptor (ER) domain, a heavy chain variable region (VH) of an anti-nicotinic antibody, a light chain variable region (VL) of an anti-nicotinic antibody, a progesterone receptor domain, an FKBP domain, and an FRB domain, or a functional fragment thereof. 73. Isolated cells according to Embodiment 72, wherein the ABI domain contains the amino acid sequence of Sequence ID No. 31. 74. The isolated cell according to Embodiment 72, wherein the PYL domain contains the amino acid sequence of Sequence ID No. 53. 75. Isolated cells according to Embodiment 72, wherein the caffeine-conjugated single-domain antibody comprises the amino acid sequence of SEQ ID NO: 33. 76. The isolated cell according to Embodiment 72, wherein the cannabidiol-binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 35, 36, 37, and 38. 77. Isolated cells according to Embodiment 72, wherein the hormone-binding domain of the estrogen receptor contains the amino acid sequence of SEQ ID NO: 42. 78. Isolated cells according to Embodiment 72, wherein the heavy chain variable region (VH) of the anti-nicotinic antibody contains the amino acid sequence of SEQ ID NO: 50. 79. Isolated cells according to Embodiment 72, wherein the light chain variable region (VL) of the anti-nicotinic antibody contains the amino acid sequence of SEQ ID NO: 51. 80. Isolated cells according to Embodiment 72, wherein the progesterone receptor domain contains the amino acid sequence of SEQ ID NO: 52. 81. Isolated cells according to Embodiment 72, wherein the FKBP domain contains the amino acid sequence of Sequence ID No. 43. 82. Isolated cells according to Embodiment 72, wherein the FRB domain contains the amino acid sequence of Sequence ID No. 44. 83. Isolated cells according to Embodiment 71, wherein the nucleic acid binding domain includes a DNA-binding zinc finger protein domain (ZF protein domain). 84. Isolated cells according to Embodiment 83, wherein the ZF protein domain is a modular design and comprises a zinc finger array (ZFA). 85. The transcription effector domains include: herpes simplex virus protein 16 (VP16) activation domain; activation domain containing four tandem copies of VP16; VP64 activation domain; p65 activation domain of NFκB; Epstein-Barr virus R trans-activator (Rta) activation domain; ternary activator containing VP64, p65, and Rta activation domains (VPR activation domain); ternary activator containing VP64, p65, and HSF1 activation domains (VPH activation domain); histone acetyltransferase (HAT) core domain of human E1A-related protein p300 (p300 Isolated cells according to any one of embodiments 70 to 84, selected from the group consisting of: HAT core activating domain; Kruppel association box (KRAB) repression domain; repressor element silencing transcription factor (REST) ​​repression domain; WRPW motif of hairy-associated basic helix-loop-helix repressor protein, known as the WRPW repression domain; DNA (cytosine-5)-methyltransferase 3B (DNMT3B) repression domain; and HP1 alpha chromoshadow repression domain. 86. Isolated cells according to any one of Embodiments 70 and 72-85, further comprising a linker localized between a nucleic acid-binding domain and a transcription effector domain of the chimeric polypeptide. 87. Isolated cells according to Embodiment 86, wherein the linker comprises one or more 2A ribosome skipping tags. 88. Isolated cells according to Embodiment 87, wherein each 2A ribosome skipping tag is selected from the group consisting of P2A, T2A, E2A, and F2A. 89. Isolated cells according to any one of embodiments 71 to 88, wherein the chimeric polypeptide comprises a first ligand-binding domain operably linked to a nucleic acid-binding domain and a second ligand-binding domain operably linked to a transcription effector domain. 90. Isolated cells according to any one of embodiments 71 to 89, wherein each of the first and second ligand-binding domains comprises a hormone-binding domain of an estrogen receptor (ER) domain. 91. Isolated cells according to Embodiment 90, wherein the homologous ligand is tamoxifen or a metabolite thereof. 92. Isolated cells according to Embodiment 91, wherein the tamoxifen metabolite is selected from the group consisting of 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen. 93. An isolated cell according to any one of embodiments 71 to 89, wherein each of the first and second ligand-binding domains comprises a progesterone receptor domain. 94. Isolated cells according to Embodiment 93, wherein the homologous ligand is mifepristone or a derivative thereof. 95. Isolated cells according to any one of Embodiments 1 to 89, wherein the ligand-binding domain includes an ABI domain or a PYL domain, and the homologous ligand is abscisic acid. 96. Isolated cells according to any one of Embodiments 1 to 89, wherein the ligand-binding domain contains a caffeine-binding single-domain antibody, and the homologous ligand is caffeine or a derivative thereof. 97. An isolated cell according to any one of Embodiments 1 to 89, wherein the ligand-binding domain includes a cannabidiol-binding domain, and the homologous ligand is cannabidiol or a plant cannabinoid. 98. Isolated cells according to Embodiment 97, wherein the cannabidiol-binding domain comprises a single-domain antibody or nanobody. 99. The isolated cell according to Embodiment 98, wherein the cannabidiol-binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 35, 36, 37, and 38. 100. Isolated cells according to any one of Embodiments 1 to 89, wherein the ligand-binding domain includes the hormone-binding domain of the estrogen receptor (ER) domain, and the homologous ligand is tamoxifen or a metabolite thereof. 101. Isolated cells according to Embodiment 100, wherein the tamoxifen metabolite is selected from the group consisting of 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen. 102. Isolated cells according to any one of Embodiments 1 to 89, wherein the ligand-binding domain includes the heavy chain variable region (VH) or the light chain variable region (VL) of an anti-nicotinic antibody, and the homologous ligand is nicotine or a derivative thereof. 103. Isolated cells according to any one of Embodiments 1 to 89, wherein the ligand-binding domain is a progesterone receptor domain, and the homologous ligand is mifepristone or a derivative thereof. 104. Isolated cells according to any one of Embodiments 1 to 89, wherein the ligand-binding domain includes an FKBP domain or an FRB domain, and the homologous ligand is rapamycin, AP1903, AP20187, FK1012, a derivative thereof, or an analog thereof. 105. An isolated cell according to any one of Embodiments 70 to 104, wherein the nucleic acid binding domain includes a DNA-binding zinc finger protein domain (ZF protein domain). 106. Isolated cells according to Embodiment 105, wherein the ZF protein domain is a modular design and comprises a zinc finger array (ZFA). 107. Isolated cells according to Embodiment 106, wherein the ZF protein domain contains one to ten ZFAs. 108. An isolated cell according to any one of embodiments 105 to 107, wherein the nucleic acid binding domain binds to an ACP-responsive promoter. 109. Isolated cells according to any one of Embodiments 70 to 108, wherein the ACP-responsive promoter comprises an ACP-binding domain sequence and a promoter sequence. 110. Isolated cells according to Embodiment 109, wherein the promoter sequence is derived from a promoter selected from the group consisting of minP, NFkB response element, CREB response element, NFAT response element, SRF response element 1, SRF response element 2, AP1 response element, TCF-LEF response element promoter fusion, hypoxia-responsive element, SMAD binding element, STAT3 binding site, minCMV, YB_TATA, min_TATA, minTK, inductive factor molecule-responsive promoter, and tandem repeats thereof. 111. Isolated cells according to Embodiment 109 or Embodiment 110, wherein the ACP-responsive promoter comprises a synthetic promoter. 112. Isolated cells according to any one of embodiments 105 to 111, wherein the ACP-responsive promoter comprises a minimal promoter. 113. Isolated cells according to any one of embodiments 105 to 111, wherein the ACP-binding domain includes one or more zinc finger binding sites. 114. Isolated cells according to any one of Embodiments 71 to 113, wherein the transcriptional activation domain is selected from the group consisting of: herpes simplex virus protein 16 (VP16) activation domain; activation domain containing four tandem copies of VP16; VP64 activation domain; p65 activation domain of NFκB; Epstein-Barr virus R trans-activator (Rta) activation domain; ternary activator containing VP64, p65, and Rta activation domains (VPR activation domain); ternary activator containing VP64, p65, and HSF1 activation domains (VPH activation domain); and histone acetyltransferase (HAT) core domain of human E1A-related protein p300 (p300 HAT core activation domain). 115. Isolated cells containing activated conditionally controlled polypeptides (ACPs), ACP includes a ligand-binding domain and a transcription effector domain. In isolated cells, ACP can regulate the transcriptional expression of a gene of interest operably linked to an ACP-responsive promoter upon binding of its ligand-binding domain to a congener ligand. 116. Isolated cells according to Embodiment 115, wherein the ligand-binding domain is localized to the 5' or 3' of the transcription effector domain. 117. Isolated cells according to Embodiment 115 or Embodiment 116, wherein the transcription effector domain includes a transcription repressor. 118. Isolated cells according to Embodiment 115, wherein the transcriptional repressor comprises a transcriptional repressor domain selected from the group consisting of a Kruppel association box (KRAB) repressor domain; a repressor element silencing transcription factor (REST) ​​repressor domain; a WRPW motif of the hairy-associated basic helix-loop-helix repressor protein, the motif known as the WRPW repressor domain; a DNA (cytosine 5) methyltransferase 3B (DNMT3B) repressor domain; and an HP1 alpha-chromoshadow repressor domain. 119. Isolated cells according to Embodiment 115 or Embodiment 116, wherein the transcription effector domain contains a transcription activator. 120. Isolated cells according to Embodiment 119, comprising a transcriptional activation domain selected from the group consisting of a herpes simplex virus protein 16 (VP16) activation domain; an activation domain containing four tandem copies of VP16; a VP64 activation domain; a p65 activation domain of NFκB; an Epstein-Barr virus R trans-activator (Rta) activation domain; a ternary activator containing VP64, p65, and Rta activation domains (VPR activation domain); a ternary activator containing VP64, p65, and HSF1 activation domains (VPH activation domain); and a histone acetyltransferase (HAT) core domain of human E1A-related protein p300 (p300 HAT core activation domain). 121. Isolated cells according to any one of Embodiments 115 to 120, wherein ACP is a transcription factor. 122. Isolated cells according to any one of Embodiments 115 to 121, wherein ACP is a zinc finger-containing transcription factor. 123. Isolated cells according to Embodiment 122, wherein the zinc finger-containing transcription factor comprises a DNA-binding zinc finger protein domain (ZF protein domain) and a transcriptional repressor domain or transcriptional activator domain. 124. Isolated cells according to Embodiment 123, wherein the ZF protein domain is a modular design and comprises a zinc finger array (ZFA). 125. Isolated cells according to Embodiment 124, wherein the ZF protein domain contains one to ten ZFAs. 126. Isolated cells according to any one of embodiments 123 to 125, wherein the DNA-binding zinc finger protein domain binds to an ACP-responsive promoter. 127. Isolated cells according to any one of Embodiments 115 to 126, wherein the ACP-responsive promoter comprises an ACP-binding domain and a promoter sequence. 128. Isolated cells according to Embodiment 127, wherein the promoter sequence is derived from a promoter selected from the group consisting of minP, NFkB response element, CREB response element, NFAT response element, SRF response element 1, SRF response element 2, AP1 response element, TCF-LEF response element promoter fusion, hypoxia-responsive element, SMAD binding element, STAT3 binding site, minCMV, YB_TATA, min_TATA, minTK, inductive factor molecule-responsive promoter, and tandem repeats thereof. 129. Isolated cells according to any one of Embodiments 115 to 128, wherein the ACP-responsive promoter is a synthetic promoter. 130. Isolated cells according to any one of embodiments 115 to 129, wherein the ACP-responsive promoter comprises a minimal promoter. 131. Isolated cells according to any one of embodiments 127 to 130, wherein the ACP-binding domain includes one or more zinc finger binding sites. 132. An isolated cell according to any one of embodiments 115 to 131, wherein the gene of interest is a cell death-inducing polypeptide. 133. The cell death induction domain is found in caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, diphtheria toxin fragment A (DTA), Bax, Bak, Bok, Bad, Bcl-xS, Bak, Bik, Bcl-2-interacting protein 3 (BNIP3), Fas, Fas-related protein with death domain (FADD), tumor necrosis factor receptor 1-associated death domain protein (TRADD), TNF receptor (TNF-R), APAF-1, granzyme B, second mitochondrial-derived activator of caspase (SMAC), Omi, Bmf, Bid, Bim, and p53 upregulator of apoptosis (PU). Isolated cells according to Embodiment 132, derived from a protein selected from the group consisting of MA), Noxa, Blk, Hrk, cytochrome c, Arts, TNF-associated cell death induction ligand (TRAIL), herpes simplex virus thymidine kinase (HSV-TK), varicella-zoster virus thymidine kinase (VZV-TK), viral spike protein, carboxylesterase, cytosine deaminase, nitroreductase Fksb, carboxypeptidase G2, carboxypeptidase A, horseradish peroxidase, linamorase, hepatic cytochrome P450-2B1, and purine nucleoside phosphorylase. 134. Isolated cells according to Embodiment 132, wherein the cell death-inducing polypeptide is caspase 9 or a functional cleavage thereof. 135. Isolated cells according to Embodiment 134, wherein the cell death induction domain comprises the amino acid sequence of Sequence ID No. 39. 136. Isolated cells according to Embodiment 132, wherein the cell death-inducing polypeptide is diphtheria toxin fragment A (DTA). 137. The isolated cell according to Embodiment 136, wherein the cell death induction domain comprises the amino acid sequence of Sequence ID No. 41. 138. Isolated cells according to Embodiment 132, wherein the cell death-inducing polypeptide is granzyme B. 139. The isolated cell according to Embodiment 138, wherein the cell death induction domain comprises the amino acid sequence of Sequence ID No. 47. 140. Isolated cells according to Embodiment 132, wherein the cell death-inducing polypeptide is Bax. 141. The isolated cell according to Embodiment 140, wherein the cell death induction domain comprises the amino acid sequence of Sequence ID No. 32. 142. Isolated cells comprising controllable cell survival polypeptides and cell death-inducing polypeptides, wherein the cell survival polypeptide comprises a ligand-binding domain, and when expressed, the cell survival polypeptide can inhibit the cell death-inducing polypeptide, and when bound to a congener ligand, the congener ligand inhibits the cell survival-promoting polypeptide. 143. Isolated cells according to Embodiment 142, wherein the cell survival polypeptide is selected from the group consisting of XIAP, modified XIAP, Bcl-2, Bcl-xL, Bcl-w, Bcl-2-related protein A1 (BCL2A1), Mcl-1, FLICE-like inhibitory protein (c-FLIP), and adenovirus E1B-19K protein. 144. Isolated cells according to Embodiment 142, wherein the cell survival polypeptide is XIAP or modified XIAP. 145. Isolated cells according to any one of embodiments 142 to 144, wherein the ligand-binding domain is localized to the N-terminal region or the C-terminal region of the survival-promoting polypeptide. 146. Isolated cells according to any one of Embodiments 115 to 145, wherein the ligand-binding domain comprises a domain selected from the group consisting of an ABI domain, a PYL domain, a caffeine-binding single-domain antibody, a cannabidiol-binding domain, a hormone-binding domain of an estrogen receptor (ER domain), a heavy chain variable region (VH) of an anti-nicotinic antibody, a light chain variable region (VL) of an anti-nicotinic antibody, a progesterone receptor domain, an FKBP domain, and an FRB domain, or a functional fragment thereof. 147. Isolated cells according to Embodiment 146, wherein the ABI domain contains the amino acid sequence of Sequence ID No. 31. 148. The isolated cell according to Embodiment 146, wherein the PYL domain contains the amino acid sequence of Sequence ID No. 53. 149. Isolated cells according to Embodiment 146, wherein the caffeine-conjugated single-domain antibody comprises the amino acid sequence of SEQ ID NO: 33. 150. The isolated cell according to Embodiment 146, wherein the cannabidiol-binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 35, 36, 37, and 38. 151. Isolated cells according to Embodiment 146, wherein the hormone-binding domain of the estrogen receptor comprises the amino acid sequence of SEQ ID NO: 42. 152. Isolated cells according to Embodiment 146, wherein the heavy chain variable region (VH) of the anti-nicotinic antibody contains the amino acid sequence of SEQ ID NO: 50. 153. Isolated cells according to Embodiment 146, wherein the light chain variable region (VL) of the anti-nicotinic antibody contains the amino acid sequence of SEQ ID NO: 51. 154. The isolated cell according to Embodiment 146, wherein the progesterone receptor domain comprises the amino acid sequence of Sequence ID No. 52. 155. The isolated cell according to Embodiment 146, wherein the FKBP domain contains the amino acid sequence of SEQ ID NO: 43. 156. The isolated cell according to Embodiment 146, wherein the FRB domain contains the amino acid sequence of SEQ ID NO: 44. 157. An isolated cell according to any one of Embodiments 115 to 156, wherein the ligand-binding domain includes an ABI domain or a PYL domain, and the homologous ligand is abscisic acid. 158. Isolated cells according to any one of Embodiments 115 to 156, wherein the ligand-binding domain contains a caffeine-binding single-domain antibody, and the homologous ligand is caffeine or a derivative thereof. 159. An isolated cell according to any one of Embodiments 115 to 156, wherein the ligand-binding domain includes a cannabidiol-binding domain, and the homologous ligand is cannabidiol or a plant cannabinoid. 160. Isolated cells according to any one of Embodiments 115 to 156, wherein the ligand-binding domain includes the hormone-binding domain of the estrogen receptor (ER) domain, and the homologous ligand is tamoxifen or a metabolite thereof. 161. Isolated cells according to Embodiment 160, wherein the tamoxifen metabolite is selected from the group consisting of 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen. 162. Isolated cells according to any one of Embodiments 115 to 156, wherein the ligand-binding domain includes the heavy chain variable region (VH) or the light chain variable region (VL) of an anti-nicotinic antibody, and the homologous ligand is nicotine or a derivative thereof. 163. Isolated cells according to any one of Embodiments 115 to 156, wherein the ligand-binding domain is a progesterone receptor domain, and the homologous ligand is mifepristone or a derivative thereof. 164. Isolated cells according to any one of Embodiments 115 to 156, wherein the ligand-binding domain includes an FKBP domain or an FRB domain, and the homologous ligand is rapamycin, AP1903, AP20187, FK1012, a derivative thereof, or an analog thereof. 165. An isolated cell according to any one of embodiments 115 to 164, wherein the ligand-binding domain contains degron. 166. Isolated cells according to Embodiment 165, in which degron can induce the degradation of controllable cell survival polypeptides. 167. Degron is HCV NS4 degron, PEST (two copies of human IκBα residues 277-307), GRR (residues 352-408 of human p105), DRR (residues 210-295 of yeast Cdc34), SNS (tandem repeat of SP2 and NB (SP2-NB-SP2 of influenza A or influenza B)), RPB (four copies of yeast RPB residues 1688-1702), Spmix (tandem repeat of SP1 and SP2) Repeat (SP2-SP1-SP2-SP1-SP2 of influenza A virus M2 protein), NS2 (three copies of residues 79-93 of influenza A virus NS protein), ODC (residues 106-142 of ornithine decarboxylase), Nek2A, mouse ODC (residues 422-461), mouse ODC_DA (residues 422-461 of mODC containing point mutations D433A and D434A), APC / C Isolated cells according to Embodiment 165 or Embodiment 166, selected from the group consisting of degron, COP1 E3 ligase-conjugated degron motif, CRL4-Cdt2-conjugated PIP degron, actinphylline-conjugated degron, KEAP1-conjugated degron, KLHL2 and KLHL3-conjugated degron, MDM2-conjugated motif, N degron, hydroxyproline modification in hypoxia signaling, plant hormone-dependent SCF-LRR-conjugated degron, SCF ubiquitin ligase-conjugated phosphodegron, plant hormone-dependent SCF-LRR-conjugated degron, SCF ubiquitin ligase-conjugated phosphodegron, plant hormone-dependent SCF-LRR-conjugated degron, DSGxxS phosphate-dependent degron, Siah-conjugated motif, SPOP SBC-docking motif, and PCNA-conjugated PIP box. 168. Isolated cells according to any one of Embodiments 165 to 167, wherein degron comprises a cerebron (CRBN) polypeptide substrate domain capable of binding to CRBN in response to an immunomodulatory drug (IMiD), thereby promoting ubiquitin pathway-mediated degradation of the polypeptide. 169. Isolated cells of Embodiment 168, wherein the CRBN polypeptide substrate domain is selected from IKZF1, IKZF3, CK1a, ZFP91, GSPT1, MEIS2, GSS E4F1, ZN276, ZN517, ZN582, ZN653, ZN654, ZN692, ZN787, and ZN827 or a fragment thereof capable of drug-inducible binding to CRBN. 170. Isolated cells according to Embodiment 168 or Embodiment 169, wherein the CRBN polypeptide substrate domain is a chimeric fusion product of a natural CRBN polypeptide sequence. 171. An isolated cell according to any one of Embodiments 168 to 170, wherein the CRBN polypeptide substrate domain is an IKZF3 / ZFP91 / IKZF3 chimeric fusion product having the amino acid sequence FNVLMVHKRSHTGERPLQCEICGFTCRQKGNLLRHIKLHTGEKPFKCHLCNYACQRRDAL (SEQ ID NO: 103). 172. Isolated cells according to any one of embodiments 115 to 171, wherein the ligand is IMiD. 173. ImmiD is an FDA-approved drug, as described in Embodiment 172. 174. Isolated cells according to Embodiment 172 or Embodiment 173, wherein IMiD is selected from the group consisting of thalidomide, lenalidomide, and pomalidomide. 175. The cell death induction domain is found in caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, diphtheria toxin fragment A (DTA), Bax, Bak, Bok, Bad, Bcl-xS, Bak, Bik, Bcl-2-interacting protein 3 (BNIP3), Fas, Fas-related protein with death domain (FADD), tumor necrosis factor receptor 1-associated death domain protein (TRADD), TNF receptor (TNF-R), APAF-1, granzyme B, second mitochondrial-derived activator of caspase (SMAC), Omi, Bmf, Bid, Bim, p53 upregulator of apoptosis (PUMA), No Isolated cells according to any one of Embodiments 142 to 174, derived from a protein selected from the group consisting of xa, Blk, Hrk, cytochrome c, Arts, TNF-associated cell death induction ligand (TRAIL), herpes simplex virus thymidine kinase (HSV-TK), varicella-zoster virus thymidine kinase (VZV-TK), viral spike protein, carboxylesterase, cytosine deaminase, nitroreductase Fksb, carboxypeptidase G2, carboxypeptidase A, horseradish peroxidase, linamorase, hepatic cytochrome P450-2B1, and purine nucleoside phosphorylase. 176. Isolated cells according to any one of embodiments 142 to 174, wherein the cell death-inducing polypeptide is caspase 9 or a functional cleavage thereof. 177. The isolated cell according to Embodiment 176, wherein the cell death induction domain comprises the amino acid sequence of Sequence ID No. 39. 178. Isolated cells according to any one of embodiments 142 to 174, wherein the cell death-inducing polypeptide is diphtheria toxin fragment A (DTA). 179. The isolated cell according to Embodiment 178, wherein the cell death induction domain comprises the amino acid sequence of SEQ ID NO: 41. 180. Isolated cells according to any one of embodiments 142 to 174, wherein the cell death-inducing polypeptide is Bax. 181. The isolated cell according to Embodiment 180, wherein the cell death induction domain comprises the amino acid sequence of Sequence ID No. 32. 182. Manipulated nucleic acids, An expression cassette comprising a promoter and an exogenous polynucleotide sequence encoding an inducible cell death polypeptide monomer, wherein the promoter comprises an expression cassette operably ligated to the exogenous polynucleotide, Inducible cell death polypeptide monomers comprise one or more ligand-binding domains and cell death-inducing domains. Each of the one or more ligand-binding domains contains a domain selected from the group consisting of an ABI domain, a PYL domain, a caffeine-binding single-domain antibody, a cannabidiol-binding domain, a hormone-binding domain of an estrogen receptor (ER) domain, a heavy chain variable region (VH) of an anti-nicotine antibody, a light chain variable region (VL) of an anti-nicotine antibody, a progesterone receptor domain, an FKBP domain, an FRB domain, a cerebron domain optionally containing an amino acid sequence specified in one of sequence numbers 127 and 129, or a degron optionally containing an amino acid sequence specified in one of sequence numbers 131 and 133, or a functional fragment thereof. When expressed, the cell death polypeptide monomer can be oligomerized via a homologous ligand that binds to the ligand-binding domain. A modified nucleic acid in which a cell death-inducing signal is generated in a cell when a ligand oligomerizes two or more cell death polypeptide monomers. 183. The cell death induction domain is found in caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, diphtheria toxin fragment A (DTA), Bax, Bak, Bok, Bad, Bcl-xS, Bak, Bik, Bcl-2-interacting protein 3 (BNIP3), Fas, Fas-related protein with death domain (FADD), tumor necrosis factor receptor 1-associated death domain protein (TRADD), TNF receptor (TNF-R), APAF-1, granzyme B, second mitochondrial-derived activator of caspase (SMAC), Omi, Bmf, Bid, Bim, and p53 upregulator of apoptosis (PU). The manipulated nucleic acids of Embodiment 182 are derived from proteins selected from the group consisting of MA), Noxa, Blk, Hrk, cytochrome c, Arts, TNF-associated cell death induction ligand (TRAIL), herpes simplex virus thymidine kinase (HSV-TK), varicella-zoster virus thymidine kinase (VZV-TK), viral spike protein, carboxylesterase, cytosine deaminase, nitroreductase Fksb, carboxypeptidase G2, carboxypeptidase A, horseradish peroxidase, linamorase, hepatic cytochrome P450-2B1, and purine nucleoside phosphorylase. 184. The engineered nucleic acid according to Embodiment 182, wherein the cell death induction domain includes caspase 9 or a functional cleavage thereof. 185. The manipulated nucleic acid according to Embodiment 184, wherein the cell death induction domain comprises the amino acid sequence of Sequence ID No. 39. 186. The manipulated nucleic acid according to Embodiment 182, wherein the cell death-inducing domain includes Bid or a functional cleavage thereof. 187. The manipulated nucleic acid according to Embodiment 186, wherein the cell death induction domain comprises the amino acid sequence of Sequence ID No. 54. 188. The manipulated nucleic acid according to Embodiment 182, wherein the ABI domain comprises the amino acid sequence of SEQ ID NO: 31. 189. The manipulated nucleic acid according to Embodiment 182, wherein the PYL domain comprises the amino acid sequence of Sequence ID No. 53. 190. The manipulated nucleic acid according to Embodiment 182, comprising the amino acid sequence of SEQ ID NO: 33, wherein the caffeine-conjugated single-domain antibody. 191. The engineered nucleic acid according to Embodiment 182, wherein the cannabidiol-binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 35, 36, 37, and 38. 192. The engineered nucleic acid according to Embodiment 182, wherein the hormone-binding domain of the estrogen receptor (ER) comprises the amino acid sequence of SEQ ID NO: 42. 193. The manipulated nucleic acid according to Embodiment 182, wherein the heavy chain variable region (VH) of the anti-nicotinic antibody comprises the amino acid sequence of SEQ ID NO: 50. 194. The manipulated nucleic acid according to Embodiment 182, wherein the light chain variable region (VL) of the anti-nicotinic antibody comprises the amino acid sequence of SEQ ID NO: 51. 195. The engineered nucleic acid according to Embodiment 182, wherein the progesterone receptor comprises the amino acid sequence of SEQ ID NO: 52. 196. The manipulated nucleic acid according to Embodiment 182, wherein the FKBP domain comprises the amino acid sequence of SEQ ID NO: 43. 197. The manipulated nucleic acid according to Embodiment 182, wherein the FRB domain comprises the amino acid sequence of Sequence ID No. 44. 198. An engineered nucleic acid according to any one of Embodiments 182 to 197, wherein each monomer contains the same ligand-binding domain. 199. The engineered nucleic acid according to Embodiment 198, wherein the inducible cell death polypeptide comprises a homooligomer. 200. The manipulated nucleic acid according to Embodiment 199, wherein the homooligomer comprises a homodimer. 201. An engineered nucleic acid according to any one of Embodiments 198 to 200, wherein each monomer comprises an FKBP domain. 202. The engineered nucleic acid according to Embodiment 201, wherein the ligand is FK1012, a derivative thereof, or an analog thereof. 203. The manipulated nucleic acid according to Embodiment 201 or Embodiment 202, wherein the cell death induction domain includes Bid or a functional cleavage thereof. 204. The manipulated nucleic acid according to Embodiment 203, wherein the cell death induction domain comprises the amino acid sequence of Sequence ID No. 54. 205. An engineered nucleic acid according to any one of Embodiments 182 to 188, wherein each monomer comprises an ABI domain and a PYL domain. 206. The engineered nucleic acid according to Embodiment 205, wherein the ligand is abscisic acid. 207. The engineered nucleic acid according to Embodiment 205 or Embodiment 206, wherein the cell death induction domain includes caspase 9 or a functional cleavage thereof. 208. The manipulated nucleic acid according to Embodiment 207, wherein the cell death induction domain comprises the amino acid sequence of Sequence ID No. 39. 209. An engineered nucleic acid according to any one of Embodiments 182 to 188, wherein each monomer comprises a cannabidiol-binding domain comprising the amino acid sequence of SEQ ID NO: 34 and a cannabidiol-binding domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 35, 36, 37, and 38. 210. An engineered nucleic acid according to any one of Embodiments 182 to 188, wherein each monomer comprises a hormone-binding domain of the estrogen receptor (ER) domain and an FKBP domain. 211. An engineered nucleic acid according to any one of Embodiments 182 to 188, wherein each monomer comprises a hormone-binding domain of an FRB domain and an estrogen receptor (ER) domain. 212. The engineered nucleic acid according to Embodiment 210 or Embodiment 211, wherein the cell death induction domain includes caspase 9 or a functional cleavage thereof. 213. The manipulated nucleic acid according to Embodiment 212, wherein the cell death induction domain comprises the amino acid sequence of Sequence ID No. 39. 214. The engineered nucleic acid according to any one of embodiments 210 to 215, wherein the ligand is rapamycin, a derivative thereof, or an analog thereof. 215. An engineered nucleic acid according to any one of embodiments 210 to 214, wherein the ligand is tamoxifen or a metabolite thereof. 216. The engineered nucleic acid according to Embodiment 215, wherein the tamoxifen metabolite is selected from the group consisting of 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen. 217. An engineered nucleic acid according to any one of Embodiments 182 to 188, wherein each monomer comprises two caffeine-conjugated single-domain antibodies. 218. The manipulated nucleic acid according to Embodiment 217, wherein each caffeine-conjugated single-domain antibody comprises the amino acid sequence of SEQ ID NO: 33. 219. The manipulated nucleic acid according to Embodiment 217 or Embodiment 218, wherein the ligand is caffeine or a derivative thereof. 220. An engineered nucleic acid according to any one of Embodiments 182 to 219, wherein each monomer comprises a progesterone receptor domain having the amino acid sequence of SEQ ID NO: 52. 221. The engineered nucleic acid according to Embodiment 220, wherein the ligand is mifepristone or a derivative thereof. 222. An engineered nucleic acid according to any one of Embodiments 182 to 188, wherein the first monomer comprises a first ligand-binding domain and the second monomer comprises a second ligand-binding domain. 223. The engineered nucleic acid according to Embodiment 222, wherein the inducible cell death polypeptide comprises a heterooligomer. 224. The manipulated nucleic acid according to Embodiment 223, wherein the heterooligomer comprises a heterodimer. 225. An engineered nucleic acid according to any one of Embodiments 222 to 224, wherein the first monomer comprises an FKBP domain and the second monomer comprises an FRB domain. 226. The manipulated nucleic acid according to Embodiment 225, wherein the cell death-inducing domain includes Bid or a functional cleavage thereof. 227. The manipulated nucleic acid according to Embodiment 226, wherein the cell death induction domain comprises the amino acid sequence of Sequence ID No. 54. 228. An engineered nucleic acid according to any one of Embodiments 222 to 224, wherein the first monomer comprises a hormone-binding domain of an estrogen receptor (ER) domain, and the second monomer comprises an FKBP domain. 229. An engineered nucleic acid according to any one of Embodiments 222 to 224, wherein the first monomer comprises an FRB domain and the second monomer comprises a hormone-binding domain of an estrogen receptor (ER) domain. 230. The manipulated nucleic acid according to any one of Embodiments 222 to 224, wherein the first monomer comprises a hormone-binding domain and an FKBP domain of the estrogen receptor (ER) domain, the second monomer comprises an FRB domain, and the third monomer comprises a hormone-binding domain of the estrogen receptor (ER) domain. 231. An engineered nucleic acid according to any one of embodiments 228 to 230, wherein the cell death induction domain includes caspase 9 or a functional cleavage thereof. 232. The manipulated nucleic acid according to Embodiment 231, wherein the cell death induction domain comprises the amino acid sequence of Sequence ID No. 39. 233. The engineered nucleic acid according to any one of embodiments 225 to 232, wherein the ligand is rapamycin, a derivative thereof, or an analog thereof. 234. An engineered nucleic acid according to any one of Embodiments 228 to 232, wherein the ligand is tamoxifen or a metabolite thereof. 235. The engineered nucleic acid according to Embodiment 234, wherein the tamoxifen metabolite is selected from the group consisting of 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen. 236. An engineered nucleic acid according to any one of Embodiments 222 to 224, wherein the first monomer comprises an ABI domain and the second monomer comprises a PYL domain. 237. The engineered nucleic acid according to Embodiment 236, wherein the ligand is abscisic acid. 238. The engineered nucleic acid according to any one of Embodiments 222 to 224, wherein the first monomer comprises the heavy chain variable region (VH) of an anti-nicotinic antibody and the second monomer comprises the light chain variable region (VL) of an anti-nicotinic antibody. 239. The manipulated nucleic acid according to Embodiment 238, wherein the anti-nicotine antibody is a Nic12 antibody. 240.VH is an engineered nucleic acid according to Embodiment 238 or Embodiment 239, comprising the amino acid sequence of Sequence ID No. 50. The manipulated nucleic acid according to any one of embodiments 238 to 240, wherein 241.VL contains the amino acid sequence of SEQ ID NO: 51. 242. An engineered nucleic acid according to any one of embodiments 238 to 241, wherein the ligand is nicotine or a derivative thereof. 243. An engineered nucleic acid according to any one of Embodiments 222 to 224, wherein the first monomer comprises a cannabidiol-binding domain having an amino acid sequence selected from the group consisting of SEQ ID NOs. 35, 36, 37, and 38, and the second monomer comprises a cannabidiol-binding domain having an amino acid sequence of SEQ ID NO. 34. 244. The engineered nucleic acid according to Embodiment 243, wherein the ligand is cannabidiol or a plant-derived cannabinoid. 245. An engineered nucleic acid according to any one of Embodiments 222 to 224, wherein the first monomer comprises a cerebron domain having an amino acid sequence specified in one of Sequence IDs 127 and 129, and the second monomer comprises degron having an amino acid sequence specified in one of Sequence IDs 131 and 133. 246. The manipulated nucleic acid according to Embodiment 245, wherein the ligand is IMiD. 247. The engineered nucleic acid described in Embodiment 246, wherein IMiD is an FDA-approved drug. 248. The manipulated nucleic acid according to Embodiment 245 or Embodiment 246, wherein IMiD is selected from the group consisting of thalidomide, lenalidomide, and pomalidomide. 249. An engineered nucleic acid according to any one of embodiments 176 to 248, wherein each monomer further comprises a linker localized between each ligand-binding domain and a cell death-inducing domain. 250. The manipulated nucleic acid according to Embodiment 249, wherein the linker comprises an amino acid sequence selected from the group consisting of GGGGSGGGGSGGGGSVDGF (SEQ ID NO: 104) and ASGGGGSAS (SEQ ID NO: 105). 251. Manipulated nucleic acids, An expression cassette comprising an exogenous polynucleotide sequence encoding a promoter and an activated conditionally controlled polypeptide (ACP), wherein the promoter comprises an expression cassette operably ligated to the exogenous polynucleotide, ACP comprises a transcription factor including one or more ligand-binding domains, as well as nucleic acid-binding domains and transcription effector domains. When expressed, ACP undergoes nuclear localization upon binding of its ligand-binding domain to a homologous ligand. When localized in the cell nucleus, ACP is a modified nucleic acid that can induce the transcriptional expression of a gene of interest operably linked to an ACP-responsive promoter. 252. Manipulated nucleic acids, Promoter and formula: C1-L-C2 During the ceremony, C1 comprises a polynucleotide sequence encoding a first chimeric polypeptide that includes a first ligand-binding domain and a transcriptional activation domain. L contains a linker polynucleotide sequence, C2 comprises an expression cassette containing an exogenous polynucleotide having a polynucleotide sequence encoding a second chimeric polypeptide including a second ligand-binding domain and a nucleic acid-binding domain, The promoter is operably linked to the exogenous polynucleotide, Upon expression, the first and second chimeric polypeptides multimerize to form activated conditionally controlled polypeptides (ACPs) via homologous ligands that bind to each ligand-binding domain, and A modified nucleic acid, wherein the multimerized ACP is capable of inducing the transcriptional expression of a gene of interest operably linked to an ACP-responsive promoter. The modified nucleic acid according to Embodiment 251 or Embodiment 252, wherein each ligand-binding domain comprises a domain selected from the group consisting of an ABI domain, a PYL domain, a caffeine-binding single-domain antibody, a cannabidiol-binding domain, a hormone-binding domain of an estrogen receptor (ER) domain, a heavy chain variable region (VH) of an anti-nicotine antibody, a light chain variable region (VL) of an anti-nicotine antibody, a progesterone receptor domain, an FKBP domain, and an FRB domain, or a functional fragment thereof. 253. The manipulated nucleic acid according to Embodiment 252, wherein the ABI domain comprises the amino acid sequence of SEQ ID NO: 31. 254. The manipulated nucleic acid according to Embodiment 252, wherein the PYL domain comprises the amino acid sequence of Sequence ID No. 53. 255. The manipulated nucleic acid according to Embodiment 252, comprising the amino acid sequence of SEQ ID NO: 33, wherein the caffeine-conjugated single-domain antibody. 256. The engineered nucleic acid according to Embodiment 252, wherein the cannabidiol-binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 35, 36, 37, and 38. 257. The engineered nucleic acid according to Embodiment 252, wherein the hormone-binding domain of the estrogen receptor (ER) comprises the amino acid sequence of SEQ ID NO: 42. 258. The engineered nucleic acid according to Embodiment 252, wherein the heavy chain variable region (VH) of the anti-nicotinic antibody comprises the amino acid sequence of SEQ ID NO: 50. 259. The manipulated nucleic acid according to Embodiment 252, wherein the light chain variable region (VL) of the anti-nicotinic antibody comprises the amino acid sequence of SEQ ID NO: 51. 260. The engineered nucleic acid according to Embodiment 252, wherein the progesterone receptor domain comprises the amino acid sequence of Sequence ID No. 52. 261. The manipulated nucleic acid according to Embodiment 252, wherein the FKBP domain comprises the amino acid sequence of Sequence ID No. 43. 262. The manipulated nucleic acid according to Embodiment 252, wherein the FRB domain comprises the amino acid sequence of Sequence ID No. 44. 263. The engineered nucleic acid according to Embodiment 250, wherein the nucleic acid binding domain comprises a DNA-binding zinc finger protein domain (ZF protein domain). 264. The manipulated nucleic acid according to Embodiment 263, wherein the ZF protein domain is a modular design and comprises a zinc finger array (ZFA). 265. The transcription effector domains include: herpes simplex virus protein 16 (VP16) activation domain; activation domain containing four tandem copies of VP16; VP64 activation domain; p65 activation domain of NFκB; Epstein-Barr virus R trans-activator (Rta) activation domain; ternary activator containing VP64, p65, and Rta activation domains (VPR activation domain); ternary activator containing VP64, p65, and HSF1 activation domains (VPH activation domain); histone acetyltransferase (HAT) core domain of human E1A-related protein p300 (p300 The engineered nucleic acid according to Embodiment 263 or Embodiment 264, selected from the group consisting of: HAT core activating domain; Kruppel association box (KRAB) repression domain; repressor element silencing transcription factor (REST) ​​repression domain; WRPW motif of hairy-associated basic helix-loop-helix repressor protein, known as the WRPW repression domain; DNA (cytosine-5)-methyltransferase 3B (DNMT3B) repression domain; and HP1 alpha chromoshadow repression domain. 266. The manipulated nucleic acid according to any one of Embodiments 250 and 263-265, wherein the chimeric polypeptide further comprises a linker localized between the nucleic acid-binding domain and the transcription effector domain. 267. The engineered nucleic acid according to Embodiment 266, wherein the linker comprises one or more 2A ribosome skipping tags. 268. The manipulated nucleic acid according to Embodiment 267, wherein each 2A ribosome skipping tag is selected from the group consisting of P2A, T2A, E2A, and F2A. 269. The manipulated nucleic acid according to any one of embodiments 250 and 263-268, wherein the chimeric polypeptide comprises a first ligand-binding domain operably linked to a nucleic acid-binding domain and a second ligand-binding domain operably linked to a transcription effector domain. 270. The engineered nucleic acid according to any one of embodiments 259 and 263-269, wherein each of the first and second ligand-binding domains comprises a hormone-binding domain of an estrogen receptor (ER) domain. 271. The engineered nucleic acid according to Embodiment 270, wherein the homologous ligand is tamoxifen or a metabolite thereof. 272. The engineered nucleic acid according to Embodiment 271, wherein the tamoxifen metabolite is selected from the group consisting of 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen. 273. The engineered nucleic acid according to any one of embodiments 250 to 269, wherein each of the first and second ligand-binding domains comprises a progesterone receptor domain. 274. The engineered nucleic acid according to Embodiment 273, wherein the homologous ligand is mifepristone or a derivative thereof. 275. The engineered nucleic acid according to any one of Embodiments 182-249 and 251-269, wherein the ligand-binding domain includes an ABI domain or a PYL domain, and the homologous ligand is abscisic acid. 276. The engineered nucleic acid according to any one of Embodiments 182-249 and 251-269, wherein the ligand-binding domain contains a caffeine-binding single-domain antibody, and the homologous ligand is caffeine or a derivative thereof. 277. The engineered nucleic acid according to any one of Embodiments 182-249 and 251-269, wherein the ligand-binding domain includes a cannabidiol-binding domain, and the homologous ligand is a cannabidiol or a plant cannabinoid. 278. The engineered nucleic acid according to Embodiment 277, wherein the cannabidiol-binding domain comprises a single-domain antibody or nanobody. 279. The manipulated nucleic acid according to Embodiment 278, wherein the cannabidiol-binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 35, 36, 37, and 38. 280. The engineered nucleic acid according to any one of Embodiments 182-249 and 251-269, wherein the ligand-binding domain includes the hormone-binding domain of the estrogen receptor (ER) domain, and the homologous ligand is tamoxifen or a metabolite thereof. 281. The engineered nucleic acid according to Embodiment 280, wherein the tamoxifen metabolite is selected from the group consisting of 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen. 282. The engineered nucleic acid according to any one of Embodiments 182-249 and 251-269, wherein the ligand-binding domain includes the heavy chain variable region (VH) or the light chain variable region (VL) of an anti-nicotine antibody, and the homologous ligand is nicotine or a derivative thereof. 283. The engineered nucleic acid according to any one of embodiments 182-249 and 251-269, wherein the ligand-binding domain is a progesterone receptor domain, and the homologous ligand is mifepristone or a derivative thereof. 284. The engineered nucleic acid according to any one of Embodiments 182-249 and 251-269, wherein the ligand-binding domain includes an FKBP domain or an FRB domain, and the homologous ligand is rapamycin, AP1903, AP20187, FK1012, a derivative thereof, or an analog thereof. 285. The engineered nucleic acid according to any one of Embodiments 250 to 284, wherein the nucleic acid binding domain includes a DNA-binding zinc finger protein domain (ZF protein domain). 286. The manipulated nucleic acid according to Embodiment 285, wherein the ZF protein domain is a modular design and comprises a zinc finger array (ZFA). 287. The engineered nucleic acid of Embodiment 286, wherein the ZF protein domain contains one to ten ZF motifs. 288. The manipulated nucleic acid according to any one of embodiments 285 to 287, wherein the nucleic acid binding domain binds to an ACP-responsive promoter. 289. An engineered nucleic acid according to any one of Embodiments 250 to 288, wherein the ACP-responsive promoter comprises an ACP-binding domain sequence and a promoter sequence. 290. The manipulated nucleic acid according to Embodiment 289, wherein the promoter sequence is derived from a promoter selected from the group consisting of minP, NFkB response element, CREB response element, NFAT response element, SRF response element 1, SRF response element 2, AP1 response element, TCF-LEF response element promoter fusion, hypoxia-responsive element, SMAD binding element, STAT3 binding site, minCMV, YB_TATA, min_TATA, minTK, inductive molecule-responsive promoter, and tandem repeats thereof. 291. The engineered nucleic acid according to Embodiment 289 or Embodiment 290, wherein the ACP-responsive promoter comprises a synthetic promoter. 292. The engineered nucleic acid according to any one of embodiments 285 to 291, wherein the ACP-responsive promoter comprises a minimal promoter. 293. The manipulated nucleic acid according to any one of embodiments 285 to 292, wherein the ACP-binding domain comprises one or more zinc finger binding sites. 294. An engineered nucleic acid according to any one of Embodiments 250 to 293, wherein the transcriptional activation domain is selected from the group consisting of: herpes simplex virus protein 16 (VP16) activation domain; activation domain containing four tandem copies of VP16; VP64 activation domain; p65 activation domain of NFκB; Epstein-Barr virus R trans-activator (Rta) activation domain; ternary activator containing VP64, p65, and Rta activation domains (VPR activation domain); ternary activator containing VP64, p65, and HSF1 activation domains (VPH activation domain); and the histone acetyltransferase (HAT) core domain of human E1A-related protein p300 (p300 HAT core activation domain). 295. The engineered nucleic acid according to Embodiment 252, wherein the linker polynucleotide sequence is operably associated with the translation of each chimeric polypeptide as a distinct polypeptide. 296. The manipulated nucleic acid according to Embodiment 252 or Embodiment 295, wherein the linker polynucleotide sequence encodes a 2A ribosome skipping tag. The manipulated nucleic acid according to Embodiment 296, wherein the 297.2A ribosome skipping tag is selected from the group consisting of P2A, T2A, E2A, and F2A. 298. The engineered nucleic acid according to Embodiment 252 or Embodiment 295, wherein the linker polynucleotide sequence encodes an intra-sequence ribosome entry site (IRES). 299. An engineered nucleic acid according to any one of embodiments 252 to 298, wherein the linker polynucleotide sequence encodes a cleavable polypeptide. 300. The engineered nucleic acid according to Embodiment 299, wherein the cleavable polypeptide comprises a furin polypeptide sequence. 301. Manipulated nucleic acids, The expression cassette comprises a promoter and an exogenous polynucleotide sequence encoding an activated conditionally controlled polypeptide (ACP) including a ligand-binding domain and a transcription effector domain. The promoter is operably ligated to the exogenous polynucleotide, and ACP is a modified nucleic acid that can regulate the transcriptional expression of a gene of interest operably linked to an ACP-responsive promoter, both when expressed and when its ligand-binding domain binds to a homologous ligand. 302. The engineered nucleic acid according to Embodiment 301, wherein the ligand-binding domain is localized to the 5' or 3' of the transcription effector domain. 303. The manipulated nucleic acid according to Embodiment 301 or Embodiment 302, wherein the transcription effector domain includes a transcription repressor. 304. The manipulated nucleic acid according to Embodiment 303, wherein the transcriptional repressor domain comprises a transcriptional repressor domain selected from the group consisting of a Kruppel association box (KRAB) repressor domain; a repressor element silencing transcription factor (REST) ​​repressor domain; a WRPW motif of the hairy-associated basic helix-loop-helix repressor protein, the motif known as the WRPW repressor domain; a DNA (cytosine 5) methyltransferase 3B (DNMT3B) repressor domain; and an HP1 alpha-chromoshadow repressor domain. 305. The manipulated nucleic acid according to Embodiment 301 or Embodiment 302, wherein the transcription effector domain contains a transcription activator. 306. The manipulated nucleic acid according to Embodiment 305, wherein the transcription activator comprises a transcription activator selected from the group consisting of a herpes simplex virus protein 16 (VP16) activating domain; an activating domain containing four tandem copies of VP16; a VP64 activating domain; a p65 activating domain of NFκB; an Epstein-Barr virus R trans-activator (Rta) activating domain; a ternary activator containing VP64, p65, and Rta activating domains (VPR activating domain); a ternary activator containing VP64, p65, and HSF1 activating domains (VPH activating domain); and a histone acetyltransferase (HAT) core domain of human E1A-related protein p300 (p300 HAT core activating domain). 307. An engineered nucleic acid according to any one of embodiments 301 to 306, wherein ACP is a transcription factor. 308. The manipulated nucleic acid according to any one of embodiments 301 to 307, wherein ACP is a zinc finger-containing transcription factor. 309. The manipulated nucleic acid according to Embodiment 308, wherein the zinc finger-containing transcription factor comprises a DNA-binding zinc finger protein domain (ZF protein domain) and a transcriptional repressor domain or transcriptional activator domain. 310. The manipulated nucleic acid according to Embodiment 309, wherein the ZF protein domain is a modular design and comprises a zinc finger array (ZFA). 311. The engineered nucleic acid of Embodiment 210, wherein the ZF protein domain contains one to ten ZFAs. 312. The engineered nucleic acid according to any one of embodiments 309 to 311, wherein the DNA-binding zinc finger protein domain binds to an ACP-responsive promoter. 313. The manipulated nucleic acid according to any one of embodiments 301 to 312, wherein the ACP-responsive promoter comprises an ACP-binding domain and a promoter sequence. 314. The manipulated nucleic acid according to Embodiment 313, wherein the promoter sequence is derived from a promoter selected from the group consisting of minP, NFkB response element, CREB response element, NFAT response element, SRF response element 1, SRF response element 2, AP1 response element, TCF-LEF response element promoter fusion, hypoxia-responsive element, SMAD binding element, STAT3 binding site, minCMV, YB_TATA, min_TATA, minTK, inductive molecule-responsive promoter, and tandem repeats thereof. 315. The engineered nucleic acid according to any one of embodiments 301 to 314, wherein the ACP-responsive promoter is a synthetic promoter. 316. The engineered nucleic acid according to any one of embodiments 301 to 315, wherein the ACP-responsive promoter comprises a minimal promoter. 317. The manipulated nucleic acid according to any one of embodiments 313 to 316, wherein the ACP-binding domain comprises one or more zinc finger binding sites. 318. An engineered nucleic acid according to any one of embodiments 301 to 317, wherein the gene of interest is a cell death-inducing polypeptide. 319. The cell death induction domain is found in caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, diphtheria toxin fragment A (DTA), Bax, Bak, Bok, Bad, Bcl-xS, Bak, Bik, Bcl-2-interacting protein 3 (BNIP3), Fas, Fas-related protein with death domain (FADD), tumor necrosis factor receptor 1-associated death domain protein (TRADD), TNF receptor (TNF-R), APAF-1, granzyme B, second mitochondrial-derived activator of caspase (SMAC), Omi, Bmf, Bid, Bim, and p53 upregulator of apoptosis (PU). The manipulated nucleic acids of Embodiment 318 are derived from proteins selected from the group consisting of MA), Noxa, Blk, Hrk, cytochrome c, Arts, TNF-associated cell death induction ligand (TRAIL), herpes simplex virus thymidine kinase (HSV-TK), varicella-zoster virus thymidine kinase (VZV-TK), viral spike protein, carboxylesterase, cytosine deaminase, nitroreductase Fksb, carboxypeptidase G2, carboxypeptidase A, horseradish peroxidase, linamorase, hepatic cytochrome P450-2B1, and purine nucleoside phosphorylase. 320. The engineered nucleic acid according to Embodiment 318, wherein the cell death-inducing polypeptide is caspase 9 or a functional cleavage thereof. 321. The manipulated nucleic acid according to Embodiment 320, wherein the cell death induction domain comprises the amino acid sequence of Sequence ID No. 39. 322. The engineered nucleic acid according to Embodiment 318, wherein the cell death-inducing polypeptide is diphtheria toxin fragment A (DTA). 323. The manipulated nucleic acid according to Embodiment 322, wherein the cell death induction domain comprises the amino acid sequence of Sequence ID No. 41. 324. The engineered nucleic acid according to Embodiment 318, wherein the cell death-inducing polypeptide is granzyme B. 325. The manipulated nucleic acid according to Embodiment 324, wherein the cell death induction domain comprises the amino acid sequence of Sequence ID No. 47. 326. The engineered nucleic acid according to Embodiment 318, wherein the cell death-inducing polypeptide is Bax. 327. The manipulated nucleic acid according to Embodiment 326, wherein the cell death induction domain comprises the amino acid sequence of Sequence ID No. 32. 328. Manipulated nucleic acids, An expression cassette comprising an exogenous polynucleotide sequence encoding a controllable cell survival polypeptide including a promoter and a ligand-binding domain, wherein the promoter comprises an expression cassette operably linked to the exogenous polynucleotide, When expressed, cell survival polypeptides can inhibit cell death-inducing polypeptides, and When bound to a related ligand, the related ligand is a modified nucleic acid that inhibits a survival-promoting polypeptide. 329. The manipulated nucleic acid according to Embodiment 328, wherein the cell survival polypeptide is selected from the group consisting of XIAP, modified XIAP, Bcl-2, Bcl-xL, Bcl-w, Bcl-2-related protein A1 (BCL2A1), Mcl-1, FLICE-like inhibitory protein (c-FLIP), and adenovirus E1B-19K protein. 330. The engineered nucleic acid according to Embodiment 328, wherein the cell survival polypeptide is XIAP or modified XIAP. 331. The engineered nucleic acid according to any one of embodiments 328 to 330, wherein the ligand-binding domain is localized to the N-terminal region or the C-terminal region of the survival-promoting polypeptide. 332. An engineered nucleic acid according to any one of Embodiments 301 to 331, wherein the ligand-binding domain comprises a domain selected from the group consisting of an ABI domain, a PYL domain, a caffeine-binding single-domain antibody, a cannabidiol-binding domain, a hormone-binding domain of an estrogen receptor (ER domain), a heavy chain variable region (VH) of an anti-nicotinic antibody, a light chain variable region (VL) of an anti-nicotinic antibody, a progesterone receptor domain, an FKBP domain, and an FRB domain, or a functional fragment thereof. 333. The manipulated nucleic acid according to Embodiment 332, wherein the ABI domain comprises the amino acid sequence of SEQ ID NO: 31. 334. The manipulated nucleic acid according to Embodiment 332, wherein the PYL domain comprises the amino acid sequence of Sequence ID No. 53. 335. The manipulated nucleic acid according to Embodiment 332, comprising the amino acid sequence of SEQ ID NO: 33. 336. The manipulated nucleic acid according to Embodiment 332, wherein the cannabidiol-binding domain comprises an amino acid sequence sele...

Claims

1. 1. An inducible cell death system comprising two or more polypeptide monomers; each polypeptide monomer comprises one or more ligand-binding domains and a cell death-inducing domain, said polypeptide monomer being configured to oligomerize upon contact of said polypeptide monomer with a cognate ligand of said one or more ligand-binding domains and to generate a cell death-inducing signal in a cell in which said polypeptide monomer is expressed; and The one or more ligand binding domains of each of the two or more polypeptide monomers a hormone-binding domain of an estrogen receptor (ER) domain optionally comprising the amino acid sequence of SEQ ID NO: 42, an ABI domain optionally comprising the amino acid sequence of SEQ ID NO: 31, a PYL domain optionally comprising the amino acid sequence of SEQ ID NO: 53, a caffeine-binding single domain antibody optionally comprising the amino acid sequence of SEQ ID NO: 33, a cannabidiol-binding domain optionally comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 35, 36, 37, and 38, a heavy chain variable region (VH) of an anti-nicotine antibody optionally comprising the amino acid sequence of SEQ ID NO: 50 and / or a light chain variable region (VL) of an anti-nicotine antibody optionally comprising the amino acid sequence of SEQ ID NO: 51, an FKBP domain optionally comprising the amino acid sequence of SEQ ID NO: 43, and a progesterone receptor domain optionally comprising the amino acid sequence of SEQ ID NO:

52. or a functional fragment thereof selected from the group consisting of the one or more ligand-binding domains of a first of the two or more polypeptide monomers comprise a cereblon domain optionally comprising an amino acid sequence set forth in one of SEQ ID NOs: 127 and 129, and the one or more ligand-binding domains of a second of the two or more polypeptide monomers comprise a degron optionally comprising an amino acid sequence set forth in one of SEQ ID NOs: 131 and 133; or the one or more ligand-binding domains of a first of the two or more polypeptide monomers comprise an FKBP domain optionally comprising the amino acid sequence of SEQ ID NO:43, and the one or more ligand-binding domains of a second of the two or more polypeptide monomers comprise an FRB domain optionally comprising the amino acid sequence of SEQ ID NO:44; and Optionally, the cell death inducing domain comprises: Caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, diphtheria toxin fragment A (DTA), Bax, Bak, Bok, Bad, Bcl-xS, Bak, Bik, Bcl-2-interacting protein 3 (BNIP3), Fas, Fas-associated protein with death domain (FADD), tumor necrosis factor receptor type 1-associated death domain protein (TRADD), TNF receptor (TNF-R), APAF-1, granzyme B, second mitochondrial-derived activator of caspases (SMAC), Omi, Bmf, Bid, Bim, apoptosis p5 upregulated regulator of 3 (PUMA), Noxa, Blk, Hrk, cytochrome c, Arts, TNF-related cell death-inducing ligand (TRAIL), herpes simplex virus thymidine kinase (HSV-TK), varicella-zoster virus thymidine kinase (VZV-TK), viral spike protein, carboxylesterase, cytosine deaminase, nitroreductase Fksb, carboxypeptidase G2, carboxypeptidase A, horseradish peroxidase, linamarase, hepatic cytochrome P450-2B1, and purine nucleoside phosphorylase wherein optionally the caspase 9 or a functional cleavage thereof comprises the amino acid sequence of SEQ ID NO: 39; optionally the DTA comprises the amino acid sequence of SEQ ID NO: 41; optionally the granzyme B comprises the amino acid sequence of SEQ ID NO: 47; and optionally the Bax comprises the amino acid sequence of SEQ ID NO:

32. Inducible cell death system.

2. Each polypeptide monomer comprises the same ligand-binding domain, and optionally each polypeptide monomer comprises: an FKBP domain, optionally wherein said cognate ligand is FK1012, a derivative or an analogue thereof; or an ABI domain and a PYL domain, optionally wherein said cognate ligand is abscisic acid; or a first cannabidiol binding domain comprising the amino acid sequence of SEQ ID NO: 34, and a second cannabidiol binding domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 35, 36, 37, and 38, optionally wherein said cognate ligand is a phytocannabinoid, and optionally wherein said phytocannabinoid is cannabidiol; or a hormone binding domain and an FKBP domain of an estrogen receptor (ER) domain, optionally wherein said cognate ligand is rapamycin or a derivative or analog thereof, and / or tamoxifen or a metabolite thereof, and optionally wherein said tamoxifen metabolite is selected from the group consisting of 4-hydroxy tamoxifen, N-desmethyl tamoxifen, tamoxifen-N-oxide, and endoxifen; two caffeine-binding single domain antibodies, optionally each comprising the amino acid sequence of SEQ ID NO: 33, and optionally said cognate ligand being caffeine or a derivative thereof; or A first progesterone receptor domain comprising the amino acid sequence of SEQ ID NO:52, and a second first progesterone receptor domain comprising the amino acid sequence of SEQ ID NO:52, optionally wherein said cognate ligand is mifepristone or a derivative thereof. Including, Optionally, the polypeptide monomers are configured to form homo-oligomers upon contact with the cognate ligand, and optionally, the homo-oligomers comprise homo-dimers. The inducible cell death system of claim 1 .

3. The first polypeptide monomer comprises a first ligand binding domain, the second polypeptide monomer comprises a second ligand binding domain, and optionally the first monomer comprises an FKBP domain and the second monomer comprises an FRB domain, and optionally the cognate ligand is rapamycin or a derivative thereof; or the first polypeptide monomer comprises a hormone binding domain of an estrogen receptor (ER) domain, and the second polypeptide monomer comprises an FKBP domain, and optionally the cognate ligand is rapamycin or a derivative thereof, and / or tamoxifen or a metabolite thereof; or the first polypeptide monomer comprises an FRB domain and the second polypeptide monomer comprises a hormone binding domain of an estrogen receptor (ER) domain, and optionally the cognate ligand is rapamycin or a derivative thereof, and / or tamoxifen or a metabolite thereof; or the first polypeptide monomer comprises a hormone binding domain of an estrogen receptor (ER) domain and an FKBP domain, the second polypeptide monomer comprises an FRB domain and a hormone binding domain of an estrogen receptor (ER) domain, and optionally the cognate ligand is rapamycin or a derivative thereof and / or tamoxifen or a metabolite thereof, or the first polypeptide monomer comprises an ABI domain and the second polypeptide monomer comprises a PYL domain, and optionally the cognate ligand comprises abscisic acid; or the first polypeptide monomer comprises a heavy chain variable region (VH) of an anti-nicotine antibody and the second polypeptide monomer comprises a light chain variable region (VL) of an anti-nicotine antibody, optionally wherein the anti-nicotine antibody is a Nic12 antibody, optionally wherein the VH comprises the amino acid sequence of SEQ ID NO:50, and optionally wherein the VL comprises the amino acid sequence of SEQ ID NO:51, and optionally wherein the cognate ligand is nicotine or a derivative thereof; or the first polypeptide monomer comprises a cannabidiol binding domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 35, 36, 37, and 38, and the second polypeptide monomer comprises a cannabidiol binding domain comprising the amino acid sequence of SEQ ID NO: 34, optionally wherein the cognate ligand is a phytocannabinoid, optionally wherein the phytocannabinoid is cannabidiol, or said first polypeptide monomer comprises a cereblon domain comprising an amino acid sequence set forth in one of SEQ ID NOs: 127 and 129, and said second polypeptide monomer comprises a degron domain comprising an amino acid sequence set forth in one of SEQ ID NOs: 131 and 133; optionally, said cognate ligand is an IMiD, optionally, said IMiD is an FDA approved drug, optionally, said IMiD is selected from the group consisting of thalidomide, lenalidomide, and pomalidomide; Optionally, the polypeptide monomers are configured to form hetero-oligomers upon contact with the cognate ligand, and optionally, the hetero-oligomers comprise heterodimers. The inducible cell death system of claim 1 .

4. The inducible cell death system of any one of claims 1 to 3, wherein at least one of the two or more polypeptide monomers further comprises a linker located between each ligand-binding domain and the cell death-inducing domain, optionally wherein the linker comprises an amino acid sequence selected from the group consisting of GGGGSGGGGSGGGGSVDGF (SEQ ID NO: 101) and ASGGGGSAS (SEQ ID NO: 102), and optionally wherein each polypeptide monomer further comprises a linker located between each ligand-binding domain and the cell death-inducing domain.

5. 1. An inducible cell death system comprising an activating conditionally controlled polypeptide (ACP), The ACP comprises a ligand binding domain and a transcriptional effector domain; and Upon binding of the ligand-binding domain to a cognate ligand, the ACP is capable of regulating the transcriptional expression of a gene of interest operably linked to an ACP-responsive promoter; the gene of interest comprises a cell death-inducing polypeptide; and Optionally, the ligand binding domain comprises a degron, optionally, the degron is capable of inducing degradation of the ACP; and Optionally, said degron comprises: HCV NS4 degron, PEST (two copies of residues 277-307 of human IκBα), GRR (residues 352-408 of human p105), DRR (residues 210-295 of yeast Cdc34), SNS (tandem repeats of SP2 and NB (influenza A or influenza B SP2-NB-SP2)), RPB (four copies of residues 1688-1702 of yeast RPB), SPmix (tandem repeats of SP1 and SP2), Muli repeats (SP2-SP1-SP2-SP1-SP2 of influenza A virus M2 protein)), NS2 (three copies of residues 79-93 of influenza A virus NS protein), ODC (residues 106-142 of ornithine decarboxylase), Nek2A, mouse ODC (residues 422-461), mouse ODC_DA (residues 422-461 of mODC containing point mutations D433A and D434A), APC / C Degron, COP1 E3 ligase binding degron motif, CRL4-Cdt2 binding PIP degron, actinfilin binding degron, KEAP1 binding degron, KLHL2 and KLHL3 binding degron, MDM2 binding motif, N degron, hydroxyproline modification in hypoxia signaling, plant hormone dependent SCF-LRR binding degron, SCF ubiquitin ligase binding phosphodegron, plant hormone dependent SCF-LRR binding degron, DSGxxS phosphate dependent degron (SEQ ID NO: 154), Siah binding motif, SPOP SBC docking motif, and PCNA binding PIP box. or the degron comprises a cereblon (CRBN) polypeptide substrate domain capable of binding to CRBN in response to an immunomodulatory drug (IMiD), thereby promoting degradation of a regulatory polypeptide via the ubiquitin pathway, and optionally the CRBN polypeptide substrate domain is selected from the group consisting of IKZF1, IKZF3, CK1a, ZFP91, GSPT1, MEIS2, GSS E4F1, ZN276, ZN517, ZN582, ZN653, ZN654, ZN692, ZN787, and ZN827, or a fragment thereof capable of drug-inducible binding of CRBN, and optionally said CRBN polypeptide substrate domain is a chimeric fusion product of a native CRBN polypeptide sequence, and optionally said CRBN polypeptide substrate domain is an IKZF3 / ZFP91 / IKZF3 chimeric fusion product having the amino acid sequence of FNVLMVHKRSHTGERPLQCEICGFTCRQKGNLLRHIKLHTGEKPFKCHLCNYACQRRDAL (SEQ ID NO: 103). Inducible cell death system.

6. 1. An inducible cell death system comprising an activating conditionally controlled polypeptide (ACP), the ACP comprising one or more ligand binding domains, and a transcription factor comprising a nucleic acid binding domain and a transcription effector domain; the ACP undergoes nuclear localization upon binding to the ligand-binding domain and its cognate ligand; and when localized to the cell nucleus, the ACP is capable of inducing the transcriptional expression of a gene of interest operably linked to an ACP responsive promoter; the gene of interest comprises a cell death induction domain; Optionally, the transcription effector domain comprises: herpes simplex virus protein 16 (VP16) activation domain; an activation domain containing four tandem copies of VP16, the VP64 activation domain; the p65 activation domain of NFκB; the Epstein-Barr virus R transactivator (Rta) activation domain; a tripartite activator containing VP64, p65, and the Rta activation domain (VPR activation domain); a tripartite activator containing VP64, p65, and the HSF1 activation domain (VPH activation domain); the histone acetyltransferase (HAT) core domain of human E1A-associated protein p300 (p300 activation domain) HAT core activation domain); Kruppel-associated box (KRAB) repression domain; repressor element silencing transcription factor (REST) ​​repression domain; the WRPW motif of hairy-related basic helix-loop-helix repressor protein (SEQ ID NO:152), which motif is known as the WRPW repression domain ("WRPW" disclosed as SEQ ID NO:152); DNA (cytosine-5)-methyltransferase 3B (DNMT3B) repression domain; and HP1 alpha chromoshadow repression domain. and Optionally, the ligand binding domain comprises: A hormone-binding domain of an estrogen receptor (ER) domain, optionally comprising the amino acid sequence of SEQ ID NO: 42, wherein optionally said cognate ligand is tamoxifen or a metabolite thereof, and optionally said tamoxifen metabolite is selected from the group consisting of 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen; or a progesterone receptor domain, optionally comprising the amino acid sequence of SEQ ID NO: 52, wherein optionally said cognate ligand is mifepristone or a derivative thereof. Including, Optionally, The one or more ligand binding domains of each of the two or more polypeptide monomers an ABI domain, optionally comprising the amino acid sequence of SEQ ID NO:31, optionally wherein said cognate ligand is abscisic acid; an PYL domain, optionally comprising the amino acid sequence of SEQ ID NO:33, optionally wherein said cognate ligand is caffeine or a derivative thereof; a cannabidiol binding domain, optionally comprising the amino acid sequence of SEQ ID NO:34, 35, 36, 37, and 38, optionally wherein said cognate ligand is a phytocannabinoid, optionally wherein said phytocannabinoid is cannabidiol; a hormone binding domain of an estrogen receptor (ER) domain, optionally comprising the amino acid sequence of SEQ ID NO:50, whereby the cognate ligand is nicotine or a derivative thereof; a heavy chain variable region (VH) of an anti-nicotine antibody, optionally comprising the amino acid sequence of SEQ ID NO:51, whereby the cognate ligand is nicotine or a derivative thereof; a light chain variable region (VL) of an anti-nicotine antibody, optionally comprising the amino acid sequence of SEQ ID NO:52, whereby the cognate ligand is mifepristone or a derivative thereof; a progesterone receptor domain, optionally comprising the amino acid sequence of SEQ ID NO:44, whereby the cognate ligand is rapamycin, AP1903, AP20187, FK1012, a derivative thereof, or an analog thereof; or a functional fragment thereof selected from the group consisting of the one or more ligand binding domains of a first of the two or more polypeptide monomers comprise an FKBP domain optionally comprising the amino acid sequence of SEQ ID NO:43, and the one or more ligand binding domains of a second of the two or more polypeptide monomers comprise an FRB domain optionally comprising the amino acid sequence of SEQ ID NO:44, and optionally the cognate ligand is rapamycin, AP1903, AP20187, FK1012, a derivative, or an analog thereof; or the one or more ligand binding domains of a first of the two or more polypeptide monomers optionally comprise a cereblon domain comprising an amino acid sequence set forth in one of SEQ ID NOs: 127 and 129, and the one or more ligand binding domains of a second of the two or more polypeptide monomers optionally comprise a degron comprising an amino acid sequence set forth in one of SEQ ID NOs: 131 and 133; optionally, the cognate ligand is an IMiD, optionally, the IMiD is an FDA approved drug, optionally, the IMiD is selected from the group consisting of thalidomide, lenalidomide, and pomalidomide; Optionally, the nucleic acid binding domain comprises a DNA-binding zinc finger protein domain (ZF protein domain), optionally the ZF protein domain is modular in design and composed of an array of zinc finger motifs, optionally the ZF protein domain comprises one to ten zinc finger motifs; Optionally, the gene of interest is a cell death-inducing polypeptide, and optionally, the cell death-inducing domain comprises: Caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, diphtheria toxin fragment A (DTA), Bax, Bak, Bok, Bad, Bcl-xS, Bak, Bik, Bcl-2-interacting protein 3 (BNIP3), Fas, Fas-associated protein with death domain (FADD), tumor necrosis factor receptor type 1-associated death domain protein (TRADD), TNF receptor (TNF-R), APAF-1, granzyme B, second mitochondrial-derived activator of caspases (SMAC), Omi, Bmf, Bid, Bim, apoptosis p5 upregulated regulator of 3 (PUMA), Noxa, Blk, Hrk, cytochrome c, Arts, TNF-related cell death-inducing ligand (TRAIL), herpes simplex virus thymidine kinase (HSV-TK), varicella-zoster virus thymidine kinase (VZV-TK), viral spike protein, carboxylesterase, cytosine deaminase, nitroreductase Fksb, carboxypeptidase G2, carboxypeptidase A, horseradish peroxidase, linamarase, hepatic cytochrome P450-2B1, and purine nucleoside phosphorylase wherein optionally the caspase 9 or a functional cleavage thereof comprises the amino acid sequence of SEQ ID NO: 39; optionally the DTA comprises the amino acid sequence of SEQ ID NO: 41; optionally the granzyme B comprises the amino acid sequence of SEQ ID NO: 47; and optionally the Bax comprises the amino acid sequence of SEQ ID NO:

32. Inducible cell death system.

7. 1. An inducible cell death system comprising an engineered, controllable cell survival polypeptide, said cell survival polypeptide comprising a survival-promoting polypeptide and a heterologous ligand-binding domain; upon binding of said ligand-binding domain to its cognate ligand, said cognate ligand inhibits said survival-promoting polypeptide; Optionally, said survival-promoting polypeptide is selected from the group consisting of XIAP, modified XIAP, Bcl-2, Bcl-xL, Bcl-w, Bcl-2-related protein A1 (BCL2A1), Mcl-1, FLICE-like inhibitory protein (c-FLIP), and adenovirus E1B-19K protein; Optionally, the ligand-binding domain is localized to the N-terminal region of the survival-promoting polypeptide or the C-terminal region of the survival-promoting polypeptide. Inducible cell death system.

8. An inducible cell death system comprising a controllable cell survival polypeptide and a cell death-inducing polypeptide, the cell survival polypeptide comprises a survival-promoting polypeptide and a heterologous ligand-binding domain; When expressed, the cell survival polypeptide is capable of inhibiting the cell death-inducing polypeptide; and upon binding to its cognate ligand, said cognate ligand inhibits said survival-promoting polypeptide, and optionally said cell survival polypeptide is selected from the group consisting of XIAP, modified XIAP, Bcl-2, Bcl-xL, Bcl-w, Bcl-2-related protein A1 (BCL2A1), Mcl-1, FLICE-like inhibitory protein (c-FLIP), and adenovirus E1B-19K protein; Optionally, the ligand-binding domain is localized to the N-terminal region of the survival-promoting polypeptide or the C-terminal region of the survival-promoting polypeptide. Inducible cell death system.

9. The one or more ligand binding domains of each of the two or more polypeptide monomers an ABI domain, optionally comprising the amino acid sequence of SEQ ID NO:31, optionally wherein said cognate ligand is abscisic acid; an PYL domain, optionally comprising the amino acid sequence of SEQ ID NO:33, optionally wherein said cognate ligand is caffeine or a derivative thereof; a cannabidiol binding domain, optionally comprising the amino acid sequence of SEQ ID NO:34, 35, 36, 37, and 38, optionally wherein said cognate ligand is a phytocannabinoid, optionally wherein said phytocannabinoid is cannabidiol; a hormone binding domain of an estrogen receptor (ER) domain, optionally comprising the amino acid sequence of SEQ ID NO:50, whereby the cognate ligand is nicotine or a derivative thereof; a heavy chain variable region (VH) of an anti-nicotine antibody, optionally comprising the amino acid sequence of SEQ ID NO:51, whereby the cognate ligand is nicotine or a derivative thereof; a light chain variable region (VL) of an anti-nicotine antibody, optionally comprising the amino acid sequence of SEQ ID NO:52, whereby the cognate ligand is mifepristone or a derivative thereof; a progesterone receptor domain, optionally comprising the amino acid sequence of SEQ ID NO:44, whereby the cognate ligand is rapamycin, AP1903, AP20187, FK1012, a derivative thereof, or an analog thereof; or the one or more ligand binding domains of a first of the two or more polypeptide monomers comprise an FKBP domain optionally comprising the amino acid sequence of SEQ ID NO:43, and the one or more ligand binding domains of a second of the two or more polypeptide monomers comprise an FRB domain optionally comprising the amino acid sequence of SEQ ID NO:44, and optionally the cognate ligand is rapamycin, AP1903, AP20187, FK1012, a derivative, or an analog thereof; or the one or more ligand binding domains of a first of the two or more polypeptide monomers optionally comprise a cereblon domain comprising an amino acid sequence set forth in one of SEQ ID NOs: 127 and 129, and the one or more ligand binding domains of a second of the two or more polypeptide monomers optionally comprise a degron comprising an amino acid sequence set forth in one of SEQ ID NOs: 131 and 133; optionally, the cognate ligand is an IMiD, optionally, the IMiD is an FDA approved drug, and optionally, the IMiD is selected from the group consisting of thalidomide, lenalidomide, and pomalidomide.

9. An inducible cell death system according to claim 7 or 8.

10. The ligand binding domain comprises a degron, optionally the degron is capable of inducing degradation of the controllable cell survival polypeptide, and optionally the degron HCV NS4 degron, PEST (two copies of residues 277-307 of human IκBα), GRR (residues 352-408 of human p105), DRR (residues 210-295 of yeast Cdc34), SNS (tandem repeats of SP2 and NB (influenza A or influenza B SP2-NB-SP2)), RPB (four copies of residues 1688-1702 of yeast RPB), SPmix (tandem repeats of SP1 and SP2), Muli repeats (SP2-SP1-SP2-SP1-SP2 of influenza A virus M2 protein)), NS2 (three copies of residues 79-93 of influenza A virus NS protein), ODC (residues 106-142 of ornithine decarboxylase), Nek2A, mouse ODC (residues 422-461), mouse ODC_DA (residues 422-461 of mODC containing point mutations D433A and D434A), APC / C Degron, COP1 E3 ligase binding degron motif, CRL4-Cdt2 binding PIP degron, actinfilin binding degron, KEAP1 binding degron, KLHL2 and KLHL3 binding degron, MDM2 binding motif, N degron, hydroxyproline modification in hypoxia signaling, plant hormone dependent SCF-LRR binding degron, SCF ubiquitin ligase binding phosphodegron, plant hormone dependent SCF-LRR binding degron, DSGxxS phosphate dependent degron (SEQ ID NO: 154), Siah binding motif, SPOP SBC docking motif, and PCNA binding PIP box. and optionally said degron comprises a cereblon (CRBN) polypeptide substrate domain capable of binding to CRBN in response to an immunomodulatory drug (IMiD), thereby promoting degradation of a regulatory polypeptide via the ubiquitin pathway, and optionally said CRBN polypeptide substrate domain is selected from the group consisting of IKZF1, IKZF3, CK1a, ZFP91, GSPT1, MEIS2, GSS and optionally said CRBN polypeptide substrate domain is selected from the group consisting of: E4F1, ZN276, ZN517, ZN582, ZN653, ZN654, ZN692, ZN787, and ZN827, or a fragment thereof capable of drug-inducible binding of CRBN; and optionally said CRBN polypeptide substrate domain is a chimeric fusion product of a native CRBN polypeptide sequence, and optionally said CRBN polypeptide substrate domain is selected from the group consisting of: FNVLMVHKRSHTGERP LQCEICGFTCRRQKGNLLRHIKLHTGEKPFKCHLCNYACQRRDAL (SEQ ID NO: 103), optionally wherein said cognate ligand is an IMiD, optionally wherein said IMiD is an FDA approved drug, and optionally wherein said IMiD is selected from the group consisting of thalidomide, lenalidomide, and pomalidomide. The inducible cell death system according to any one of claims 7 to 9.

11. The cell death induction domain is Caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, diphtheria toxin fragment A (DTA), Bax, Bak, Bok, Bad, Bcl-xS, Bak, Bik, Bcl-2-interacting protein 3 (BNIP3), Fas, Fas-associated protein with death domain (FADD), tumor necrosis factor receptor type 1-associated death domain protein (TRADD), TNF receptor (TNF-R), APAF-1, granzyme B, second mitochondrial-derived activator of caspases (SMAC), Omi, Bmf, Bid, Bim, apoptosis p5 upregulated regulator of 3 (PUMA), Noxa, Blk, Hrk, cytochrome c, Arts, TNF-related cell death-inducing ligand (TRAIL), herpes simplex virus thymidine kinase (HSV-TK), varicella-zoster virus thymidine kinase (VZV-TK), viral spike protein, carboxylesterase, cytosine deaminase, nitroreductase Fksb, carboxypeptidase G2, carboxypeptidase A, horseradish peroxidase, linamarase, hepatic cytochrome P450-2B1, and purine nucleoside phosphorylase wherein optionally the caspase 9 or a functional cleavage thereof comprises the amino acid sequence of SEQ ID NO: 39, optionally the DTA comprises the amino acid sequence of SEQ ID NO: 41, and optionally the Bax comprises the amino acid sequence of SEQ ID NO: 32; The inducible cell death system according to any one of claims 8 to 10.

12. a) a first chimeric polypeptide comprising a first ligand binding domain and a transcriptional activation domain; b) a second chimeric polypeptide comprising a second ligand binding domain and a nucleic acid binding domain; 1. An activated conditionally controlled polypeptide (ACP) comprising: said first chimeric polypeptide and said second chimeric polypeptide oligomerize to form a multimeric ACP via cognate ligand binding to each ligand binding domain; The multimeric ACP is capable of inducing the transcriptional expression of a gene of interest operably linked to an ACP responsive promoter; and Optionally, the transcription activation domain comprises herpes simplex virus protein 16 (VP16) activation domain; an activation domain containing four tandem copies of VP16; the VP64 activation domain; the p65 activation domain of NFκB; the Epstein-Barr virus R transactivator (Rta) activation domain; a tripartite activator containing VP64, p65, and Rta activation domains (VPR activation domain); a tripartite activator containing VP64, p65, and HSF1 activation domains (VPH activation domain); and the histone acetyltransferase (HAT) core domain of human E1A-associated protein p300 (p300 HAT core activation domain). is selected from the group consisting of Optionally, The one or more ligand binding domains of each of the two or more polypeptide monomers an ABI domain, optionally comprising the amino acid sequence of SEQ ID NO:31, optionally wherein said cognate ligand is abscisic acid; an PYL domain, optionally comprising the amino acid sequence of SEQ ID NO:33, optionally wherein said cognate ligand is caffeine or a derivative thereof; a cannabidiol binding domain, optionally comprising the amino acid sequence of SEQ ID NO:34, 35, 36, 37, and 38, optionally wherein said cognate ligand is a phytocannabinoid, optionally wherein said phytocannabinoid is cannabidiol; a hormone binding domain of an estrogen receptor (ER) domain, optionally comprising the amino acid sequence of SEQ ID NO:50, whereby the cognate ligand is nicotine or a derivative thereof; a heavy chain variable region (VH) of an anti-nicotine antibody, optionally comprising the amino acid sequence of SEQ ID NO:51, whereby the cognate ligand is nicotine or a derivative thereof; a light chain variable region (VL) of an anti-nicotine antibody, optionally comprising the amino acid sequence of SEQ ID NO:52, whereby the cognate ligand is mifepristone or a derivative thereof; a progesterone receptor domain, optionally comprising the amino acid sequence of SEQ ID NO:44, whereby the cognate ligand is rapamycin, AP1903, AP20187, FK1012, a derivative thereof, or an analog thereof; or the one or more ligand binding domains of a first of the two or more polypeptide monomers comprise an FKBP domain optionally comprising the amino acid sequence of SEQ ID NO:43, and the one or more ligand binding domains of a second of the two or more polypeptide monomers comprise an FRB domain optionally comprising the amino acid sequence of SEQ ID NO:44, and optionally the cognate ligand is rapamycin, AP1903, AP20187, FK1012, a derivative, or an analog thereof; or the one or more ligand binding domains of a first of the two or more polypeptide monomers optionally comprise a cereblon domain comprising an amino acid sequence set forth in one of SEQ ID NOs: 127 and 129, and the one or more ligand binding domains of a second of the two or more polypeptide monomers optionally comprise a degron comprising an amino acid sequence set forth in one of SEQ ID NOs: 131 and 133; optionally, the cognate ligand is an IMiD, optionally, the IMiD is an FDA approved drug, optionally, the IMiD is selected from the group consisting of thalidomide, lenalidomide, and pomalidomide; Optionally, the gene of interest is a cell death-inducing polypeptide, and optionally, the cell death-inducing domain comprises: Caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, diphtheria toxin fragment A (DTA), Bax, Bak, Bok, Bad, Bcl-xS, Bak, Bik, Bcl-2-interacting protein 3 (BNIP3), Fas, Fas-associated protein with death domain (FADD), tumor necrosis factor receptor type 1-associated death domain protein (TRADD), TNF receptor (TNF-R), APAF-1, granzyme B, second mitochondrial-derived activator of caspases (SMAC), Omi, Bmf, Bid, Bim, apoptosis p5 upregulated regulator of 3 (PUMA), Noxa, Blk, Hrk, cytochrome c, Arts, TNF-related cell death-inducing ligand (TRAIL), herpes simplex virus thymidine kinase (HSV-TK), varicella-zoster virus thymidine kinase (VZV-TK), viral spike protein, carboxylesterase, cytosine deaminase, nitroreductase Fksb, carboxypeptidase G2, carboxypeptidase A, horseradish peroxidase, linamarase, hepatic cytochrome P450-2B1, and purine nucleoside phosphorylase wherein optionally the caspase 9 or a functional cleavage thereof comprises the amino acid sequence of SEQ ID NO: 39; optionally the DTA comprises the amino acid sequence of SEQ ID NO: 41; optionally the granzyme B comprises the amino acid sequence of SEQ ID NO: 47; and optionally the Bax comprises the amino acid sequence of SEQ ID NO:

32. Activating conditional regulatory polypeptides (ACPs).

13. The ACP of claim 12, wherein the nucleic acid binding domain comprises a DNA-binding zinc finger protein domain (ZF protein domain), optionally the ZF protein domain is modular in design and composed of an array of zinc finger motifs, optionally the ZF protein domain comprises one to ten zinc finger motifs.

14. The ACP of claim 12 or claim 13, wherein the chimeric polypeptide further comprises a linker located between the nucleic acid binding domain and the transcriptional effector domain, and optionally the linker comprises one or more 2A ribosomal skipping tags, and optionally each 2A ribosomal skipping tag is selected from the group consisting of P2A, T2A, E2A, and F2A.

15. the chimeric polypeptide comprises a first ligand binding domain operably linked to the nucleic acid binding domain and a second ligand binding domain operably linked to the transcriptional effector domain, and optionally each of the first and second ligand binding domains comprises a hormone binding domain of an estrogen receptor (ER) domain, and optionally the cognate ligand is tamoxifen or a metabolite thereof, and optionally the tamoxifen metabolite is selected from the group consisting of 4-hydroxy tamoxifen, N-desmethyl tamoxifen, tamoxifen-N-oxide, and endoxifen; or each of the first and second ligand binding domains comprises a progesterone receptor domain, optionally wherein the cognate ligand is mifepristone or a derivative thereof, optionally wherein when the ligand binding domain comprises an ABI domain or a PYL domain, the cognate ligand is abscisic acid; or each of said first and second ligand binding domains comprises a caffeine-binding single domain antibody, optionally wherein said cognate ligand is caffeine or a derivative thereof; or Each of the first and second ligand binding domains comprises a cannabidiol binding domain, optionally wherein the cognate ligand is cannabidiol or a phytocannabinoid, optionally wherein the cannabidiol binding domain comprises a single domain antibody or a nanobody, optionally wherein the cannabidiol binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 35, 36, 37, and 38. An ACP according to any one of claims 12 to 14.

16. the nucleic acid binding domain binds to the ACP responsive promoter, optionally the ACP responsive promoter comprises an ACP binding domain sequence and a promoter sequence, optionally the promoter sequence comprises a minimal promoter, optionally the promoter sequence is an inducible promoter; and NFκB response element, CREB response element, NFAT response element, SRF response element 1, SRF response element 2, AP1 response element, TCF-LEF response element promoter fusion, hypoxia response element, SMAD binding element, STAT3 binding site, inducible factor molecule responsive promoter, and tandem repeats thereof and optionally, the ACP responsive promoter comprises a synthetic promoter, and optionally, the ACP binding domain comprises one or more zinc finger binding sites.

17. The ACP of any one of claims 12 to 16, wherein the ligand-binding domain is localized N-terminal to the transcription effector domain or C-terminal to the transcription effector domain.

18. An isolated cell comprising an inducible cell death system according to any one of claims 1 to 11 or an ACP according to any one of claims 12 to 17.

19. An engineered nucleic acid encoding an inducible cell death system according to any one of claims 1 to 11 or an ACP according to any one of claims 12 to 17.